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ABSTRACT 
Introduction: Serum squalene and non-cholesterol sterols, cholesterol precursor 
sterols (∆8-cholestenol, desmosterol, and lathosterol) and absorption marker sterols 
(plant sterols and cholestanol) reflect in general cholesterol metabolism, but limited 
data exist on their distribution in different lipoproteins. Dietary plant stanols and 
sterols, called phytosterols, can lower serum cholesterol levels by inhibiting 
cholesterol absorption. In addition, dietary plant stanols decrease and plant sterols 
increase the serum plant sterol levels, whereas both phytosterol products increase the 
serum levels of cholesterol precursor sterols. Recent data have suggested that high 
serum plant sterol levels are associated with coronary heart disease (CHD), indicating 
that dietary plant sterols increasing their own serum concentrations could be harmful 
especially in subjects with high risk for CHD, such as patients with familial 
hypercholesterolemia (FH). Furthermore, statin treatment increases the serum plant 
sterol levels, but the data from combination therapy of statins and plant sterols are 
limited. Accordingly, we measured squalene and non-cholesterol sterols in serum, 
lipoproteins, and red cells of hypercholesterolemic subjects, mainly those with FH, at 
baseline and during consumption of dietary phytosterol esters off and on statin 
treatment. In addition, the effects of dietary phytosterols on clearance of postprandial 
lipoproteins were studied. 
Subjects and methods: In Study I, we measured non-cholesterol sterols in serum and 
different lipoproteins in 18 FH and 29 non-FH children. In Studies II and III, we 
studied the effects of dietary phytosterols on serum and red cell non-cholesterol sterol 
levels in 23 hypercholesterolemic children (aged 2-9 years) and in 18 statin-treated 
FH adults consuming 1.7-2.0 g/day of plant stanols and sterols for five and four 
weeks, respectively with a cross-over design. We evaluated the non-cholesterol sterol 
levels in different lipoproteins at baseline and during consumption of dietary 
phytosterol esters in Study III as well as in the FH family study (Study IV) including 
one homozygous FH subject. Study V was a substudy of Study III and consisted of 
five statin-treated FH subjects, in whom we evaluated the effects of dietary 
phytosterols on the clearance of postprandial lipids using intravenous Intralipid-
squalene fat emulsion.  
Results: Serum concentrations of non-cholesterol sterols were higher in FH than in 
non-FH children, whereas the ratios of non-cholesterol sterols to cholesterol in serum 
and lipoproteins were similar in the two groups. Low density lipoprotein (LDL) is 
responsible for the transport of the major part of the non-cholesterol sterols similarly 
as it transports cholesterol. The ratios of cholesterol precursors to cholesterol were 
higher in very low density lipoproteins (VLDL) than in serum, whereas those of plant 
sterols and cholestanol were mostly higher in high density lipoprotein (HDL) than in 
serum in both groups of children, in statin-treated FH subjects, and in the 
homozygous FH subject, also during consumption of dietary phytosterols. Serum 
total and LDL cholesterol were decreased by dietary phytosterol esters. In all 
intervention studies serum plant sterol concentrations and ratios to cholesterol were 
increased by up to 75% by plant sterol esters and decreased by up to 40% by plant 
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stanol esters. The increase of serum plant sterols by plant sterol esters was highest in 
those subjects with the highest baseline serum plant sterol levels, in 
hypercholesterolemic children and in statin-treated FH, whereas the highest serum 
baseline plant sterol ratios predicted the greatest decrease in serum plant sterols by 
the consumption of plant stanol ester spread. In particular, the changes occurring in 
the levels of plant sterols in red cells were in close correlation with the respective 
changes in serum. The ratios of serum cholesterol precursor sterols to cholesterol 
which can be viewed as a marker of increased cholesterol synthesis were increased in 
hypercholesterolemic children and also in statin-treated FH subjects. The changes of 
non-cholesterol sterols in lipoproteins were similar to those seen in serum. The 
consumption of dietary phytosterols unexpectedly impaired the clearance of Intralipid 
squalene, and to a lesser extent of plant sterols, especially in chylomicrons.  
Conclusions: Despite differences in the concentrations of non-cholesterol sterols in 
serum and lipoproteins, the ratios of non-cholesterol sterols to cholesterol in serum 
and lipoproteins were similar in FH and non-FH children. The different values of 
non-cholesterol sterols in lipoproteins compared with serum values suggest that even 
though the serum ratios of non-cholesterol sterols do provide some kind of picture of 
cholesterol metabolism in general, the ratios of non-cholesterol sterols in different 
lipoproteins may reveal more precisely the changes in cholesterol synthesis and 
absorption. The serum, lipoprotein, and red cell plant sterol levels were increased by 
plant sterol ester spread and decreased by plant stanol ester spread in all of the 
intervention studies, especially in those statin-treated FH subjects who had high 
baseline serum plant sterol levels. According to the literature, an increase in the 
serum plant sterol levels could be harmful to the arterial wall. The close correlation 
between serum and red cell plant sterol does suggest that the change of serum plant 
sterols is accompanied by respective change in the red cells. Thus, especially in FH 
subjects who already are at high risk of CHD, the dietary agents such as plant stanol 
esters, which lower both LDL cholesterol and plant sterol levels in serum are 
recommended for use as monotherapy and in combination with statins. The reason for 
impaired clearance of postprandial lipoproteins in statin-treated FH subjects is not 
clear, but could be related to altered lipoprotein metabolism due to impaired LDL 
apolipoprotein B receptor and statin therapy. 
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1. INTRODUCTION 
A high concentration of cholesterol in serum, i.e., hypercholesterolemia, is a well-
known risk factor for coronary heart disease (CHD). Familial hypercholesterolemia 
(FH) is an inherited disease leading in the heterozygous form to a two- to three-fold 
and in the homozygous form to a four- to five-fold increase in serum cholesterol 
levels compared with normolipidemic subjects. This elevation is accompanied by an 
increased risk for premature CHD (Goldstein et al. 2001). Early atherosclerotic 
lesions have been detected even in children with FH (Tonstad et al. 1996). Thus, early 
treatment with a diet low in saturated fat combined with medications, such as statins 
and bile acid sequestrants is recommended. 
Plant sterols and stanols, in general called phytosterols, are constituents of plants and 
have chemical structures which resemble cholesterol. Sitosterol and campesterol are 
the most common naturally occurring plant sterols, whereas their saturated 
derivatives sitostanol and campestanol are much less abundant in plant materials. 
Phytosterols lower serum cholesterol levels by inhibiting cholesterol absorption 
(Grundy et al. 1969, Heinemann et al. 1991), and since the 1950’s they have been 
used as cholesterol-lowering agents, first in a free form (Pollak and Kritchevsky 
1981) and recently mainly as esterified phytosterols (Katan et al. 2003). Plant stanol 
and sterol esters as monotherapy reduce low density lipoprotein (LDL) cholesterol by 
~15% in different study populations including FH subjects (Katan et al. 2003). A 
similar additional reduction in LDL cholesterol has been obtained by adding 
phytosterols to concurrent statin treatment. In addition, during consumption of plant 
stanol esters, the clearance of postprandial lipoproteins was improved in 
normolipidemic subjects (Relas et al. 2000), probably by an upregulation of the LDL 
apolipoprotein (apo) B receptors (Plat and Mensink 2002a). However, little is known 
about the effects of phytosterols on postprandial lipoproteins in FH. 
Dietary plant sterols, but not plant stanols, increase the concentrations of serum plant 
sterols (Vanhanen and Miettinen 1992b, Hallikainen et al. 2000), since ~5-10% of the 
plant sterols are absorbed from the intestine (Heinemann et al. 1993). In fact, even 
low amounts of dietary plant sterols consumed in their free form by children 
increased the serum plant sterol levels up to ~9 mg/dl (Mellies et al. 1976a). 
However, nothing is known about the effects of esterified plant sterols on serum plant 
sterol values in children. In addition to dietary plant sterols, statin treatment increases 
the serum plant sterol levels (Vanhanen et al. 1992, Miettinen et al. 2000a). 
Combination of plant sterols to statin treatment further increases the serum plant 
sterol levels (Neil et al. 2001), while plant stanols inhibit the statin-induced increase 
in serum plant sterols (Vuorio et al. 2000). 
In phytosterolemia, high serum concentrations of plant sterols (~20-93 mg/dl) put 
subjects at risk of suffering premature CHD (Björkhem et al. 2001). In addition, in 
non-phytosterolemic subjects, indirect evidence exists for an association between the 
increased levels of serum plant sterols and the risk of CHD (Glueck et al. 1991, 
Assmann et al. 2003). Further, serum plant sterols can be incorporated into red blood 
cell membranes (Salen et al. 1970), and increased levels of plant sterols in red cells 
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may increase their tendency to undergo hemolysis and the cells have decreased 
deformability (Bruckdorfer et al. 1969, Björkhem et al. 2001). Thus, these factors 
raise concerns about whether increased serum and red cell plant sterol levels may 
have harmful effects, especially in FH subjects with increased risk for CHD. 
In addition to cholesterol and plant sterols, serum contains small amounts of other 
non-cholesterol sterols and squalene. Of these, serum ratios of cholesterol precursor 
sterols to cholesterol reflect cholesterol synthesis, while those of plant sterols and 
cholestanol reflect cholesterol absorption (Miettinen et al. 1989, Miettinen et al. 
1990b). Non-cholesterol sterols and squalene are transported in lipoproteins, but only 
limited data exist on their distribution in different lipoproteins, especially in FH and 
during consumption of phytosterols. It was speculated that perhaps some additional 
information on cholesterol metabolism could be obtained by analyzing the squalene 
and non-cholesterol sterol levels in different lipoproteins. 
Therefore, the present study concentrated on serum, lipoprotein, and red cell levels of 
cholesterol, squalene, and non-cholesterol sterols in normolipidemic children and in 
hypercholesterolemic subjects, including children with FH, adults with heterozygous 
FH with or without statin treatment, and in one homozygous FH subject. In particular, 
we wanted to evaluate the effects of plant stanol and sterol esters on serum, 
lipoprotein, and red cell plant sterol values in these atherosclerosis-prone subjects. In 
addition, the effects of plant stanol and sterol esters on postprandial lipid clearance 
measured with an intravenously administered fat emulsion were evaluated.  
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2. REVIEW OF THE LITERATURE 
2.1. Overview of lipoprotein metabolism 
In addition to cholesterol, serum contains small amounts of squalene and non-
cholesterol sterols such as the cholesterol precursors ∆8-cholestenol, desmosterol, and 
lathosterol, and the plant sterols (mainly campesterol and sitosterol) and cholestanol. 
Since these lipids along with phospholipids and triglycerides (TG) are water-
insoluble, they are transported by lipoproteins in human blood. Lipoproteins carry the 
lipids between the site of their absorption i.e., small intestine, the liver, and 
extrahepatic tissues. Lipoprotein particles contain a hydrophobic core of TG and 
cholesterol esters, and a hydrophilic surface of free cholesterol, phospholipids, and 
apolipoproteins. Plasma lipoproteins are classified based on their density into five 
classes: chylomicrons (CM, d < 0.94 g/ml), very low density lipoprotein (VLDL, d = 
0.94-1.006 g/ml), intermediate density lipoprotein (IDL, d = 1.006-1.019 g/ml), LDL 
(d=1.019-1.063 g/ml), and high density lipoprotein (HDL, d = 1.063-1.210 g/ml). 
Due to their high TG content, CM and VLDL are called triglyceride-rich lipoproteins 
(TRL). The transport of different lipoproteins is summarized in the following text and 
in Figure 1. This summary is mainly based on references by Gotto (1986), Bruce et 
al. (1998) and Havel and Kane (2001). 
CM, which have a particle diameter of 75-1200 nm, are the largest lipoproteins. They 
are secreted by the enterocyte. ApoB-48, synthesized by the enterocyte, is the primary 
structural protein of CM, but CM contain also small amounts of apoA-I and apoA-II 
synthesized by the intestine. In addition, after secretion of CM, apoC-I-III and apoE 
are acquired by transfer from HDL. After absorption, TG, cholesterol, and other 
sterols are packed in CM and are transported via lymph to blood where most of the 
TG of the CM are hydrolyzed by lipoprotein lipase (LPL) on the surface of capillary 
endothelial cells to form CM remnants. Concomitantly, apoA, most of the apoC, and 
phospholipids are transferred to HDL by phospholipid transfer protein (PLTP). The 
remnant particles are taken up by the liver via several mechanisms that will be 
described in detail later. The sterols are either stored as esters, excreted into bile as 
such, or as acidic derivatives, or they can be released into circulation in VLDL.  
VLDL particles (30-80 nm) are synthesized in the liver and contain apoB-100 as the 
main structural protein. In addition, VLDL contains also apoC-I-III and apoE. VLDL 
particles transport not only endogenously synthesized sterols but also exogenously 
derived TG and sterols that are not excreted in bile. The release from the liver is 
followed by hydrolysis of TG by LPL similarly although slower than with CM, 
leading to the formation of VLDL remnant particles. As hydrolysis proceeds, 
phospholipids and most of the apoC are transferred to HDL by PLTP followed by 
transformation of the remnant particles into IDL particles (25-35 nm) and further by 
lipolysis by hepatic lipase (HL) into LDL. In humans, about 50% of VLDL is 
converted to LDL. Part of the remnants and IDL particles are taken up by the liver 
receptors, mostly via apoE. 
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LDL, with a particle diameter of 18-25 nm, is a major carrier of cholesterol in 
plasma. It contains only one molecule of apoB-100 as a structural protein. Most of the 
LDL particles are taken up into the liver by receptor-mediated pathways by 
recognition of apoB-100, but peripheral tissues that also contain LDL receptors can 
take up an appreciable portion of LDL. 
 
 
Figure 1. Overview of lipoprotein metabolism. 
A, apolipoprotein A; ABCA1, adenosine triphosphate-binding cassette transporter A1; B-48, 
apolipoprotein B-48; B-100, apolipoprotein B-100; C, apolipoprotein C; CETP, cholesterol 
ester transfer protein; CM, chylomicron; CMR, chylomicron remnant; E, apolipoprotein E; 
FFA, free fatty acids; HDL, high density lipoprotein; HL, hepatic lipase; HSPG, heparan 
sulfate proteoglycans; IDL, intermediate density lipoprotein; LCAT, lecithin:cholesterol 
acyltransferase; LDL, low density lipoprotein; LDL-R, low density lipoprotein receptor; LPL, 
lipoprotein lipase; LRP, low density lipoprotein receptor-related protein; PLTP, 
phospholipid transfer protein; SR-B1, scavenger receptor class B type 1 
HDL particle (5-12 nm) contains apoA-I, apoA-II, and apoA-IV, which are 
synthesized by the liver and intestine and are carried to HDL either as free apos or by 
PLTP from CM. HDL contains also apoC-I-III and apoE mainly transported from 
CM, VLDL, and their remnants by PLTP. HDL contains also small apoD originating 
from many tissues. Discoidal nascent pre-β-HDL contains apoA-I, phospholipids, and 
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cholesterol but not cholesterol esters. This nascent HDL carries lecithin:cholesterol 
acyltransferase (LCAT), which is capable of esterifying free cholesterol. The 
substrate for LCAT is derived from plasma membranes, where the adenosine 
triphosphate-binding cassette transporter A1 (ABCA1) facilitates the transport of free 
cholesterol to nascent HDL. As the cholesterol is esterified by LCAT, pre-β-HDL is 
matured to HDL. Cholesterol ester transfer protein (CETP) facilitates the transport of 
cholesterol esters in exchange for TG to apoB containing lipoproteins, which are 
taken up by the liver as explained above. HDL cholesterol can also be selectively 
taken up by the liver either via scavenger receptor class B type 1 (SR-B1) or in the 
case of a small part of apoE containing HDL via the LDL apoB receptor. TG derived 
from apoB containing lipoproteins in HDL are hydrolyzed by HL and smaller 
discoidal pre-β-HDL are regenerated to restart the cycle. Thus, HDL accompanied by 
CETP mediates the reverse cholesterol transport from the peripheral tissues to the 
liver to be eventually delivered into the bile. 
2.2. Phytosterols - structure, function, and sources 
Plant sterols and stanols, in general called phytosterols, resemble structurally 
mammalian cholesterol such that they are made of a tetracyclic 
cyclopent[a]phenanthrene ring with a 3β-hydroxyl group and an alkyl side chain at 
the C-17 carbon atom (Figure 2) (Piironen et al. 2000a). The most common 
phytosterols are 4-desmethyl sterols that lack methyl groups at C-4 position. They 
differ structurally from cholesterol in their side-chain substitution, in that campesterol 
possesses an additional methyl and sitosterol has an ethyl group at C-24 position. 
Some plant sterols, e.g., stigmasterol have a ∆22-double bond in their side chain. The 
position of double bond at B ring can also be changed, categorizing the plant sterols 
as ∆5-sterols, ∆7-sterols, or ∆5,7-sterols. Saturation of the ring structure at carbon 5 
leads to formation of plant stanols, such as campestanol and sitostanol. The 3β-
hydroxyl group may be esterified by a fatty acid or a phenolic acid to produce steryl 
esters (sterol esters), or it may be linked to a carbohydrate to form steryl glycosides or 
acyl steryl glycosides.  
Phytosterols are synthesized, as cholesterol, from acetyl coenzyme-A via squalene 
(Piironen et al. 2000a). They occur as membrane constituents in plants, where they 
regulate the fluidity and permeability of membranes (Hartmann 1998). They also 
serve as precursors for plant steroid hormones, the brassinosteroids (Clouse 2000). 
Phytosterol esters are located intracellularly and act as a storage form of the sterols. 
Human cells are not able to synthesize phytosterols (Salen et al. 1970). Thus, the only 
source of these sterols for humans is the diet. Various plant and marine materials 
include over 250 different phytosterols and related compounds (Akihisa et al. 1991), 
of which sitosterol (65%) is the most common, followed by campesterol (32%) and 
stigmasterol (3%) (Weihrauch and Gardner 1978, Björkhem et al. 2001). The intake 
of phytosterols varies among different populations according to the food products 
being consumed, but the average daily Western diet is reported to contain 150-300 
mg of these sterols (de Vries et al. 1997, Phillips et al. 1999, Björkhem et al. 2001). 
However, vegetarians may consume up to 1 g of phytosterols each day (Vuoristo and 
Miettinen 1994). 
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Figure 2. Structure of most common plant sterols and stanols. 
 
The major part of the dietary phytosterols are plant sterols, whereas the intake of 
saturated plant stanols is about 10% of the intake of plant sterols (Czubayko et al. 
1991). Vegetable oils and fats are the richest sources of plant sterols in diet 
(Weihrauch and Gardner 1978, Piironen et al. 2000a). In addition, cereals, nuts, 
seeds, vegetables, fruits, and berries contain different amounts of plant sterols.  On 
average, vegetable oils contain 100 to 500 mg of plant sterols per 100 g oil, while 
corn, rapeseed, rice bran, and wheat germ oils contain higher amounts of plant sterols. 
In Finland, the most common oil used in margarines, rapeseed oil, contains 700 mg 
plant sterol per 100 g oil (Piironen et al. 2000b). Accordingly, the soft margarines 
mostly used in Finland with fat contents from 40% to 80%, contain 130-540 mg/100g 
of plant sterols. From the cereal products mostly used in Finland, rye is the best 
source of plant sterols (~90 mg/100g of fresh weight) (Piironen et al. 2000b) and, 
accordingly, is an important source of plant sterols due to its high daily consumption. 
In addition, rye and wheat also contain plant stanols in small amounts (~20 mg/100g). 
Nuts and seeds are rich in plant sterols, the content ranging from 22 mg/100g 
(chestnut) to 714 mg/100g (sesame seed) (Weihrauch and Gardner 1978). Vegetables, 
fruits, and berries are poor sources of plant sterols (~5-40 mg/100 g of fresh weight) 
because of their high water content. 
2.3. Sterol absorption 
In addition to 150-300 mg of phytosterols, the diet in Western countries contains 
daily approximately 300-500 mg of cholesterol (Grundy 1983), which makes a 
miniscale (i.e., about 0.5%) contribution to the total dietary fat, the major part of 
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dietary fat being TG (95%) (Jones and Kubow 1999). In addition to dietary sterols, 
the intestinal sterols consist of biliary sterols (e.g., cholesterol 800-1200 mg/day) and 
of variable amounts of cholesterol synthesized by the intestinal cells (Grundy 1983, 
Wilson and Rudel 1994). All of the biliary sterols are in a free form, but the 
proportion of esterified sterols obtained from the diet varies greatly, ranging from 1% 
up to 73% for cholesterol (Vuoristo and Miettinen 2000), and from ~10% up to 80% 
for phytosterols (Piironen et al. 2000a). Thus, the bulk of intestinal sterols consists of 
up to 1.5-2.0 g of free and esterified sterols from endogenous and exogenous sources. 
On average, 40-60% of the dietary cholesterol is absorbed (Grundy 1983, Wilson and 
Rudel 1994), whereas despite the structural similarity, the intestinal absorption of 
phytosterols is much less. Thus, in humans, when measured with different techniques, 
the absorption of sitosterol and stigmasterol has been found to be ~5% (Gould et al. 
1969, Salen et al. 1970, Heinemann et al. 1993), while the absorption of campesterol 
is higher (~10-16%) (Heinemann et al. 1993, Lütjohann et al. 1995). Saturation of the 
∆5-double bond further decreases the absorption leading to absorption portions of 
~2% for plant stanols (Miettinen et al. 2000b, Miettinen et al. 2000c), even though up 
to 13% absorption of campestanol has also been observed (Heinemann et al. 1993). 
Recently, Ostlund et al. (2002) reported extremely low absorption rates for both plant 
sterols (0.5-1.9%) and stanols (0.04-0.16%) by using a dual stable isotopic tracer 
technique. These controversial results suggest that the reported absorption rates are 
dependent on the method used, or may be related to the small sample sizes employed 
(Heinemann et al. 1993). Generally, the absorption of different sterols decreases with 
an increased length of side chain in C-24 (Bhattacharyya 1981, Child and Kuksis 
1983, Heinemann et al. 1993). 
2.3.1. Absorption from intestinal lumen to enterocyte 
While the ingested fat is mostly water insoluble, the basic step in fat absorption is 
conversion of this hydrophobic oil to hydrophilic compounds that can be efficiently 
absorbed from the intestine. After emulsification and initial hydrolysis by lingual and 
gastric lipase, the hydrolysis of TG, phospholipids, and esterified sterols takes place 
in the small intestine principally by pancreatic lipases activated by colipase 
(Borgström 1975), cholesterol esterase (Vahouny et al. 1964), and phospholipase A2 
(van Deenen et al. 1963). However, in addition to free sterols, some absorption of 
esterified sterols also occurs (Compassi et al. 1995). While the hydrolyzed sterols still 
have only limited solubility in an aqueous environment, bile acids are needed to form 
micelles (Siperstein et al. 1952, Swell et al. 1958) to assist the sterols to diffuse 
across the unstirred water layer to reach the mucosal cell membrane (Westergaard 
and Dietschy 1976). The micellar solubility of phytosterols has been shown to be 
poorer than that of cholesterol (Slota et al. 1983, Armstrong and Carey 1987), thus 
partly explaining the low absorption rate of the phytosterols. 
The sterol absorption from the micelles occurs at the brush border membrane of the 
enterocyte. According to recent data, the cellular uptake is an active event mediated 
by a transport protein at the brush border membrane (Thurnhofer and Hauser 1990, 
Thurnhofer et al. 1991, Detmers et al. 2000). Two proteins, pancreatic esterase 
(Lopez-Candales et al. 1993) and SR-B1 (Hauser et al. 1998) have been postulated as 
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candidate transport proteins, but animal studies evaluating their role in sterol 
absorption has not been able to prove this hypothesis (Howles et al. 1996, Mardones 
et al. 2001, Altmann et al. 2002). Recent studies suggest that at least cholesterol 
uptake is mediated by a complex of several proteins (Kramer et al. 2003), and it has 
been postulated that Niemann-Pick C1 like 1 protein (Altmann et al. 2004) and a 
complex of proteins named annexin2 and caveolin (Smart et al. 2004) would have a 
critical role in the cholesterol absorption process.  
The enterocyte has a crucial role in regulating the uptake of sterols. Integral 
membrane proteins ABC transporters G5 (ABCG5) and G8 (ABCG8) (Berge et al. 
2000, Lee et al. 2001) at the apical surface of the enterocyte pump variable amounts 
of sterols back into intestinal lumen, thereby regulating the absorption of different 
sterols. In addition, ABCA1, located at the basolateral surface of the enterocyte has 
been suggested to have a role in sterol absorption (Repa et al. 2000, McNeish et al. 
2000), probably also promoting the efflux of sterols out of the enterocyte. However, 
the cholesterol absorption efficiency of patients with absent ABCA1 was similar as in 
non-affected subjects (Schaefer et al. 2001), suggesting that the role of ABCA1 in 
sterol absorption should be confirmed in humans. Overall, it has been proposed that 
the efflux from the enterocyte rather than the uptake of intestinal cells is the main 
process in determining the absorption of different sterols (Igel et al. 2003).  
In the endoplasmic reticulum of the enterocytes, cholesterol is re-esterified by 
acylcoenzyme A:cholesterol acyltransferase (ACAT) (Norum et al. 1979), which is 
capable of esterifying also sitosterol to some extent (Field and Mathur 1983). 
However, the limited esterification of sitosterol by ACAT (Field and Mathur 1983, 
Ikeda et al. 1988a) further contributes to the poorer absorbability of phytosterols. The 
newly formed sterol esters and TG along with apoB-48 are incorporated into CM this 
being facilitated by microsomal transfer protein (MTP) (Wetterau et al. 1997, Gordon 
and Jamil 2000) followed by transport via lymph to bloodstream. 
2.3.2. Factors affecting sterol absorption 
Cholesterol absorption efficiency exhibits a wide interindividual variation, ranging 
from 20% to 80% (Sehayek et al. 1998, Bosner et al. 1999). The reasons for this 
variablity are not completely understood, but several dietary, physiologic, and genetic 
factors can influence the absorption of cholesterol. Most studies have evaluated the 
effect of these factors on cholesterol absorption, whereas much less is known about 
the regulation of phytosterol absorption. 
The absorbed mass of dietary cholesterol is increased with the increased intake 
(Quintão et al. 1971a, Miettinen and Kesäniemi 1989, Sehayek et al. 1998, Ostlund et 
al. 1999), but the percentual absorption of cholesterol is reported to remain similar 
(Miettinen and Kesäniemi 1989, Sehayek et al. 1998, Bosner et al. 1999) or may even 
be decreased (McNamara et al. 1987, Ostlund et al. 1999). In subjects with a high 
intake of cholesterol, cholesterol absorption was lower in older subjects (75-year-old) 
than in the younger ones (50-year-old) (Gylling et al. 1994), while no age-related 
differences were reported in other studies with lower intakes of cholesterol (Bosner et 
al. 1999). Some conditions with metabolic disturbances, such as high-normal blood 
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glucose levels in non-diabetic subjects (Strandberg et al. 1996), type 2 diabetes 
(Simonen et al. 2002), and obesity (Miettinen and Gylling 2000) are associated with 
low cholesterol absorption efficiency. 
In the Finnish population with a high intake of cholesterol, apoE-4/4 and apoE-4/3 
phenotypes are related with the highest absorption efficiency of cholesterol in adults 
(Kesäniemi et al. 1987), in children (Tammi et al. 2001), and in FH (Gylling et al. 
1989a), while those with apoE-2 phenotype have been reported to absorb less 
cholesterol. However, the relationship between apoE phenotype and cholesterol 
absorption could not be seen in some other studies where there were different intakes 
of dietary cholesterol (Sehayek et al. 1998, von Bergmann et al. 2003) and in subjects 
consuming a diet low in cholesterol (Miettinen et al. 1992a, Bosner et al. 1999). 
The action of the ABC transporters is mediated by a nuclear hormone receptor called 
liver X receptor (LXR), which forms a heterodimer with another receptor, retinoid X 
receptor (Repa et al. 2000, Repa et al. 2002). These nuclear receptors are activated by 
oxysterols, thereby controlling the sterol absorption. The role of ABCG5 and ABCG8 
in the regulation of sterol absorption has been confirmed by the study by Yu et al 
(2002b), which showed that the overexpression of the two transporter genes reduced 
the fractional absorption of dietary cholesterol. In addition, polymorphisms in gene 
coding for ABCG8 have been found to affect the serum plant sterol levels (Berge et 
al. 2002), suggesting that sterol absorption is heritably controlled.  
Phytosterols interfere with cholesterol absorption (Grundy et al. 1969). The effects 
and mechanisms are described in detail later. However, even without added dietary 
phytosterols, the intake of phytosterols correlated negatively with the cholesterol 
absorption efficiency, thus contributing to lower total and LDL cholesterol levels 
(Miettinen et al. 2000b). This result indicates that phytosterols of normal food explain 
some variability of cholesterol absorption efficiency. 
In earlier studies with hypercholesterolemic and FH subjects, lovastatin and 
pravastatin decreased the cholesterol absorption efficiency (Miettinen et al. 1990a, 
Miettinen 1991, Vanhanen et al. 1992), while in another study there was no change in 
cholesterol absorption after pravastatin treatment (Vanhanen and Miettinen 1995). 
The reduced cholesterol absorption efficiency by statins was thought to be mediated 
by reduced ACAT activity in enterocytes (Ishida et al. 1989) and/or by reduced 
synthesis of bile acids (Miettinen 1991). However, in a recent study, atorvastatin 
increased the intestinal cholesterol absorption in subjects with type 2 diabetes who 
had low baseline absorption of cholesterol (Miettinen and Gylling 2003). Thus, it 
remains to be determined whether the effect of statins on cholesterol absorption 
depends on the statin used, or is it attributable to baseline cholesterol metabolism. 
The statin treatment leads to increased serum plant sterol levels (Uusitupa et al. 1992, 
Miettinen et al. 2000a), but the effect of statins on phytosterol absorption has not 
been studied. 
Ezetimibe is the first of a new class of the cholesterol absorption inhibitors. Recent 
studies suggest that Niemann-Pick C1 like 1 protein (Altmann et al. 2004) or a 
complex of annexin2 and caveolin proteins (Smart et al. 2004) are the possible targets 
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for the action of this drug. Ezetimibe inhibits cholesterol absorption by 54% 
compared with placebo with ~20% reduction in LDL cholesterol (Sudhop et al. 
2002b). Due to the compensatory increase of cholesterol synthesis, ezetimibe is 
recommended to be used in combination with statins. Other cholesterol absorption 
inhibitors such as ACAT and MTP inhibitors have also been under recent 
pharmacological development (Sudhop and von Bergmann 2002). 
The cholesterol absorption efficiency correlated positively with serum total and LDL 
cholesterol levels in a random Finnish male population (Kesäniemi and Miettinen 
1987, Miettinen and Kesäniemi 1988, Miettinen and Kesäniemi 1989) but not in 
postmenopausal women (Karjalainen et al. 2000). In addition, there was no 
association between the cholesterol absorption efficiency and serum lipids in recent 
studies (Sehayek et al. 1998, Bosner et al. 1999), probably due to large variability in 
cholesterol absorption efficiency and the use of different methods. However, only 
insignificant correlations between cholesterol synthesis and serum lipid levels have 
been reported (Miettinen and Kesäniemi 1989, Miettinen et al. 1990b), suggesting 
that cholesterol absorption is a more important determinator of serum lipid levels than 
cholesterol synthesis. Thus, the factors regulating the cholesterol absorption may also 
have an effect on serum total and LDL cholesterol levels. 
2.3.3. Measurement of sterol absorption 
Sterol absorption can be measured by several different methods, mostly based on the 
use of radioactive compounds (Borgström 1969, Quintão et al. 1971b, Sodhi et al. 
1974, Crouse and Grundy 1978, Samuel et al. 1978), and thus these are not at all 
suitable e.g., for children. Even though a recently developed method to study 
cholesterol absorption by stable isotopes (Bosner et al. 1993, Lütjohann et al. 1993) 
avoids the use of radioactive tracers, the measurement of cholesterol absorption by 
this method is still laborious. The ratios of serum plant sterols and cholestanol, a 
metabolite of cholesterol, to cholesterol are positively correlated with the cholesterol 
absorption efficiency measured by sterol balance technique (Tilvis and Miettinen 
1986, Miettinen et al. 1989, Miettinen et al. 1990b) and are thus called cholesterol 
absorption markers. Accordingly, measurement of these non-cholesterol sterols by 
gas liquid chromatography (GLC) provides a simple method to assess cholesterol 
absorption and is especially suitable in large-scale studies and for detecting changes 
in cholesterol absorption during experimental studies. 
2.3.4. Cholestanol  
Cholestanol is a 5α-saturated derivative of cholesterol. Less than 2 mg/day 
cholestanol is present in the Finnish diet, and the absorption of cholestanol is only 
~9% (Blomstrand and Gürtler 1968). Endogenous synthesis of cholestanol from 
cholesterol occurs in liver at a rate of ~12 mg/day. In serum, cholestanol is 
transported in lipoproteins, mainly in LDL (Salen and Grundy 1973). Elimination of 
cholestanol occurs via bile as such or as its acidic conversion products (Salen and 
Grundy 1973).  
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Considering the low dietary intake and low absorption of cholestanol in conjunction 
with the finding that during consumption of a cholestanol-free diet, the serum 
cholestanol levels remained fairly stable, it seems that most of serum cholestanol is 
derived from endogenous cholestanol synthesis. However, it has been shown that 
serum levels of cholestanol are heritably controlled (Gylling and Miettinen 2002b), 
and that polymorphisms in ABCG8 contributes to serum cholestanol levels (Berge et 
al. 2002). This would suggest that serum cholestanol levels are regulated by intestinal 
absorption and biliary secretion, since ABC transporters regulate these two metabolic 
events. In fact, the study by Yu et al. (2002a) revealed that in ABCG5/G8 knockout 
mice in addition to plant sterols, the absorption of dietary cholestanol was increased. 
In addition, reduction of biliary secretion of sterols by ursodeoxycholic acid increased 
the serum cholestanol levels (Lindenthal et al. 2002), indicating that biliary excretion 
of cholestanol has a role in the regulation of its serum levels. Thus, the regulation of 
serum cholestanol levels is not totally understood, but it seems that ABCG 
transporters in intestine and liver could at least partly regulate the serum levels of 
cholestanol. Accordingly, upregulation of intestinal ABCG5 and/or G8 would lead to 
decreased absorption of cholesterol as well as cholestanol. Subsequently, the serum 
levels of cholestanol would be decreased, and thus could be used as a marker of 
decreased cholesterol absorption. This would provide one explanation for the 
correlation between serum ratios of cholestanol and cholesterol absorption efficiency 
(Miettinen et al. 1989). 
Serum plant sterol ratios are not reliable markers of cholesterol absorption efficiency 
during consumption of dietary phytosterols (Vanstone and Jones 2004). Instead, 
measurement of serum cholestanol ratios does offer a method to evaluate cholesterol 
absorption efficiency also in that state. Accordingly, cholesterol malabsorption 
induced by consumption of phytosterol esters leads to a ~6-15% decrease in serum 
cholestanol to cholesterol ratios (Gylling and Miettinen 1994b, Miettinen and 
Vanhanen 1994a, Gylling et al. 1997, Gylling et al. 1999, Hallikainen et al. 2000), 
also in FH children (Gylling et al. 1995, Vuorio et al. 2000) and FH adults receiving 
statin treatment (Vuorio et al. 2000). However, also non-significant changes in serum 
cholestanol ratios have been reported (Vanhanen and Miettinen 1992b, Vanhanen et 
al. 1993, Vanhanen et al. 1994).  
Statin treatment, on the other hand, increases the serum ratios of cholestanol to 
cholesterol (Miettinen and Gylling 2003, Miettinen et al. 2003), probably by inducing 
the increase in cholesterol absorption (Miettinen and Gylling 2003). However, the 
increase in serum cholestanol ratios to cholesterol was diminished by unknown 
reasons in the course of a 5-year study with simvastatin (Miettinen et al. 2000a). High 
serum baseline cholestanol, reflecting high cholesterol absorption and low cholesterol 
synthesis, predicted a poor response to statin treatment with increased risk for 
recurrent coronary events in a long-term study with simvastatin compared with the 
subjects with low baseline cholestanol levels (Miettinen et al. 1998). This suggests 
that a subgroup of patients not responding to statin treatment could be revealed by 
measuring serum cholestanol levels. This would offer an opportunity to treat such 
patients with a combination of statins and cholesterol absorption inhibitors. 
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2.4. Postprandial lipoproteins 
Postprandial lipoproteins are reflections of the lipids appearing in blood circulation 
mostly in CM and CM remnants after a fatty meal. Many genetic, environmetal, and 
dietary factors regulate the elimination of postprandial lipids. Since 1970’s it has been 
known that postprandial lipids are associated with CHD (Zilversmit 1979). Further, it 
was shown that especially the remnants of TRL were atherogenic (Havel 1994, Karpe 
1999). VLDL synthesized by the liver with apoB-100 as its structural protein has the 
same density as CM remnants with apoB-48. Lipoproteins with apoB-48 and apoB-
100 compete for the same lipolytic pathway (Karpe et al. 1993, Björkegren et al. 
1996) which explains the significant increase in apoB-100 containing lipoproteins in 
postprandium (Cohn et al. 1988, Karpe et al. 1993). Thus, in addition to apoB-48 
containing lipoproteins, TRL in postprandial serum include also apoB-100 containing 
lipoproteins. 
2.4.1. Liver receptors 
After formation of CM by the enterocyte, they are released and lipolyzed by LPL, 
resulting in the formation of CM remnants. The clearance of CM remnants is 
dependent on apoE, which is bound to heparan sulfate proteoglycans (HSBG) in the 
space of Disse (Cooper 1997). In addition to apoE, HL facilitates the endocytosis of 
remnants to different receptors involved in uptake of CM remnants. The most 
important receptors are LDL apoB receptor and LDL receptor-related protein (LRP), 
but also other receptors, such as liver cell remnant receptor, asialoglycoprotein, and 
lipolysis stimulated receptor have been reported to participate in this process (Cooper 
1997, Mahley and Ji 1999). In addition, remnants may be taken up directly by HSBG. 
In mice, ~50-60% of the CM remnant clearance is thought to be mediated by LDL 
apoB receptor (Cooper 1997), but the role of different receptors in the clearance of 
remnants in humans is unclear. 
2.4.2. Measurement of postprandial lipoproteins 
Vitamin A added to fat meals can label postprandial lipoproteins (Hazzard and 
Bierman 1976, Weintraub et al. 1987), but it was found also in more dense 
lipoproteins. Thus, apoB-48 was suggested to be a more reliable marker of 
postprandial lipoproteins (Krasinski et al. 1990, Karpe et al. 1993). Due to laborious 
determination of apoB-48, simple markers for postprandial lipoproteins were needed. 
Accordingly, in addition to single measurement of apoB-48 (Smith et al. 1999) and 
remnant-like particle (RLP) cholesterol (Nakajima et al. 1993), squalene was found to 
reflect postprandial lipoproteins (Gylling and Miettinen 1994a, Rajaratnam et al. 
1999). In fact, squalene labeled postprandial lipoproteins even more specifically than 
vitamin A, and the postprandial curves resembled those of apoB-48 (Rajaratnam et al. 
1999). Most recently, a breath test using a stable isotope was validated to provide 
information about CM remnant metabolism (Redgrave et al. 2001).  
CM-like emulsions have been used to assess more accurately the metabolism of TRL 
(Hallberg 1965, Carlson and Rössner 1972), and in this way one can avoid the intra-
individual differences in intestinal absorption of lipids. One example of these 
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emulsions is commercially available Intralipid, which is rich in plant sterols (Carlson 
and Rössner 1972, Björkegren et al. 1996). In plasma, apolipoproteins from 
circulating lipoproteins become attached to the emulsions (Carlson 1980), and this 
particle activates LPL. The metabolism of the CM-like emulsion resembles mostly 
the metabolism of CM (Carlson and Rössner 1972, Redgrave et al. 1987), even 
though also slower clearance rates for emulsions have been reported (Hultin et al. 
1995). Double-labeling of the CM-like emulsions revealed diminished removal of 
postprandial lipoproteins in CHD (Maranhão et al. 1996) and their enhanced removal 
during lipid-lowering medication (Santos et al. 2000). To avoid the use of radioactive 
labels, a second possibility is to add squalene to Intralipid in order to measure 
postprandial lipoproteins (Relas et al. 2001b).  
2.5. Phytosterols in blood 
2.5.1. Serum and lipoprotein phytosterols 
Due to their low absorption and effective excretion, only small amounts (~0.7-1.0 
mg/dl) of phytosterols may be detected in normal human serum, thus accounting for 
less than 1% of respective cholesterol levels (Salen et al. 1970, Tilvis and Miettinen 
1986, Björkhem et al. 2001). In order to eliminate the influence of varying cholesterol 
concentrations, the phytosterol values are usually standardized and expressed, in 
addition to concentrations, also as ratios to cholesterol, in terms of 102 x mmol/mol of 
cholesterol. In a random Finnish adult population aged 52 years, the average serum 
sitosterol ratio was 122±11 102 x mmol/mol of cholesterol and serum campesterol 
ratio 190±17 102 x mmol/mol of cholesterol (Nissinen et al. 2000). An extensive 
inter-individual variation exists in serum plant sterol levels, which were recently 
found to be heritably controlled (Gylling and Miettinen 2002b) by polymorphisms in 
the ABCG8 transporter gene (Berge et al. 2002). Hypercholesterolemic subjects, such 
as subjects with FH, have elevated concentrations of serum plant sterols, probably 
due to increased amounts of LDL. However, even when adjusted to the respective 
cholesterol values, the levels of plant sterols in serum were higher in the FH men 
compared with the randomly selected healthy men (Gylling and Miettinen 1988). In 
serum, LCAT is capable of esterifying plant sterols (Nordby and Norum 1975) and 
the esterification percentage of plant sterols resembles that of cholesterol. 
Accordingly, approximately 70% of plant sterols in serum are transported in an 
esterified form (Salen et al. 1970, Tilvis and Miettinen 1986). Plant stanols are 
present in serum only in trace amounts (~0.03 mg/dl), and they are usually detectable 
only after consumption of plant stanol esters (Gylling et al. 1999).  
Only a few studies have defined the distribution of phytosterols in different 
lipoproteins in humans. The concentrations of plant sterols seem to parallel those of 
cholesterol. Thus, LDL and HDL are the major transporters of phytosterols. However, 
as ratios to cholesterol, plant sterols are mostly accumulated in HDL in subjects with 
familial hypertriglyceridemia (Tilvis and Miettinen 1986), in FH with and without 
ileal bypass (Koivisto and Miettinen 1988a), and in type 2 diabetes (Miettinen and 
Gylling 2003). On the other hand, the lowest ratios of plant sterols were seen in 
VLDL. It has been suggested that the high ratios of plant sterols in HDL could be 
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associated with reverse cholesterol transport by HDL, as shown in sitosterolemia 
(Robins and Fasulo 1997).  
2.5.2. Red cell phytosterols 
The red cell has a complex cell membrane composed of mainly lipids and proteins 
and an interior containing metabolic mechanisms e.g., those involved in hemoglobin 
synthesis (Mohandas and Morrow 2000). The lipid compartment of the membrane 
contains in addition to phospholipids and free cholesterol also other sterols, including 
plant sterols (Kuksis et al. 1976). Since red cells are not able to synthesize sterols, all 
the sterols in the cell membrane must be obtained from the plasma. Indeed, sterols are 
freely exchanged and there seems to be an equilibrium between plasma and red cells 
(Ashworth and Green 1964, Salen et al. 1970). Cholesterol is taken up by the red cells 
more readily than the plant sterols (Edwards and Green 1972, Child and Kuksis 1982, 
Child and Kuksis 1983), possibly due to the longer side chain present in plant sterols. 
However, other sterols, including plant sterols and lathosterol, may replace a small 
amount (~20-30%) of cholesterol in red cells (Bruckdorfer et al. 1969, Edwards and 
Green 1972). The regulated assembly of proteins and lipids in the membrane leads to 
the unique shape of the red cell and its ability to become deformed during its passage 
through the narrow blood vessels in the circulation. Any disruption to the structure of 
the red cell, as a result of changes in any of its components, may lead to altered cell 
shape, deformability characteristics, and overall hemorrheology properties. Thus, 
increased levels of cholesterol in red cells in hypercholesterolemic subjects may lead 
to increased osmotic fragility and decreased deformability (Kanakaraj and Singh 
1989, Kohno et al. 1997). Statins decrease the cholesterol level in red cells and result 
in improvement of reduced red cell deformability and blood rheology (Martínez et al. 
1996, Kohno et al. 1997, Koter et al. 2002). 
In phytosterolemia the total plant sterol content in red cells is high (12-13 mg/dl) 
(Bhattacharyya and Connor 1974), possibly causing the episodes of hemolysis 
(Björkhem et al. 2001) due to the increased fragility of the red cells (Bruckdorfer et 
al. 1969). In addition, in stroke-prone spontaneously hypertensive rats, plant sterol-
enriched diet increased the red cell concentrations of plant sterols and made the red 
cells less deformable (Ratnayake et al. 2000, Naito et al. 2003). In rats the increase of 
plant sterols in red cells by feeding a sterol-enriched diet was three to four times 
higher than the respective increase of plant stanols from a stanol-enriched diet 
(Ratnayake et al. 2003). In addition, the deformability of the red cells was lower by 
the sterol-enriched diet than with the stanol-enriched diet. Hence, the increase of 
plant sterols in red cells seems to contribute to their reduced deformability. However, 
the life span of the rats was reduced even more with the plant stanol- than with the 
plant sterol-enriched diet (Ratnayake et al. 2003). Moreover, in apoE-deficient mice, 
a reduction of serum cholesterol by plant sterols appeared to be protective to their red 
cells (Moghadasian et al. 1999b). There is little information about the effects of 
consumption of phytosterols on the red cell phytosterol levels in humans. In a recent 
study, consumption of 1.6 g/day of plant sterols esters by 89 adult 
hypercholesterolemic subjects increased the total plant sterol concentrations in red 
cells by ~80% without having any effect on red cell deformability (Hendriks et al. 
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2003). The dietary plant sterol esters did not affect red cell cholesterol concentrations, 
and thus it was concluded that plant sterols could not replace cholesterol in red cell 
membranes. 
2.5.3. Effects of dietary phytosterols on their serum levels 
Dietary intake of plant sterols reflects their serum levels (Salen et al. 1970, Vanhanen 
and Miettinen 1992b). In vegetarians who have a high dietary intake of plant sterols, 
serum levels of plant sterols can be doubled compared with controls (Vuoristo and 
Miettinen 1994). The effect of dietary phytosterols on the respective levels in serum 
has been evaluated in several studies, but no data exist on the phytosterol distribution 
in different lipoproteins during phytosterol-enriched diet.  
Plant sterols, even from normal food, affect their serum levels, since consumption of 
rapeseed oil spreads, containing naturally ~360 mg/100 g of plant sterols, increases 
the levels of serum plant sterols (Vanhanen and Miettinen 1992b, Vanhanen et al. 
1993, Miettinen and Vanhanen 1994b). The major increase (up to 50-60%) occurs in 
campesterol compared with an up to 20% increase in sitosterol.  
Phytosterol-enriched diet 
The effect of phytosterol-enriched diet on serum levels of phytosterols has been 
studied by adding free or esterified phytosterols to the diet with daily doses ranging 
from 0.7 g up to 18 g. In earlier studies with free plant sterols, daily intake of 18 g of 
soy derived plant sterols led to extremely high serum plant sterol levels (Lees et al. 
1977). Accordingly, the serum campesterol concentration increased up to 21 mg/dl 
and sitosterol up to 0.8 mg/dl. However, in the same study, daily consumption of 3g 
of tall oil sterols led to only a moderate increase (up to 2.5 mg/dl) in plasma plant 
sterol levels. Even smaller doses (0.7-1 g/day) of dietary sitosterol resulted in a 40% 
increase in plasma sitosterol levels (Vanhanen and Miettinen 1992b, Miettinen and 
Vanhanen 1994a). In infants fed commercial formulas enriched with vegetable oils 
containing 300-400 mg/day of plant sterols, the serum total plant sterol concentration 
was increased up to 9 mg/dl (Mellies et al. 1976a). The authors speculated that 
children have a limited capability to discriminate between these sterols in terms of 
their absorption. On the other hand, consumption of 12 g/day of free sitosterol 
increased the serum sitosterol levels only up to 1.5 mg/dl in children and adolescents 
aged 8 to 20 years (Schlierf et al. 1978), and only a 14-22% increase in serum 
sitosterol was reported in children aged 5 to 11 and 10 to 14 years during daily 
consumption of 6 g of free sitosterol (Becker et al. 1992, Becker et al. 1993). 
However, there are no studies evaluating the effects of the dietary plant sterols in 
their esterified form on serum plant sterol levels in children. 
In adults, consumption of plant sterol esters with doses of 1.6-2.4 g/day increased the 
levels of serum campesterol by 50-90% and serum sitosterol by 35-40% in different 
hypercholesterolemic populations (Weststrate and Meijer 1998, Jones et al. 2000, 
Hallikainen et al. 2000, Nestel et al. 2001, Mussner et al. 2002, Hendriks et al. 2003). 
The absolute increase was highest in subjects with the highest baseline serum plant 
sterol levels (Hendriks et al. 2003). Despite the marked percentual increase of serum 
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plant sterol levels during consumption of plant sterol ester products, the mean 
concentrations of total plant sterols have remained < 2.0 mg/dl, even in subjects with 
heterozygous phytosterolemia (Stalenhoef et al. 2001, Kwiterovich et al. 2003).  
On the other hand, since plant stanols inhibit also the absorption of plant sterols, the 
consumption of free (Vanhanen and Miettinen 1992b, Becker et al. 1993, Miettinen 
and Vanhanen 1994a) and esterified (Vanhanen et al. 1993, Vanhanen et al. 1994, 
Gylling et al. 1995, Gylling et al. 1999, Hallikainen et al. 2000) plant stanols decrease 
the serum levels of both campesterol and sitosterol by 15-45%. The decrease of 
serum plant sterols is negatively correlated with the respective baseline levels, 
suggesting that serum plant sterols are decreased more in subjects with high baseline 
plant sterol levels and high sterol absorption (Vanhanen et al. 1993, Gylling et al. 
1995, Gylling et al. 1997, Vuorio et al. 2000). The percentual increase of serum plant 
stanols by consumption of plant stanols is even higher than that of plant sterols during 
consumption of a sterol-enriched diet. However, the actual amounts remain very 
small, ranging from 11 µg/dl to 16 µg/dl for campestanol and from 27 µg/dl to 53 
µg/dl for sitostanol (Gylling et al. 1999, Hallikainen et al. 2000).  
2.5.4. Phytosterol elimination  
The absorbed phytosterols are mostly eliminated through bile, even though some 
excretion via the skin surface may also occur (Bhattacharyya et al. 1983). The 
secretion of campesterol and sitosterol through bile occurs along with cholesterol and 
is dependent on ABCG5 and ABCG8 (Berge et al. 2000). Biliary secretion of plant 
sterols is more rapid than that of cholesterol (Salen et al. 1970, Sudhop et al. 2002c), 
and campesterol is excreted slower than sitosterol (Sudhop et al. 2002c). In addition, 
the turnover of plant stanols is more rapid than that of plant sterols (Ostlund et al. 
2002). Thus, in addition to low absorption, the rapid excretion of phytosterols 
contributes to their low serum concentrations. Conflicting results exist on whether 
plant sterols can be converted into acidic products. In an earlier human study (Salen 
et al. 1970), sitosterol was converted to bile acids, but this has not been confirmed in 
further studies (Boberg et al. 1990). The unabsorbed plant sterols pass through the 
intestine and are partly converted to bacterial products, coprostanols and 
coprostanones (Miettinen et al. 1965, McNamara et al. 1981), whereas the 
unabsorbed plant stanols seem to be quite resistant to bacterial action. 
2.5.5. Effects of lipid-lowering medications on serum phytosterols  
2.5.5.1. Statins 
After an initial decrease due to the marked decrease in LDL cholesterol levels, the 
concentrations of plant sterols are increased during statin treatment (Miettinen et al. 
2000a). In addition, statins cause a consistent increase in the ratios of serum plant 
sterols to cholesterol in short- (Uusitupa et al. 1992, Vanhanen et al. 1992, Vanhanen 
and Miettinen 1992a) and long-term studies (Miettinen et al. 2000a, Miettinen and 
Gylling 2003, Miettinen et al. 2003). Long duration (Miettinen et al. 2000a) and high 
dose (Miettinen et al. 2003) statin treatment, and higher baseline absorption of sterols 
(Miettinen et al. 2000a) are the major factors predicting the increase of plant sterols 
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during statin treatment. The increased serum plant sterol levels by statins are most 
likely due to diminished excretion of plant sterols through bile (Miettinen 1991). 
Additionally, reduced biliary excretion of cholesterol (Gylling and Miettinen 1996) 
depletes the intestinal cholesterol pool, most likely favoring the absorption of dietary 
plant sterols (Miettinen and Gylling 2003). In fact, decreased biliary excretion of 
sterols has been shown to be related to the increased serum levels of plant sterols 
(Miettinen et al. 1990b). 
Two studies conducted with hypercholesterolemic subjects, including those with FH, 
have evaluated the effects of combination of statins and dietary plant sterol esters on 
serum plant sterol levels (Neil et al. 2001, O'Neill 2003). Accordingly, daily doses of 
1.4 g and 2.5 g of dietary plant sterols revealed ~40% and ~20% increase in serum 
campesterol and sitosterol levels, respectively, when compared with baseline values 
(O'Neill 2003) or with the placebo group (Neil et al. 2001). On the other hand, by 
combining plant stanol esters to statin treatment, the serum levels of both campesterol 
and sitosterol can be decreased by about 30% (Vanhanen 1994, Gylling and Miettinen 
1996, Vuorio et al. 2000, Gylling and Miettinen 2002a, Gylling and Miettinen 
2002c). Combination of a statin and plant stanols results in even lower levels of 
serum plant sterols than were present at baseline before the statin treatment was 
started. Accordingly, plant stanol esters prevent the increase of serum plant sterol 
levels caused by statin treatment.  
2.5.5.2. Other lipid-lowering medications 
Bile acid sequestrants increase the fecal elimination of cholesterol as bile acids and 
decrease the absorption of cholesterol (McNamara et al. 1980, Gylling et al. 1989b). 
However, with respect to the absorption markers, serum plant sterol levels are 
increased in monotherapy (Gylling et al. 1989b) as well as in combination with 
statins (Uusitupa et al. 1992). This increase is thought to be caused by reduced biliary 
excretion of plant sterols. However, in phytosterolemic subjects, the serum plant 
sterol levels are efficiently decreased by bile acid sequestrants due to enhanced fecal 
elimination of plant sterols and sequentally increased synthesis of bile acids 
(Björkhem et al. 2001).  
Fibrates decrease the serum ratios of plant sterols to cholesterol by about 30-40% due 
to enhanced biliary excretion and subsequently decreased absorption of sterols 
(Miettinen et al. 1992b, Vanhanen and Miettinen 1995). However, in combination 
with statins, the serum levels of plant sterols return to levels obtained at baseline 
(Miettinen et al. 1992b, Vanhanen and Miettinen 1995). The newest lipid-lowering 
drug, ezetimibe, inhibits the absorption of cholesterol, and recently was shown to 
decrease serum campesterol and sitosterol levels by 48% and 41%, respectively, in 
hypercholesterolemic subjects (Sudhop et al. 2002b).  
2.5.6. Phytosterolemia 
Phytosterolemia, or sitosterolemia, is a rare (prevalence 1:1 000 000) recessively 
inherited disease characterized by high serum plant sterols levels accompanied by 
subcutaneous and tendon xanthomas, episodes of hemolysis and arthralgias, and most 
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importantly development of atherosclerosis at a young age (Bhattacharyya and 
Connor 1974, Björkhem et al. 2001). The genetic basis of this disease was recently 
resolved by identifying mutations in genes coding ABC transporters G5 and G8 
(Berge et al. 2000, Lu et al. 2001) located in chromosome 2p21 (Patel et al. 1998). 
These two genes are expressed in the intestine and liver (Berge et al. 2000), thus 
contributing to the fundamental metabolic defects in phytosterolemia; increased sterol 
absorption and decreased sterol excretion through bile (Miettinen 1980, Björkhem et 
al. 2001). Accordingly, serum contains extremely high concentrations of serum plant 
sterols, ranging from 20 mg/dl to 94 mg/dl (Björkhem et al. 2001, Berge 2003). The 
most abundant plant sterol in serum is sitosterol, whereas campesterol concentrations 
amount to approximately half of those of sitosterol (Salen et al. 1985, Lütjohann et al. 
1995). Most patients have also increased serum levels of plant stanols and cholestanol 
(Salen et al. 1985, Björkhem et al. 2001). The phytosterols are mainly (75-85%) 
transported in LDL (Bhattacharyya and Connor 1974, Miettinen 1980, Salen et al. 
1985), while HDL contains mostly the remainder. In addition to increased serum 
levels, plant sterols are also accumulated in red cells (Bhattacharyya and Connor 
1974), which is the probable reason for hemolysis and increased fragility of the red 
cells (Björkhem et al. 2001). 
In homozygous patients, the absorption of sitosterol is increased by up to ~60% while 
the absorption of cholesterol is reported to be only slightly higher than in controls and 
mostly within the high normal range (Björkhem et al. 2001). This slight increase in 
cholesterol absorption and reduced biliary output leads to moderately increased serum 
cholesterol levels in most subjects. Heterozygous subjects are clinically normal, in 
comparison with control subjects, they have only slightly higher serum plant sterol 
levels due to the slight increase in plant sterol absorption (Salen et al. 1992). The 
higher increase of serum plant sterols by heterozygotes is avoided by the extensive 
excretion of plant sterols into bile (Salen et al. 1992).  
A diet low in cholesterol and plant sterols (Miettinen 1980, Nguyen et al. 1991, Cobb 
et al. 1997) usually results in a rapid decrease in serum plant sterol levels. In addition, 
cholestyramine (Miettinen 1980, Salen et al. 1985, Nguyen et al. 1991), and plant 
stanols (Lütjohann et al. 1995) have been used as strategies to decrease serum plant 
sterols. The recent study by Salen et al. (2004) showed that ezetimibe decreased 
serum sitosterol and campesterol levels by 21% and 24%, respectively, in 
phytosterolemic patients, providing a new tool for treatment of these patients. 
2.5.7. Phytosterols and CHD 
The finding of phytosterolemia led to speculations that plant sterols may have a role 
in atherogenesis. Plant sterols are found in human atheromas even in non-
phytosterolemic subjects, even though their concentrations are lower than that of 
cholesterol (Mellies et al. 1976b). However, plant sterol feeding in different animal 
studies (hamsters, mice, and rabbits) has revealed prevention and regression of 
atherosclerotic lesions (Ikeda et al. 1981, Moghadasian et al. 1997, Moghadasian et 
al. 1999a, Ntanios et al. 2003). Similar results were obtained by feeding plant stanols 
to mice and rabbits (Ntanios et al. 1998, Volger et al. 2001). In one study in rabbits, 
sitostanol was more effective than sitosterol at preventing the formation of atheromas 
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(Ikeda et al. 1981). Furthermore, it was recently shown that only trace amounts of 
plant sterols and stanols were deposited in the aortas of rabbits fed sitosterol and 
sitostanol preparations (Kritchevsky et al. 2003). 
In humans, Glueck and co-workers (1991) demonstrated that high serum plant sterol 
levels were associated with increased premature CHD independent of serum 
cholesterol levels. In addition, in subjects admitted to elective coronary artery bypass 
graft operation, a high serum plant sterol level predicted a positive family history of 
CHD (Sudhop et al. 2002a). Further, it was shown that a high plasma sitosterol level 
was associated with the increased extent and severity of angiographically measured 
CHD (Sutherland et al. 1998), and that increased ratios of serum plant sterols to 
cholesterol were independent risk factors of CHD in a randomly selected population 
of postmenopausal women (Rajaratnam et al. 2000). These findings were recently 
confirmed in a long-term follow-up population study where an increased risk of 
coronary events was noted in the fourth quartile of serum sitosterol with the mean 
concentration of >0.2 mg/dl as compared with other quartiles (Assmann et al. 2003). 
Thus, there is accumulating indirect evidence from human studies to suggest that 
there is an association between serum plant sterol levels and CHD. Whether this 
association is solely due to increased cholesterol absorption (indicated by high serum 
plant sterol ratios) or whether plant sterols have an independent role in development 
of atherosclerosis is not known. 
2.6. Cholesterol lowering effects of dietary phytosterols  
2.6.1. A short history 
The hypocholesterolemic property of dietary plant sterols was demonstrated over 50 
years ago (Pollak 1953). Earlier human studies consisted of interventions using 
mostly large daily doses (3-18 g) of plant sterols in their unesterifed form resulting in 
a mean of 10-20% reduction in serum cholesterol concentrations (Lees et al. 1977, 
Pollak and Kritchevsky 1981, Pollak 1985) due to inhibition of cholesterol absorption 
(Grundy et al. 1969). The poor solubility and the increase in serum plant sterol levels 
due to the high intake of free plant sterols led to preparations of plant sterol esters 
(Mattson et al. 1977, Mattson et al. 1982). These esterified sterols lowered serum 
cholesterol levels similarly as the free sterols even though there was a slightly lower 
inhibition of cholesterol absorption (33% reduction by esterified vs. 42% reduction 
by free sterols).  
Plant stanols in an unesterified form were synthesized from plant sterols, and in 
experimental animals were shown to decrease serum cholesterol levels even more 
efficiently than plant sterols (Sugano et al. 1977, Ikeda et al. 1981). However, in the 
study by Denke (1995), plant stanols in a poorly fat-soluble form even at a high dose 
(3 g/day) did not evoke any reduction in serum cholesterol. Thus, to make plant 
stanols more fat-soluble, they were transesterified making them more easily 
dissolvable in dietary oil and spreads. Accordingly, subsequent several short-term 
studies (Vanhanen et al. 1993, Miettinen and Vanhanen 1994a, Gylling and Miettinen 
1994b, Vanhanen et al. 1994) and one long-term (Miettinen et al. 1995) study using 
plant stanol esters with varying doses (0.8-3.4 g/day) led to 5-15% decrease in LDL 
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cholesterol. These studies were followed by the commercial marketing of a plant 
stanol ester spread in 1995 followed by the marketing of a plant sterol ester spread in 
the late 1990’s. Short-term studies conducted with both plant stanol and sterol ester 
spreads reported similar hypolipidemic effects with both spreads in adults (Weststrate 
and Meijer 1998, Hendriks et al. 1999, Hallikainen et al. 2000).  
2.6.2. Hypolipidemic mechanisms of phytosterols 
Phytosterols in their free (Grundy et al. 1969, Lees et al. 1977, Sugano et al. 1977, 
Ikeda et al. 1988b, Vanstone et al. 2002) and esterified forms (Mattson et al. 1977, 
Mattson et al. 1982, Vanhanen et al. 1994, Jones et al. 2000) inhibit cholesterol 
absorption. The earlier studies hinted at more effective inhibition of cholesterol 
absorption by plant stanols compared with plant sterols (Sugano et al. 1977, 
Heinemann et al. 1991), but recent studies with plant stanol and sterol esters have 
reported similar, ~30%, inhibition of cholesterol absorption (Jones et al. 2000, 
Normén et al. 2000). The precise mechanism behind the lowered cholesterol 
absorption is not fully understood, but the reduced micellar solubilization of intestinal 
cholesterol is thought to be the major mechanism behind the inhibition of cholesterol 
absorption (Slota et al. 1983, Armstrong and Carey 1987, Ikeda et al. 1988b, 
Heinemann et al. 1991, Nissinen et al. 2002). Earlier it was proposed that phytosterols 
would interfere with the esterification of cholesterol in the enterocyte, but this 
hypothesis was not confirmed, e.g., sitosterol did not compete with cholesterol for 
cholesterol esterase or ACAT-catalyzed esterification (Field and Mathur 1983, Field 
et al. 1997). Recently, it was reported that plant stanols administered once daily were 
as effective as three separate doses (Plat et al. 2000). The authors suggested that in 
addition to inhibition of the micellar solubility of cholesterol, plant stanols could have 
another mechanism for inhibition of cholesterol absorption. In fact, consumption of 
plant stanols increased the expression of intestinal ABCA1 (Plat and Mensink 
2002b). The authors speculated that since ABCA1 has been shown to have a role in 
sterol absorption, probably by mediating the efflux of sterols from the enterocyte, an 
upregulation of the transporter induced by plant stanols would be another mechanism 
for inhibition of cholesterol absorption.  
The inhibition of cholesterol absorption by phytosterols leads to diminished amounts 
of cholesterol in the circulation and liver. The plant stanol-induced decrease in liver 
cholesterol led to increased LDL apoB receptor mRNA concentrations (Plat and 
Mensink 2002a), allowing increased uptake of cholesterol into the liver. In fact, the 
conversion of VLDL and IDL to LDL was reduced in type 2 diabetes during 
consumption of a plant stanol ester-enriched diet, suggesting that the fractional 
catabolic rate of VLDL and IDL was effective (Gylling and Miettinen 1996). 
Subcutaneously or intravenously injected phytosterols lower serum cholesterol 
concentrations in experimental animals (Konlande and Fisher 1969, Vanstone et al. 
2001). This has led to speculations that other mechanisms, in addition to inhibition of 
cholesterol absorption, could contribute to reduced serum cholesterol levels. The 
proposed mechanisms include modification of enzymes acting on cholesterol 
metabolism, such as hepatic acetyl CoA carboxylase (Laraki et al. 1993). However, 
most probably injected phytosterols, even if only present in small quantities, are 
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transported via bile into the intestinal lumen where they interfere with cholesterol 
absorption. 
2.6.3. Dietary phytosterols and serum lipids 
Adults 
The results from 41 randomized trials conducted in subjects in an age range of 4 to 60 
years describing the effects of dietary phytosterols as cholesterol lowering agents 
were summarized recently by Katan and colleagues (2003). The lowest dose of 
phytosterols used, mostly in esterified form, was 0.7 g/day, but most studies used 
amounts of 1.5 to 3.0 g/day added most frequently to spread, but also to mayonnaise, 
butter, olive oil, and to some lower-fat foods, such as ground beef. The placebo-
adjusted reduction of LDL cholesterol was 10% with both plant stanols and sterols, 
and no differences were reported between the sterol and stanol products. In fact, 
closer inspection of the results from human comparative studies conducted with either 
free (Miettinen and Vanhanen 1994a, Vanstone et al. 2002) or with esterified plant 
stanols and sterols (Weststrate and Meijer 1998, Jones et al. 2000, Hallikainen et al. 
2000, Noakes et al. 2002) revealed similar mean reductions of around 11% in LDL 
cholesterol. The absolute, but not percentual, reduction in LDL cholesterol increases 
with age (Katan et al. 2003). This could simply be due to the fact that the decrease in 
LDL cholesterol is higher in those subjects with higher baseline LDL cholesterol 
levels (Miettinen et al. 1995). The percentage reduction in LDL cholesterol is dose 
dependent, but only slight further reductions were reported with doses higher than 2.5 
g/day (Katan et al. 2003). According to original data from several studies reviewed by 
Katan et al. (2003), serum HDL cholesterol and TG remain mainly unchanged during 
consumption of phytosterols. In addition, no (Hallikainen et al. 2000) or a slight but 
significant decrease (Gylling and Miettinen 1994b) in VLDL cholesterol has been 
reported.  
Recent studies using non-fat or low fat products enriched with plant sterols have 
reported contradictory results. Accordingly, a 12% decrease in LDL cholesterol was 
obtained during 8 weeks’ consumption of plant sterol-enriched (2 g/day of plant 
sterols) orange juice (Devaraj et al. 2004), but in another study, consumption of non-
fat or low fat beverages enriched with plant sterols (1.8 g/day) for 3 weeks did not 
evoke any changes in serum total or LDL cholesterol when compared with placebo 
(Jones et al. 2003). Milk, youghurt, bread, and cereal products enriched with plant 
sterols all resulted in a significant reduction (5-16%) in LDL cholesterol, but it was 
concluded that cholesterol-lowering effect of plant sterol esters may depend on the 
food matrix to which they are added (Clifton et al. 2004). 
Long-term studies 
Only two long-term studies lasting for 1 year have been published, one with stanol 
esters (Miettinen et al. 1995) and the other one with sterol esters (Hendriks et al. 
2003). The former study reported ~9% and ~13% reduction in LDL cholesterol with 
the daily doses of 1.8 g and 2.6 g of plant stanols, respectively, while the latter 
resulted in respective ~6% reduction with the daily dose of 1.6 g of plant sterols 
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compared with placebo. However, closer inspection of the results revealed that in 
women, serum total and LDL cholesterol levels were not significantly decreased by 
the sterol esters, as compared with both baseline and control subjects, only in men 
was the LDL cholesterol significantly reduced (Brink and Hendricks 2000). 
Furthermore, there was a rebound effect in total and LDL cholesterol after 
termination of supplementing with plant sterol esters (2-month study) but the 
beneficial effect of plant stanol esters persisted (O'Neill 2003). In addition, a recent 
study in subjects with type 2 diabetes illustrated the difficulties to maintain the 
cholesterol lowering effect during consumption of plant sterol ester spread for 12 
weeks (Lee et al. 2003). This transient effect has been suggested to be attributable to 
diminished bile acid synthesis (O'Neill 2003) and/or increased cholesterol synthesis, 
as shown by increased serum levels of cholesterol precursor sterols. 
Adults with FH 
Only one study has reported the effects of phytosterols in FH as monotherapy. In that 
small group of FH adults (n=4), consumption of stanol ester spread (2.2 g of 
stanols/day) for 3 months resulted in 11% lowering in LDL cholesterol levels (Vuorio 
et al. 2000). 
Children 
In healthy children, consumption of plant stanol ester spread decreased LDL 
cholesterol by 7.5% (Tammi et al. 2000) and 15.5% (Williams et al. 1999) with daily 
doses of 1.5 g and 3 g of plant stanols. Earlier studies conducted with FH children 
who consumed free sitosterol or sitostanol for three to seven months detected a 17-
30% reduction in LDL cholesterol (Becker et al. 1992, Becker et al. 1993). Sitostanol 
appeared to be more effective than sitosterol in the only comparative study conducted 
with phytosterol products in FH children (Becker et al. 1993). However, recent 
studies with FH children using either plant stanol (2.2-3.0 g/day) (Gylling et al. 1995, 
Vuorio et al. 2000) or sterol (1.6-2.3 g/day) (Amundsen et al. 2002, de Jongh et al. 
2003) ester spreads for 8 to 12 weeks have reported similar reductions in LDL 
cholesterol, ranging from 10% to 18% compared with placebo or with baseline. 
2.6.4. Cholesterol metabolism and lipid lowering properties of phytosterols 
Plant stanol esters are most effective in adult subjects with high baseline absorption 
and low synthesis of cholesterol. In contrast, high serum levels of cholesterol 
precursors, reflecting high cholesterol synthesis, predicted a lesser reduction of serum 
cholesterol (Gylling et al. 1997, Gylling et al. 1999, Gylling and Miettinen 2002a). 
However, opposite findings were observed in FH children, since LDL cholesterol was 
decreased most in those subjects with the highest serum lathosterol and ∆8-
cholestenol levels, suggesting high efficacy of cholesterol synthesis (Gylling et al. 
1995). The reason for this discrepancy is not known, i.e., more studies are required to 
evaluate the effect of baseline cholesterol metabolism on the response to phytosterol 
treatment. 
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Subjects with the apoE-4 phenotype showed more consistent decrease in serum 
cholesterol levels in some studies using plant stanol esters compared with the subjects 
with apoE-3/3 phenotype (Vanhanen et al. 1993, Miettinen and Vanhanen 1994a, 
Hallikainen et al. 2000). According to these results, it was suggested that inhibition of 
cholesterol absorption is most efficient in subjects with high cholesterol absorption 
efficiency, such as in subjects with apoE-4 phenotype (Kesäniemi et al. 1987). 
However, this association has not been confirmed in recent studies (Plat and Mensink 
2000, Tammi et al. 2002), or during consumption of plant sterol esters (Hallikainen et 
al. 2000, Geelen et al. 2002). 
2.6.5. Combination of statins and phytosterols 
Monotherapy with statins may not be sufficiently effective in lowering LDL 
cholesterol in some patient groups such as in subjects with FH. In addition, the dual 
mechanism of combination therapy acting on inhibition of cholesterol synthesis and 
cholesterol absorption may provide an even more profound cholesterol lowering 
efficacy. Further, the analysis of one large statin trial revealed a subgroup of coronary 
patients, in whom recurrent coronary events were not reduced by statin treatment 
alone (Miettinen et al. 1998). It was shown that in those subjects, the baseline serum 
absorption sterol markers were higher than in the subjects responsive to statin 
treatment. In addition, in subjects with a higher baseline sterol absorption, statin 
treatment caused a larger increase of serum plant sterols compared with the subjects 
with low baseline sterol absorption (Miettinen et al. 2000a). Accordingly, it was 
suggested that these subjects would have benefited from inhibition of cholesterol 
absorption. In fact, it was later shown that plant stanol ester spread combined with 
chronic statin treatment caused a further significant decrease in serum cholesterol 
only in subjects with high baseline absorption (Gylling and Miettinen 2002a). The 
decrease of serum plant sterols was also more marked in the same patient group. 
The effects of spreads enriched with phytosterols as an additional treatment with 
different statins in various hypercholesterolemic populations have been evaluated in 
the studies listed in Table 1. In all studies the previous statin treatment had been 
started at least for several months this being followed by addition of plant stanol or 
sterol ester spread to the diet. In addition, in one study cerivastatin and plant sterol 
ester spread were started simultaneously, and this combination led to –39% reduction 
in LDL cholesterol compared with –32% reduction with combination of cerivastatin 
and placebo (Simons 2002). The calculated mean 10-15% decrease in LDL 
cholesterol from the studies presented in Table 1 suggests that adding phytosterol 
esters to statin treatment is more effective than doubling the statin dose, which 
usually causes an additional lowering of LDL cholesterol levels of 5% to 7% (Jones 
et al. 1998). In the only comparable study using plant stanol and sterol esters (O'Neill 
2003), the results from FH subjects with statin treatment and unaffected subjects 
without any hypolipidemic treatment were pooled, since no differences existed 
between the groups. In this pooled population, the effect of plant sterol ester spread 
disappeared during the 2-month study, leading to only a nonsignificant 3% reduction 
in LDL cholesterol at 8 weeks as shown in Table 1.  
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Table 1. Studies evaluating the lipid lowering effect of dietary plant stanol and sterol ester 
spreads combined with statin treatment 
Age, Patients Statin, Plant stanol/sterol ∆LDL%  
Years1 n  dose dose, duration Reference 
55  hyperchol. pravastatin stanol ester -4% vs. placebo,  ns.  
  n=7 40 mg/day 1.5 g/day, 6 weeks       (Vanhanen 1994) 
 
60±2 DM22 pravastatin stanol ester -14% vs. placebo, p<0.05  
  n=8 40 mg/day 3 g/day, 7 weeks        (Gylling and Miettinen 1996) 
 
48-56 CHD simvastatin stanol ester -16% vs. baseline, p<0.05  
         women 10-20 mg/day 3 g/day, 7 weeks (Gylling et al. 1997) 
  n=10 
 
33-80 hyperchol. lova-, prava-, stanol ester -10% vs. placebo, p<0.0001 
  n=167 simva-,atorva- 3 g/day, 8 weeks (Blair et al. 2000) 
   statin 
   n.a. 
 
18-41 FH simvastatin stanol ester -20% vs. baseline,  p<0.001
  n=12 20-40 mg/day 2.2 g/day, 6 weeks (Vuorio et al. 2000)  
 
18-69 FH n.a. sterol ester -11% vs. placebo, p<0.001 
  n=30  2.5 g/day, 4 weeks  (Neil et al. 2001) 
 
 
53±15 FH* n.a. stanol ester 1.6 g/day -6% vs. placebo, p<0.001 
  n=65  stanol ester 2.6 g/day -7% vs. placebo, p=0.01 
    sterol ester 1.6 g/day -3% vs. placebo, ns.  
    all 8 weeks (O'Neill 2003) 
 
68±1 CHD simvastatin stanol ester -13% vs. baseline, p<0.05  
  hyperchol. 20 mg/day 2.25 g/day, 8 weeks (Gylling and Miettinen 2002c) 
  n=11 
1 Mean±SEM or range; 2 DM2, diabetes mellitus type 2; n.a., not available; ns., not 
significant; * 65 FH subjects, but the results are pooled with non-FH subjects without statin 
treatment 
Adding bile acid sequestrant, cholestyramine, to the double treatment (statin + dietary 
plant stanol ester) for eight weeks, resulted in 67% decrease in LDL cholesterol from 
baseline (Gylling and Miettinen 2002c). In that study, all subjects reached the goal of 
LDL cholesterol <2.6 mmol/l with the triple treatment. To compare the additive 
efficacy of phytosterols and ezetimibe, combination of ezetimibe with statins resulted 
in ca. 15-25% additive reduction in LDL cholesterol in different 
hypercholesterolemic populations (Davidson et al. 2002, Gagné et al. 2002a). Thus, 
only a slight additive reduction seemed to be achieved by combining ezetimibe with 
statins compared with combining phytosterols. The triple treatment with statin, 
ezetimibe, and dietary phytosterols could offer a possibility to even more marked 
 
35 
reduction in serum cholesterol levels, but the efficacy of this triple treatment has not 
been evaluated yet.  
2.6.6. Effects of dietary phytosterols on postprandial lipoproteins 
Inhibition of cholesterol absorption might affect postprandial lipoproteins by 
decreasing the cholesterol flux from the intestine to the liver, thereby upregulating the 
LDL apoB receptors (Brown and Goldstein 1986). Inhibition of cholesterol 
absorption by plant stanol ester spread for two weeks resulted in diminished 
postprandial squalene and retinyl palmitate peak times and postprandial squalene 
concentrations and area under incremental curves (AUIC) (Relas et al. 2000), 
suggesting improved clearance of postprandial lipoproteins. However, AUIC for CM 
cholesterol appeared even to be increased. Thus, the improvement of postprandial 
lipoproteinemia was not due to acute inhibition of cholesterol absorption. The most 
probable explanation for improved clearance of TRL was the metabolic changes 
evoked by plant stanols. Accordingly, decreased pool of liver cholesterol leads to 
decreased VLDL synthesis (Gylling and Miettinen 1994b, Gylling and Miettinen 
1996) and/or increased hepatic uptake of remnants by upregulated activity of LDL 
apoB receptors (Plat and Mensink 2002a).  
The clearance of postprandial plant sterols has not been widely studied. A study by 
Relas et al. (2001b) showed that the clearance of sitosterol from CM-like emulsion 
after intravenous injection was more rapid than that of campesterol and squalene. 
Serum campesterol concentrations were lower after the addition of plant stanol esters 
to the test meal in an acute experiment (Relas et al. 2001a). It was speculated that this 
decrease could be associated with acute inhibition of cholesterol and other sterol 
absorption caused by stanol esters. However, little is known about the effects of more 
prolonged use of phytosterol ester spreads on the clearance of plant sterols. 
2.7. Cholesterol synthesis and elimination 
2.7.1. Cholesterol synthesis 
Even though liver is the major organ responsible for cholesterol synthesis, most 
human cells are capable of synthesizing cholesterol (Dietschy et al. 1993). 
Cholesterol is synthesized from acetyl CoA via many biochemical steps (Figure 3), 
and the first rate-limiting step is the conversion of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) into mevalonic acid by HMG-CoA reductase. Mevalonate 
is transformed to squalene and further to lanosterol, which is then converted by 
different steps to cholesterol. The newly synthesized cholesterol is released into blood 
by VLDL, excreted into bile, or stored in an esterified form. 
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The amount of cholesterol in hepatocytes, either from endogenous synthesis or from 
diet transported by CM remnants to liver, is an important regulator of cholesterol 
synthesis. Accordingly, when the amount of cholesterol in liver cells increases, e.g., 
by increasing the dietary intake of cholesterol, cholesterol synthesis is downregulated, 
and vice versa (Brown and Goldstein 1986). In addition, the increased levels of 
hepatic cholesterol suppress the synthesis of LDL apoB receptors, therefore further 
preventing the accumulation of cholesterol in hepatocytes (Brown and Goldstein 
1983). The rate of cholesterol synthesis in humans is around 1 g/day as measured by 
sterol balance technique, but this can be markedly increased in obesity (Miettinen et 
al. 1965, Grundy et al. 1965, Miettinen 1971). The rate of cholesterol synthesis is 
highest at night and lowest in the afternoon (Parker et al. 1982, Miettinen 1982).  
 
Figure 3. Simplified presentation of cholesterol synthesis. 
 
2.7.1.1. Squalene and cholesterol precursor sterols 
The process of cholesterol synthesis includes several intermediates (Figure 3), such as 
non-steroidal squalene and desmethyl sterols. The desmethyl sterols include e.g., ∆8-
cholestenol, desmosterol, and lathosterol, and these sterols are also called cholesterol 
precursor sterols. The serum levels of these cholesterol precursor sterols correlate 
positively with HMG-CoA reductase activity (Björkhem et al. 1987) and with 
cholesterol synthesis (Kempen et al. 1988, Miettinen et al. 1990b), and negatively 
with the cholesterol absorption efficiency and with serum plant sterols (Miettinen et 
al. 1990b). In addition, by inhibiting cholesterol synthesis, statins decrease the levels 
of serum cholesterol precursor sterols, especially lathosterol (Kempen et al. 1988, 
Uusitupa et al. 1992, Vanhanen and Miettinen 1992a, Vanhanen et al. 1992, Pfohl et 
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al. 1998). However, the serum ratios of squalene to cholesterol reflect cholesterol 
synthesis less consistently (Miettinen et al. 1990b), but may still reflect synthesis rate 
in acute experiments, such as immediately after LDL apheresis (Gylling et al. 1998). 
Thus, these cholesterol precursors can be measured by GLC in order to evaluate the 
changes in cholesterol synthesis. 
Squalene is widely distributed in nature, e.g., in plant oils, and especially olive oil is 
rich in squalene (Liu et al. 1976). Thus, in addition to its endogenous synthesis, the 
normal daily human diet contains approximately 24 mg of squalene, which is readily 
absorbed (~65-80%) from the intestine (Miettinen and Vanhanen 1994b, Strandberg 
et al. 1990). The serum concentrations of squalene are approximately 35 µg/dl in 
healthy normolipidemic subjects (Liu et al. 1976). However, the serum concentrations 
of squalene may be even doubled in hypercholesterolemic subjects (Gylling and 
Miettinen 1994a, Nissinen et al. 2000). With respect to the cholesterol precursor 
sterols, the desmethyl sterols are almost exclusively endogenously synthesized in 
humans. The serum concentrations for ∆8-cholestenol, desmosterol, and lathosterol 
were approximately 35 µg/dl, 140 µg/dl, and 335 µg/dl, respectively in a randomly 
selected Finnish population with moderately increased serum cholesterol levels 
(Nissinen et al. 2000). In the same population, the respective ratios to cholesterol 
were 14, 76, and 195 102 mmol/mol of cholesterol. In FH, the concentrations of all 
cholesterol precursors were higher than in the normal population (Gylling and 
Miettinen 1988).  
Squalene and cholesterol precursor sterols are transported in lipoproteins in serum. 
Hepatic cholesterol synthesis increases the amount of cholesterol precursors in the 
liver leading to their release into the blood by VLDL. In fact, the newly synthesized 
squalene was found exclusively in VLDL (Goodman 1964). The highest ratio of 
squalene to cholesterol was also present in VLDL (Gylling and Miettinen 1994a). In 
addition, the ratio of lathosterol to cholesterol was highest in VLDL with and without 
statin treatment in type 2 diabetes (Miettinen and Gylling 2003) and in FH subjects 
with increased cholesterol synthesis due to ileal bypass (Koivisto and Miettinen 
1988b). Statin treatment decreases the ratios of ∆8-cholestenol, desmosterol, and 
lathosterol to cholesterol similarly in all lipoproteins in type 2 diabetes (Miettinen and 
Gylling 2003). Thus, it seems that changes in serum precursor sterols in all 
lipoproteins do reflect the changes occurring in cholesterol synthesis. 
2.7.2. Cholesterol elimination 
If one is to maintain a steady state in cholesterol metabolism, the human body must 
eliminate an equivalent amount of cholesterol as that synthesized by different tissues 
and absorbed from the intestine. The elimination of most of the cholesterol takes 
place in the liver, even though a small amount (~10%) of cholesterol is used in 
steroid hormone synthesis and desquamated by epithelial cells. HDL transports 
cholesterol from extrahepatic tissues to the liver, where the major pathway for 
elimination of cholesterol involves the secretion of cholesterol as such and bile acid 
synthesis by the hepatocytes. The enzymes, cholesterol 7α-hydroxylase and 27-
hydroxylase play the major role in converting cholesterol into bile acids (Shefer et al. 
1970, Björkhem 1992), mainly cholic acid and chenodeoxycholic acid. Bile acids 
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secreted from the liver pass through the intestine facilitating absorption of fats, 
sterols, and fat soluble vitamins. However, ~95% of bile acids are reabsorbed and 
returned to liver. Bile acids regulate their own synthesis by activating in conjunction 
with oxysterols, the nuclear hormone receptors, farnesoid X receptor and LXR 
(Chiang 2002). These receptors regulate the genes involved in bile acid synthesis, and 
thus an excess of bile acids can cause a feedback inhibition of bile acid synthesis. 
2.7.3. Effects of dietary phytosterols on cholesterol synthesis and biliary secretion 
Due to inhibition of cholesterol absorption by dietary phytosterols, cholesterol 
synthesis is compensatorily upregulated (Gylling and Miettinen 1994b, Gylling and 
Miettinen 1996, Gylling et al. 1997, Jones et al. 2000). In accordance with results 
from sterol balance studies, consumption of phytosterol esters increases the serum 
levels of all cholesterol precursor sterols, but most consistently that of lathosterol 
(Vanhanen et al. 1993, Gylling et al. 1997, Gylling et al. 1999, Hallikainen et al. 
2000), also in FH subjects (Gylling et al. 1995, Vuorio et al. 2000) and in 
normolipidemic children (Tammi et al. 2002). The changes in serum squalene levels 
were minor and inconsistent (Vanhanen et al. 1993, Vanhanen et al. 1994, Gylling et 
al. 1995, Hallikainen et al. 2000). In addition, even with simultaneous inhibition of 
cholesterol synthesis by statins, consumption of plant stanol esters can increase the 
serum cholesterol precursor sterols in some (Vuorio et al. 2000, Gylling and 
Miettinen 2002a, Gylling and Miettinen 2002c, O'Neill 2003), but not in all studies 
(Vanhanen 1994). Furthermore, the study by O´Neill did not show any increments of 
lathosterol during consumption of plant stanol or sterol ester spread (O'Neill 2003). 
The above mentioned studies have evaluated the levels of the cholesterol precursors 
only in serum. Thus, it is not known whether the cholesterol precursors in different 
lipoproteins reflect the predicted change in cholesterol synthesis during consumption 
of phytosterol esters. 
Contradictory results exist on the effects of phytosterols on bile acid metabolism. 
Several earlier studies have shown that consumption of free plant sterols led to an 
increase in fecal neutral, but not in acidic sterols, suggesting that bile acid synthesis 
was unchanged (Grundy et al. 1969, Kudchodkar et al. 1976, Becker et al. 1993). 
Similar results were obtained with plant stanol esters (Miettinen and Vanhanen 
1994a, Gylling and Miettinen 1994b, Gylling et al. 1997, Miettinen et al. 2000c). 
However, Becker et al. (1993) reported that consumption of plant stanols increased 
the fecal bile acid excretion in children. The authors speculated that this increase 
could be either due to upregulated cholesterol synthesis or due to decreased serum 
plant sterol levels, which could be associated with increased bile acid synthesis. In 
fact, high plasma and liver sitosterol levels in phytosterolemic subjects inhibited 7α-
hydroxylase, a rate limiting enzyme in bile acid synthesis, but did not change the total 
hepatic bile acid pool (Shefer et al. 1994). However, fecal bile acid excretion was 
decreased by 21% during consumption of plant sterol esters (Weststrate et al. 1999). 
Further, consumption of plant sterol esters decreased the concentrations of 7α-
hydroxy cholestenone, an index of cholesterol 7α-hydroxylase activity (O'Neill et al. 
2002, O'Neill 2003). There was no change in 7α-hydroxy cholestenone levels during 
consumption of plant stanol ester spread. These results suggest that serum plant sterol 
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levels may regulate the bile acid synthesis, and accordingly a high dietary intake of 
plant sterols, but not of plant stanols, may decrease bile acid synthesis, which was 
suggested to be one reason for the rebound effect in total and LDL cholesterol levels 
(O'Neill et al. 2002, O'Neill 2003).  
2.8. Familial hypercholesterolemia 
FH is a dominantly inherited metabolic disorder that affects around one in 500 
individuals in its heterozygous form (Goldstein et al. 2001). This disease is caused by 
a mutation in a gene coding for the LDL apoB receptor, leading to impaired uptake of 
LDL particles in all tissues, especially in liver. Accordingly, LDL cholesterol 
concentrations are increased approximately two- to three-fold in heterozygotes. 
Individuals with two mutated alleles of the LDL apoB receptor gene (FH 
homozygotes), with prevalence of 1:1 000 000, have no or only minor activity of 
LDL apoB receptors, leading to up to four-fold concentrations of serum LDL 
cholesterol. In addition, serum HDL cholesterol levels are slightly lower in both 
heterozygous and homozygous subjects than in normal subjects, but serum TG levels 
are normal. 
2.8.1. Clinical features and diagnosis 
In FH subjects, the excess cholesterol is accumulated in tissues causing tendon 
xanthomas, skin xanthelasmas, corneal arcus and atherosclerosis leading to CHD 
already at young age (Goldstein et al. 2001). In fact, atherosclerotic lesions have been 
obtained in children with FH already at ages 3-19 years (Tonstad et al. 1996, Virkola 
et al. 1997). Many genetic and environmental factors, including gender, smoking, the 
presence of hypertension, and hypertriglyceridemia influence the expression of CHD 
(Hill et al. 1991), explaining the wide variations in the clinical phenotype in FH 
subjects. The diagnosis of heterozygous FH in adults and children has traditionally 
been made according to typical clinical traits, including high concentrations of total 
(> 7.5-8.5 mmol/l) and LDL cholesterol, a family history of elevated concentrations 
of LDL cholesterol and premature atherosclerosis, and presence of tendon xanthomas 
(Goldstein et al. 2001). Nowadays, especially in populations with a high degree of 
genetic homogeneity, the diagnosis of FH can be made by detection of the specific 
LDL apoB receptor mutation using DNA extracted from white blood cells and 
polymerase chain reaction (PCR)-based techniques (Goldstein et al. 2001), or 
quantifying LDL apoB receptor function from cultured fibroblasts (Cuthbert et al. 
1986). 
2.8.2. Genetics 
The gene for LDL apoB receptor is located on the short arm of chromosome 19 
(Francke et al. 1984). Over 900 different LDL apoB receptor mutations have been 
identified (www.ucl.ac.uk/fh/) ranging from single nucleotide substitutions to large 
deletions of the gene. As a consequence, different mutations result in proteins with 
different structures and functions. Accordingly, LDL apoB receptor mutations can be 
divided into five classes based on their function in producing and transporting the 
protein, binding of LDL, internalizing of LDL, and recycling the protein back to the 
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cell surface (Goldstein et al. 2001). The mutation phenotype may affect the clinical 
course of the disease and e.g., the response to hypolipidemic medication (Leitersdorf 
et al. 1993). 
In Finland, ~25 different mutations of the LDL apoB receptor gene have been 
identified (Vuorio et al. 2001). However, owing to a founder effect, two major 
mutations, FH-Helsinki (FH-Hki) (Aalto-Setälä et al. 1989) and FH-North Karelia 
(FH-NK) (Koivisto et al. 1992), causing deletion of the LDL apoB receptor gene, 
accompanied with two point-mutations FH-Turku and FH-Pori (Koivisto et al. 1995) 
account for about three fourths of all the FH cases identified in Finland. 
2.8.3. Cholesterol metabolism in familial hypercholesterolemia 
2.8.3.1. Cholesterol absorption 
Cholesterol absorption in adult subjects with heterozygous FH (Connor and Lin 1974, 
Sodhi et al. 1980, Gylling and Miettinen 1989) and in children with homozygous FH 
FH (Carter et al. 1979) has been shown to be similar to normolipidemic subjects. In 
contrast to normolipidemic subjects, the serum lipid levels are not correlated with 
cholesterol absorption in FH (Gylling and Miettinen 1989). However, as in the 
normal population (Kesäniemi and Miettinen 1987, Miettinen and Kesäniemi 1989), 
the absorption of cholesterol is negatively correlated with cholesterol synthesis in FH 
(Gylling and Miettinen 1989). Accordingly, efficient absorption of cholesterol will 
result in lower synthesis of cholesterol also in FH. 
2.8.3.2. Cholesterol and bile acid synthesis  
Despite impaired cellular uptake of LDL by LDL apoB receptors in FH, hepatic 
cholesterol levels are elevated due to high serum concentrations of cholesterol and an 
appreciable amount of LDL taken up by a non-receptor mediated pathway 
(Thompson et al. 1996). This increase in hepatic cholesterol levels is sufficient to 
maintain the cholesterol synthesis at low normal limits in heterozygous and 
homozygous FH adults (Bilheimer et al. 1979, Goldstein et al. 2001) or adolescents 
(Carter et al. 1979) and in heterozygous children (Martin and Nestel 1979), even 
though wide variations between families may exist (Miettinen 1984). However, 
according to several studies, young FH homozygotes, aged under 10 years, may 
exhibit an overproduction of cholesterol (Bilheimer et al. 1975, Schwarz et al. 1979, 
Miettinen 1984) compared with heterozygous or normolipidemic subjects. As in the 
normal population, the serum levels of cholesterol precursor sterols reflect cholesterol 
synthesis in FH (Gylling and Miettinen 1988), and thus may be used as markers of 
cholesterol synthesis. 
The rate of bile acid synthesis may vary between families (Miettinen 1984), but 
mostly subnormal (Miettinen 1978, Simonen and Miettinen 1987) or normal 
(Moutafis et al. 1977, Zavoral et al. 1982) rates have been obtained. 
Even though in general overall cholesterol synthesis is normal, the increased hepatic 
cholesterol increases the production of VLDL apoB (Cummings et al. 1995), which is 
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then converted to IDL. Due to the defect in LDL apoB receptor, IDL is poorly taken 
up by the liver, and thus is converted to LDL (Brown and Goldstein 1986). 
Accordingly, in addition to reduced degradation, FH is accompanied with 
overproduction of LDL. 
2.8.3.3. Postprandial lipoproteins 
In FH, the impaired or total lack of activity of the LDL apoB receptor suggests that 
the clearance of TRL might be decreased. However, the results from earlier studies 
are controversial. Four studies showed normal clearance of TRL both in heterozygous 
(Weintraub et al. 1987, Eriksson et al. 1991, Watts et al. 2001) and homozygous FH 
(Rubinsztein et al. 1990, Watts et al. 2001) subjects, while other studies have reported 
delayed CM remnant clearance in both heterozygous and homozygous FH (Cabezas 
et al. 1998, Mamo et al. 1998, Twickler et al. 2000). In addition, fasting 
concentrations of apoB-48 and RLP cholesterol were higher in FH subjects compared 
with normolipidemic subjects (Dane-Stewart et al. 2001, de Sauvage Nolting et al. 
2002). The discrepancy in results of FH subjects reflects the variations in the clinical 
phenotype of FH, and suggests that liver receptors other than LDL apoB receptor may 
play an important role in TRL clearance. However, as in most studies in non-FH 
population (Karpe 2002), statins improve the clearance of postprandial lipoproteins 
(Twickler et al. 2000, Dane-Stewart et al. 2002) and reduce the RLP cholesterol 
levels (de Sauvage Nolting et al. 2002) also in FH. The fact that statins upregulate the 
expression of LDL apoB receptors (Brown and Goldstein 1986, Reihnér et al. 1990) 
indicates that LDL apoB receptor must, however, have a role in the clearance of TRL 
also in FH. 
2.8.4. Treatment 
Heterozygotes 
Decreased serum LDL cholesterol levels in FH may be achieved either by increasing 
the uptake of LDL particles via upregulation of LDL apoB receptors and/or a 
decrease in LDL production. Dietary interventions with reduced amount of dietary 
cholesterol and saturated fatty acids are not sufficiently effective in lowering LDL 
cholesterol in FH to the recommended levels, but must be a part of the lipid-lowering 
therapy, in combination with pharmacological agents. Resins act by inhibiting the 
absorption of bile acids, thus increasing the conversion of hepatic cholesterol into bile 
acids and promoting a compensatory rise in cholesterol synthesis and upregulation of 
LDL apoB receptors. Resins lower LDL cholesterol levels by ~15-30% (Moutafis et 
al. 1977, Miettinen and Lempinen 1977). On the other hand, statins inhibit cholesterol 
synthesis by blocking the HMG-CoA reductase activity, decreasing the amount of 
hepatic cholesterol, and thereby upregulating the LDL apoB receptors (Brown and 
Goldstein 1986, Reihnér et al. 1990, Bergström et al. 1998). This latter factor and the 
reduced production of VLDL by statins (Isusi et al. 2000) lead to an approximate 
mean reduction of 39% in LDL cholesterol in heterozygous FH with different statins 
(Hopkins 2003). However, according to a recent study by Smilde and colleagues 
(2001), at least 45% reduction in LDL cholesterol is required to achieve a regression 
in intima media thickness in heterozygous FH. Thus, combination of statins with 
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resins (Uusitupa et al. 1992, Illingworth 1993), fibrates (Muratti et al. 1994), 
ezetimibe (Davidson et al. 2002), or plant stanol or sterol esters (Vuorio et al. 2000, 
O'Neill et al. 2002) to achieve an additional 5-25% reduction in LDL cholesterol is 
recommended. In addition, up to 67% reduction in LDL cholesterol was achieved by 
triple treatment with statin, plant stanol esters, and cholestyramine in FH subjects 
(Gylling and Miettinen 2002c). 
Homozygotes 
Generally, FH homozygotes are resistant to treatments that are effective in FH 
heterozygotes, because they produce only a few functional LDL apoB receptors 
(Goldstein et al. 2001). Accordingly, at the very best, only ~30% reduction in LDL 
cholesterol levels has been obtained by monotherapy with a high statin dose (Raal et 
al. 2000) or in combination with ezetimibe (Gagné et al. 2002b). Additional treatment 
options for the homozygote FH subjects in the past included ileal by-pass or 
portacaval anastomosis, but more recent treatment options include liver 
transplantation and LDL apheresis. In addition, FH was suggested to be an excellent 
candidate for gene therapy. However, LDL apoB receptor gene replacement studies 
have been restricted mostly to animal studies (Hopkins 2003). One small pilot study 
in humans showed no or only a modest reduction in LDL cholesterol (Grossman et al. 
1995). Thus, gene therapy will require major advances and improvements in the 
future before it can become a potential treatment option for FH subjects. 
The different treatment procedures alter cholesterol metabolism in different ways. 
Ileal by-pass operation increases intestinal loss of bile acids and is accompanied by 
increased cholesterol synthesis (Miettinen 1979), while portacaval anastomosis 
causes a decrease in cholesterol synthesis resulting in 25% to 50% reduction in LDL 
cholesterol (Starzl et al. 1973, Bilheimer et al. 1975). Liver transplantation provides 
an external source of LDL apoB receptors and causes a dramatic fall in LDL 
cholesterol levels and resolution of xanthomas (Bilheimer 1989, Goldstein et al. 
2001). LDL apheresis provides a method to remove excess LDL cholesterol from 
plasma. Repeated fortnightly procedures are accompanied with ~50% reduction in 
LDL cholesterol and arrest of progression of CHD (Kroon et al. 1996). Chronic LDL 
apheresis treatment causes no or even slight decrease in cholesterol synthesis (Pfohl 
et al. 1994, Gylling et al. 1998), whereas a transient increase in cholesterol synthesis 
was observed in FH homozygotes after LDL apheresis (Pfohl et al. 1994, Gylling et 
al. 1998). Despite the fact that there may be even more profound upregulation of 
cholesterol synthesis in these subjects with statin treatment than if they are left 
untreated, statins do effectively reduce LDL cholesterol and cholesterol synthesis in 
long-term use and thus are recommended in combination with LDL apheresis 
(Yamamoto et al. 2000, Goldammer et al. 2002).  
Children 
Since the early signs of atherosclerosis can be detected already in childhood in FH 
(Tonstad et al. 1996, Virkola et al. 1997), treatment of increased LDL cholesterol 
levels shoud be started as early as possible. Initially, lifestyle advice is recommended 
to reduce serum cholesterol levels in FH children. Resins are first-line drugs for 
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treatment of children, since they are not absorbed from the intestine and are safe and 
effective achieving ~25% reduction in LDL cholesterol (Marks et al. 2003). 
However, the compliance for resin therapy is poor, with only ~50% of patients 
remaining on the treatment. Better compliance achieving ~15% decrease in LDL 
cholesterol has been obtained by plant stanol or sterol esters (Gylling et al. 1995, 
Vuorio et al. 2000, Amundsen et al. 2002, de Jongh et al. 2003). However, no effect 
on endothelial function could be obtained during consumption of plant sterol esters 
(de Jongh et al. 2003). Statins have been shown to be effective and safe in short- 
(Knipscheer et al. 1996, Lambert et al. 1996) and long-term studies resulting in 27-
40% decreases in LDL cholesterol with different statins (Stein et al. 1999, de Jongh et 
al. 2002b, McCrindle et al. 2003). Additionally, 28-week treatment with simvastatin 
improved endothelial function in children with FH (de Jongh et al. 2002a).  
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3. AIMS OF THE STUDY 
Dietary phytosterols lower serum cholesterol levels by inhibiting cholesterol 
absorption. In addition, dietary phytosterols have several effects on sterol 
metabolism. The consumption of plant sterol and stanol esters alter differently the 
serum plant sterol levels in adults, whereas the cholesterol synthesis markers are 
increased by both phytosterol products. However, nothing is known about the effects 
of plant sterol esters on the accumulation of plant sterols in blood in children and in 
homozygous FH subjects. In addition, the effects of combination of cholesterol 
synthesis inhibition by statin treatment and cholesterol absorption inhibition 
especially by plant sterol esters on serum, lipoprotein, and red cell non-cholesterol 
sterol values is limited. Further, only one study has evaluated the effects of plant 
stanols on postprandial lipoproteinemia in non-FH subjects. Accordingly, the effects 
of dietary phytosterols in statin-treated FH on clearance of postprandial lipoproteins 
have not been studied. Finally, the effects of disturbed cholesterol metabolism in FH 
with and without statin treatment, and the effects of phytosterol consumption on 
distribution of non-cholesterol sterols are not known.  
Therefore, the aims of the present study were to investigate 
• distribution of non-cholesterol sterols in different serum lipoproteins in children 
with FH and in normolipidemic children 
• effects of dietary plant stanol and sterol esters on serum and red cell plant sterol 
and other non-cholesterol sterol levels in hypercholesterolemic children 
• effects of inhibiting cholesterol absorption by plant stanol and sterol esters on 
serum, lipoprotein, and red cell plant sterol and other non-cholesterol sterol levels 
in heterozygous FH subjects during inhibition of cholesterol synthesis by statin 
treatment 
• effects of inhibiting cholesterol absorption by plant stanol and sterol esters on 
serum and lipoprotein plant sterol and other non-cholesterol sterol levels in a 
subject with homozygous FH on statin and LDL apheresis treatment 
• effects of inhibition of cholesterol absorption and alteration of serum plant sterol 
levels by dietary plant stanol and sterol esters on postprandial lipoproteinemia in 
statin-treated heterozygous FH subjects 
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4. SUBJECTS AND METHODS 
4.1. Subjects and study design 
A total of 67 children (32 with heterozygous FH, 6 hypercholesterolemic, and 29 non-
affected children) were recruited by personal letters according to patient data from 
Outpatient Clinics of the Hospital for Children and Adolescents, University of 
Helsinki. In addition, one homozygous FH subject and 20 adult patients with 
heterozygous FH were recruited from the Meilahti Hospital, University of Helsinki 
(Table 2). Diabetes, kidney, liver, and thyroid diseases were exclusion criteria in all 
of the subjects. With the exception of the intervention periods, the subjects continued 
their normal habitual diet throughout the studies. Possible use of plant stanol or sterol 
ester spreads was terminated at least three weeks prior to the studies. The dose of 
plant stanol or sterol ester spreads in Studies II-V was 25 g/day (2 g of free plant 
stanols and sterols daily). Weighing the returned unwashed spread containers 
provided an approximation of the amount of consumed spreads in Studies II-V. The 
prescribed medication was continued unchanged during the studies. All of the 
subjects or parents for children under 12 years gave their informed consent. The study 
protocols had been accepted by Ethics Committee of the Hospital for Children and 
Adolescents or the Department of Medicine, University of Helsinki.  
Table 2. Baseline characteristics of the subjects 
Variable Study I 
 FH    non-FH 
Children 
Study II 
Hyperchol. 
Children 
Study III 
FH+statin 
Adults 
Study IV 
Family Study 
HeZ    HoZ 
Study V 
FH+statin 
Adults 
n    18         29 23 18 3 5 
sex (m/f) 10/8   14/15 10/13 6/12 1/2 1/4 
FH subjects n    18          0 17 18 3 5 
age (years)1 11±0.8 11±0.6 6.8±0.5 48±2 44±7 51±4 
1Mean±SEM; FH, familial hypercholesterolemia; HeZ, heterozygous FH; HoZ, homozygous 
FH; Hyperchol., hypercholesterolemic 
Study I 
The study group consisted of 47 children aged 5 to 16 years. All of the subjects had a 
first or second degree relative with clinically or genetically documented FH, or were 
themselves patients at the Outpatient Lipid Clinics of the Hospital for Children and 
Adolescents, University of Helsinki. The subjects were divided into FH and non-FH 
subjects by DNA analysis characterizing the four most common Finnish LDL apoB 
receptor mutations (Aalto-Setälä et al. 1989, Koivisto et al. 1992, Koivisto et al. 
1995). Serum total cholesterol was < 5.0 mmol/l in non-FH group. The subjects 
visited the Outpatient Clinics once, when routine clinical status was assessed. The 
blood sample was obtained after at least 4 hours’ fasting. 
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Study II 
The study population comprised 23 prepubertal children aged 2 to 9 years. The 
inclusion criteria included total cholesterol > 5.0 mmol/l and serum TG < 2.0 mmol/l. 
None of the children were taking any hypolipidemic medication. Of the 23 children, 
16 had FH according to prior DNA analysis, and one child with lipid levels 
appropriate to FH, and with a positive family history of FH, was included in the FH 
group. The remaining six subjects were negative for LDL apoB receptor mutations 
and did not have a family history of FH. 
The study had a double-blind, randomized, cross-over design. It consisted of two 5-
week intervention periods with plant stanol and sterol ester spreads, and with a 5-
week wash-out period between the interventions.  
The subjects visited the Outpatient Clinics four times, at the beginning and end of 
every period. The routine physical examination was performed on the first and last 
visits. The blood samples were taken after an overnight fast on every visit. Due to 
small blood sample size, only plasma samples were obtained. 
Study III and V 
The study group consisted of 18 (Study III) and five (Study V) adult heterozygous FH 
subjects. All subjects had used the same statin dose for several years. Thus, the 
baseline measurement was made during statin treatment, and is called ‘baseline’ in 
the following sections. As equivalent dose of atorvastatin, the mean statin dose used 
in Study III was 40 mg/day. In addition, two subjects used bile acid sequestrants in 
Study III. 
The studies had a double-blind, randomized, cross-over design. The subjects were 
advised to consume low fat plant stanol and sterol ester spreads in a random order for 
two four-week periods without any wash-out period. The subjects visited the 
Outpatient Clinics at the beginning and end of the periods, when the physical 
examination was performed and the fasting blood samples were drawn a few days 
apart. The mean of the two samples in all serum determinations was used in statistical 
calculations. The Intralipid fat tolerance test was performed three times (Study V), at 
baseline and at the end of the two intervention periods. 
Study IV 
The study population comprised two heterozygous FH parents (LDL apoB receptor 
mutation FH-Hki for the one parent and FH-NK for the other parent) and their 29-
year-old offspring with homozygous FH with FH-Hki and FH-NK mutations. The 
diagnosis for the homozygous subject was made at the age of 4 years. The subject had 
undergone portacaval shunt, ileal bypass, aortic valve, and coronary artery operations. 
Statin therapy had been started in the late 1980’s. LDL-apheresis was started in 1990, 
and has continued since that date. The prescribed medication, atorvastatin 80 mg/day, 
as well as the LDL apheresis treatments continued as before the study. The parents 
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were not consuming any basal medications nor did they exhibit clinical signs of 
CHD. 
In the homozygous subject, LDL apheresis treatments were scheduled to occur once 
per fortnight. Due to patient-related reasons the intervals were occasionally extended 
up to three or even four weeks. LDL apheresis was performed with Liposorber MA-
01 (Kaneka Corporation, Osaka, Japan) with two columns of dextran sulphate 
cellulose beads as the adsorbent. Four liters of plasma were treated during every 
apheresis using heparin as the anticoagulant. The subject was advised to start low fat 
plant sterol ester spread for 73 days (3 apheresis treatment intervals) followed by low 
fat plant stanol ester spread for 157 days (9 apheresis treatment intervals). Pre-
apheresis blood samples were drawn after an overnight fast. Three weeks after the 
discontinuation of the stanol ester consumption, a blood sample was taken during the 
home diet. 
After a routine physical examination, the parents were advised to consume in double 
blind and in random order low fat plant stanol and sterol ester spreads both for 4 
weeks. The blood samples were taken after an overnight fast before and after each 
period, and after 4 weeks of the intervention on the home diet.  
The spreads 
In Studies II and IV, the plant stanol and plant sterol ester spreads were similar as the 
spreads in the markets (Light Benecol, Raisio Benecol Ltd, Raisio, Finland, 32% of 
fat and Becel pro.activ, Unilever BestFoods, Purfleet, UK, 35% of fat). Accordingly, 
the fatty acid compositions of the plant stanol ester and sterol ester spreads were 16% 
and 25% of saturated fatty acids, 56% and 25% of monounsaturated fatty acids, and 
28% and 50% of polyunsaturated fatty acids, respectively. Both spreads contained 6 
mg/100g and 66 mg/100g of vitamin E, respectively. The plant stanol ester spread 
contained 1.8% sitosterol, 1.5% campesterol, 0% stigmasterol, 0% avenasterol, 
0.05% cholesterol, 66.8% sitostanol, and 29.8% campestanol. The respective values 
for plant sterol ester spread were 51.5%, 24.3%, 20.5%, 1.3%, 0.4%, 1.2%, and 0.6%.  
In Studies III and V, both spreads contained 40% of fat and the fatty acid distribution 
of the spreads were similar; 22% of saturated fatty acids, 34% of monounsaturated 
fatty acids, and 44% of polyunsaturated fatty acids. The plant stanol ester spread 
contained 1.6% sitosterol, 2.0% campesterol, 0% stigmasterol, 0% avenasterol, 0% 
cholesterol, 65.6% sitostanol, and 28.8% campestanol. The respective values for plant 
sterol ester spread were 45.3%, 26.1%, 14.5%, 3.5%, 0.4%, 0%, and 1.2%. Both 
spreads contained 17 mg/100 g of vitamin E. The amounts of vitamin A (900 
µg/100g) and vitamin D (7.5 µg/100g) were similar in all of the spreads. 
4.2. Methods 
4.2.1. Clinical examination 
A routine clinical examination of the subjects included measurement of height and 
weight, puberty staging (Study I) (Tanner 1969), blood pressure measurement, 
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auscultation of heart and lungs, palpation of tendons, and inspection of the presence 
of xanthelasmas and corneal arcus. 
4.2.2. DNA diagnosis 
DNA was isolated from the frozen EDTA-anticoagulated blood samples using a 
prodedure modified from Kunkel et al. (1977) in Study I. PCR (Koivisto et al. 1993) 
was used to analyze the four most common mutations (FH-Hki, FH-NK, FH-Turku, 
and FH-Pori) (Aalto-Setälä et al. 1989, Koivisto et al. 1992, Koivisto et al. 1995) of 
the LDL apoB receptor gene in Finland. 
4.2.3. Lipoprotein separation 
CM were separated in Studies III and V by a 30-min ultracentrifugation (18000 RPM) 
in a fixed-angle Type 50 Ti rotor (Beckman, Palo Alto, CA, USA) with carefully 
overlayered 1.006 g/ml NaCl solution. In Study I, other lipoproteins were separated 
by ultracentrifugation in a fixed-angle Type 50.4 Ti rotor (Beckman, Palo Alto, CA, 
USA) (35000 RPM, 18-20 hours) according to their densities: VLDL, < 1.006 g/ml; 
IDL, 1.006-1.019 g/ml; LDL, 1.019-1.063 g/ml and HDL, 1.063-1.210 g/ml (Havel et 
al. 1955, Warnick and Alberts 1982). In Studies III-V, the lipoproteins were separated 
only into VLDL and VLDL infranatant (1.006-1.210 g/ml). From the infranatant, 
HDL was separated by precipitation of apoB containing lipoproteins with 
phosphotungstic acid and magnesium (Roche, Basel, Switzerland). The sediment 
included LDL and IDL, but will be designated as LDL in the following section. 
4.2.4. Serum and lipoprotein lipids 
In Study I, serum and lipoprotein total and free cholesterol, phospholipids, and serum 
TG as well as plasma total, free, and HDL cholesterol and TG in Study II and total, 
HDL, and VLDL cholesterol in Study IV were analyzed by enzymatic color reactions 
with commercial kits (total and lipoprotein cholesterol: CHOD-PAP; TG: GPO-PAP, 
Roche, Basel, Switzerland; phospholipids: phospholipase D choline-oxidase PAP, 
Wako Chemicals, Neuss, Germany; free cholesterol: CHOD-PAP, Boehringer-
Mannheim, Mannheim, Germany) by using a semiautomatic COBAS Mira analyzer 
(Roche, Basel, Switzerland). Cholesterol and TG were analysed from the six subjects 
in Study III in all lipoproteins and in Study V in CM and VLDL by commercial kits 
(cholesterol: CHOD-PAP, TG: GPO-PAP, ABX-Diagnostics, Parc Euromédecine, 
France). In Studies III and V, the serum total and HDL cholesterol and serum TG 
were analyzed by the routine methods of our hospital. LDL cholesterol was calculated 
by Friedewald (Friedewald et al. 1972) (Studies II, III, and V) or by subtracting the 
levels of VLDL and HDL cholesterol from serum cholesterol (Study IV).  
4.2.5. Squalene and non-cholesterol sterols 
The red cells were washed with 0.9% sodium chloride three times and centrifuged at 
3000 RPM for 5 minutes before the analyses. 
Serum, red cell, and lipoprotein cholesterol, squalene, and non-cholesterol sterols 
(cholestanol, ∆8-cholestenol, desmosterol, lathosterol, campesterol, campestanol, 
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sitosterol, avenasterol, and sitostanol) were quantified by GLC on a 50-m-long SE-30 
capillary column (Ultra-1 or Ultra-2; Hewlett-Packard, Wilmington, DE, USA) 
(Miettinen and Koivisto 1983, Miettinen 1988). Briefly, after addition of 100 µl of 
5α-cholestane as an internal standard, 200-1000 µl of serum, red cell, or lipoprotein 
samples were saponified with 99% ethanol and potassium-hydroxide (10M) (9:1, 
vol:vol) for 1.5 hour in 80 °C. The nonsaponified lipids were extracted by hexane 
once or twice in case of the smaller fractions. The hexane was evaporated under a 
stream of nitrogen and followed by silylation of lipids by trimethylsilylate to bind 
free O- groups of sterols before the GLC run. Cholesterol, squalene, and non-
cholesterol sterols were also measured from the spreads and the Intralipid-squalene 
mixture. 
To eliminate the effects of different cholesterol levels in serum, red cells, and 
lipoproteins, the values of squalene and non-cholesterol sterols are expressed as ratios 
to cholesterol in terms of 102x mmol/mol of cholesterol. In most studies, the 
concentrations of squalene and non-cholesterol sterols are also given. For simplicity, 
squalene data are given under the topic non-cholesterol sterols. 
4.2.6. Fat tolerance test with Intralipid-squalene 
Intralipid emulsion added with squalene was performed by dissolving liquid 98-100% 
squalene (Sigma, St. Louis, MO, USA) into commercially available Intralipid 200 
mg/ml fat emulsion (Pharmacia, Stockholm, Sweden). To ensure the sterility of 
squalene, it was first filtered with a sterile Millex-GV 0.22 µm pore size filter unit 
(Millipore SA, Molsheim, France), after which 80 mg (100 µl) of squalene was 
dissolved in 900 µl of 99.5% ethanol. The squalene-ethanol solution was added to 
100 ml of Intralipid. Accordingly, the emulsion contained squalene at 69.8±4.8 
mg/dl, cholesterol at 25.9 mg/dl, TG at 20 g/dl, campesterol at 6.2 mg/dl, and 
sitosterol at 20.8 mg/dl.  
After taking the fasting blood sample in the morning, 30 ml of the Intralipid+squalene 
emulsion was injected as a bolus into a forearm vein over 1-2 min. The blood samples 
were collected from the opposite forearm via an intravenous cannula 10, 20, 40, 60, 
120, and 180 min after the injection. 
In the calculations, TG, squalene, and plant sterol levels were provided as incremental 
concentrations, calculated by subtracting the basal value from the value at the 
respective time point. AUIC values were calculated by the trapezoid method. 
4.2.7. Other measurements 
The apoE phenotype was determined electrophoretically by isoelectric focusing from 
serum samples (Havekes et al. 1987) in Study I. Subjects with phenotypes apoE-2/2, 
apoE-3/2, and apoE-4/2 were combined and called apoE-2 group, those with apoE-
3/3 were called apoE-3 group, and subjects with apoE-3/4 or apoE-4/4 were called 
apoE-4 group. 
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Blood glucose was measured with a commercial kit using glucose dehydrogenase 
method (Roche, Basel, Switzerland), serum insulin was analyzed by radioimmuno-
assay (Pharmacia & Upjohn, Uppsala, Sweden), and sex hormone globulin by 
commercial kits (Wallac, Turku, Finland). 
4.2.8. Statistics 
All the statistical analyses were performed using Microsoft Excel version 6.0 and the 
Number Cruncher Statistical System (NCSS) (NCSS, 2000, Kaysville, Utah, U.S.A.). 
Continuous values are given as mean ± standard error of the mean (SEM). 
Calculations were made according to intention-to-treat principle. The carry-over 
effect was controlled by analysis of variance (ANOVA) for repeated measurements in 
Study II, and the effect of the treatment sequence was evaluated by two-way ANOVA 
with the treatment period as the repeated factor and the sequence of treatment as the 
”group” factor in Studies III and V. The statistical significances between the groups 
were calculated by one-way ANOVA, two-sided t test, or χ2 test. Paired t test was 
used to evaluate the treatment effects in Studies II, III, and V. Half-lives in Study V 
were calculated by nonlinear least-square analysis from the absolute concentrations. 
If a variable was skewed, either logarithmic transformation was made or data were 
analyzed by non-parametric tests. The correlation coefficients were calculated by 
using Pearson’s product moment or Spearman’s rank correlation test in appropriate 
cases. A p value < 0.05 was considered significant. 
Analysis for appropriate number of subjects was performed in Studies II and III. 
Thus, the calculations were made with α=0.05 and β=0.20 and a minimal detectable 
difference of 0.40 mmol/l for LDL cholesterol. 
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5. RESULTS 
5.1. Clinical characteristics and compliance 
Age, sex, height, weight, body mass index, and blood pressure were similar in the 
children with or without FH. No clinically recognizable signs of lipid accumulation, 
such as tendon xanthomas, were detected in FH children. 21 children in Study I had 
reached puberty, but the children in Study II were in prepuberty.  
In all heterozygous adults in Study III and in the homozygous subject in Study IV, 
tendon xanthomas, xanthelasmas, and corneal arcus were detected. The homozygous 
and four heterozygous FH subjects had a diagnosis of CHD.  
The compliance in the intervention studies was good. Only one child in Study II did 
not complete the two interventions. According to weight of the returned spread 
containers, the adults consumed up to 100% and children from 80% to 85% of the 
scheduled plant stanol and sterol ester spreads, respectively. No side effects were 
reported. There was no change in body weight during 15-week consumption of 
phytosterol ester spreads in children (Study II). The weight and blood pressure of the 
adult subjects consuming plant stanol and sterol ester spreads remained constant 
during the interventions (Studies III and IV). 
5.2. Baseline values 
We wanted to evaluate the non-cholesterol sterols in serum and their distribution in 
different lipoproteins in FH with marked hypercholesterolemia and in their non-
affected controls. Further, we also wanted to determine whether additional data from 
cholesterol metabolism can be obtained by analyzing the non-cholesterol sterols from 
different lipoproteins. Study I concentrated on baseline values, but we collected 
baseline data also from intervention studies, in order to obtain information on factors 
affecting the response to phytosterol ester treatment in the present study population. 
5.2.1. Serum and lipoprotein lipids 
The baseline lipid values of Studies II-IV and the lipids of Study I are shown in Table 
3. In Study IV a mean of two baseline measurements was calculated for two 
heterozygous subjects not receiving statin treatment. Serum and LDL cholesterol 
levels were higher in children with FH than in non-affected normolipidemic children, 
whereas HDL cholesterol was similar in the two groups. Despite the long-term statin 
treatment, the total and LDL cholesterol levels in FH adults (Study III) were still 
above 5.0 mmol/l and 3.0 mmol/l, respectively, but lower than in FH adult subjects 
without statin treatment (Study IV). LDL cholesterol was only insignificantly 
correlated with the statin dose in Study III (r= -0.333). Serum total and LDL 
cholesterol values were the same during the home diet in heterozygous parents 
without any lipid-lowering medication and in the homozygous offspring on statin 
treatment and repeated LDL apheresis.  
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Gender or the type of LDL apoB receptor mutations did not affect the serum lipid 
levels. In children without FH, but not in those with FH, serum total and LDL 
cholesterol levels were higher in subjects with apoE-4 phenotype than in subjects 
with combined apoE-2 and apoE-3 phenotypes (Study I). The esterification 
percentages of serum (~70%), VLDL (60-70%), and LDL (~70%) were similar in 
children with and without FH, whereas the esterification percentages of HDL (83% 
vs. 81%) and IDL (69% vs. 60%) were higher in FH than in non-FH children (Table 
2, in Study I). 
Table 3. Baseline lipids (mmol/l) of the study subjects 
Variable Study I Study II Study III a  Study IV  
 FH  non-FH   Hyperchol.   FH + statin  Family study 
 Children Children                 Adults             HeZ HoZ 
 n=18 n=29 n=23 n=18  n=2b n=1 
Serum Chol 7.5±0.3* 4.2±0.1 6.8 ±0.3 6.3±0.2 10.4, 9.6 9.4 
LDL Chol 5.5±0.3* 2.2±0.1 5.2±0.3  4.5±0.2 8.5, 8.1 8.2 
HDL Chol 1.2±0.1 1.3±0.04 1.1±0.1  1.3±0.1 1.3, 1.3 1.1 
VLDL Chol 0.2±0.03 0.2±0.03 n.a. 0.3±0.1c 0.5, 0.2 0.01  
IDL Chol 0.1±0.02 0.1±0.01 n.a.  n.a. n.a. n.a. 
CM Chol n.a. n.a. n.a.  3.0±0.4 n.a. n.a. 
Serum TG 0.8±0.1 0.9±0.1 1.0±0.1  1.2±0.1 1.6, 0.9 0.7 
Mean±SEM, except in Study IV; Chol, cholesterol; FH, familial hypercholesterolemia; HeZ, 
heterozygous FH; HoZ, homozygous FH; Hyperchol., hypercholesterolemic; n.a., not 
available; a subjects from study V are included, b mean of two measurements/person, c 
measured by GLC, * p<0.05 vs. non-FH children 
5.2.2. Serum non-cholesterol sterols 
At baseline, serum concentrations of most non-cholesterol sterols were higher in 
children with FH than in non-affected children (Table 4). In the homozygous subject, 
the concentrations of serum cholesterol precursor sterols were at the upper limits of 
heterozygous parents. The levels of plant sterols were mostly similar in both children 
and adult study populations, even though the concentration of sitosterol was lower in 
heterozygous adults not treated with statins compared with those on statin treatment. 
The serum levels of plant sterols and cholestanol, the absorption markers, were 
markedly higher in the homozygous subject than in the heterozygous parents. The 
highest plant stanol values were obtained in statin-treated FH subjects and in the 
homozygous FH subject.  
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Table 4. Baseline cholesterol (mg/dl), squalene, and non-cholesterol sterol (µg/dl) concentrations  
Variable Study I  Study II Study IIIa Study IV 
 FH non-FH   Hyperchol. FH with statin Family Study 
 Children  Children Adults HeZ  HoZ 
 n=18 n=29  n=23 n=18 n=2b n=1 
cholesterol 267±11* 152±4 248±9 212±8 375, 346 333 
squalene 63±14 51±3 60±5 59±5 70, 52 147 
∆8-cholestenol 25±4 18±2 26±1 30±4 47, 39 80 
desmosterol 160±10* 84±4 211±9 141±14 329, 280 322 
lathosterol 276±25* 165±10 181±11 138±15 406, 417 418 
campesterol 1051±114* 542±29 1112±73 1049±94 935, 992 4970 
sitosterol 470±47* 266±15 489±140 542±52 398, 390 3387 
avenasterol 135±10c* 91±7 c  127±6 123±10 110, 129 487 
cholestanol 418±21* 228±8 460±22 408±33 515, 497 1059 
campestanol n.a. n.a. 4±1 15±1 5, 0 19 
sitostanol n.a. n.a. 6±1 18±2 15, 4 32 
Mean± SEM, except in Study IV; FH, familial hypercholesterolemia; HeZ, heterozygous FH; 
HoZ, homozygous FH; Hyperchol., hypercholesterolemic; n.a., not available; a subjects from 
study V included, b mean of two measurements/person, c including also sitostanol, * p<0.05 
vs. non-FH children 
Despite the marked differences in serum sterol concentrations, the respective ratios of 
non-cholesterol sterols to cholesterol in serum were similar in FH and unaffected 
children (Table 5). The serum ratios of cholesterol precursors to cholesterol were 
lower in statin-treated FH subjects than in the two subjects without statin treatment, 
whereas the ratios of serum precursor sterols of the homozygous subject were within 
the parents’ upper limits. The serum ratios of plant sterols were higher in statin-
treated FH compared with FH subjects without statin treatment. The ratio of 
cholestanol to cholesterol in serum was higher in subjects with the higher statin dose 
(atorvastatin > 40 mg) than in the subjects with the lower dose (Figure 2, in Study 
III). In the subject with homozygous FH, the serum ratios of absorption marker 
sterols were as much as 10 times greater (twice for cholestanol) compared with the 
heterozygous parents, and two to five times higher than in the statin-treated FH 
subjects.  
In the combined group of FH and non-FH children of Study I, the serum ratio of 
sitosterol to cholesterol was lower with apoE-4 phenotype than in those with other 
phenotypes (151±9 vs. 186±11 102 x mmol/mol of cholesterol). The squalene and 
non-cholesterol sterol levels in serum were similar between the genders and subjects 
with different LDL apoB receptor mutations in all studies. In children of Study I, the 
ratios of the precursor sterols in serum (e.g., lathosterol vs. ∆8-cholestenol r = 0.664, 
p<0.01 in the FH group and r =0.743, p<0.001 in the non-FH group) and also those of 
absorption markers in serum (e.g., cholestanol vs. sitosterol, r = 0.532, p<0.05 and r = 
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0.647, p<0.001, respectively) were correlated with each other. In children of Study II, 
only absorption markers in plasma were correlated with each other (e.g., campesterol 
vs. cholestanol r = 0.581, p<0.05). In statin-treated FH subjects (Study III), positive 
correlations were seen within serum cholesterol precursor sterols (e.g., lathosterol vs. 
∆8-cholestenol r = 0.753, p<0.001) and within absorption marker sterols in serum 
(e.g., campesterol vs. sitosterol r = 0.947, p<0.001). The negative correlation between 
plasma cholesterol precursors and absorption marker sterols was obtained only in 
Study II (e.g., campesterol vs. ∆8-cholestenol r = -0.471, p<0.05). 
Table 5. Baseline ratios of squalene and non-cholesterol sterols to cholesterol (102 x mmol/mol of 
cholesterol) 
Variable Study I  Study II Study IIIa Study IV 
 FH non-FH   Hyperchol. FH with statin Family Study 
 Children  Children Adults HeZ  HoZ 
 n=18 n=29  n=23 n=18 n=2b n=1 
squalene 24±5* 34±2 25±2 28±2 18, 15 44 
∆8-cholestenol 9±2 12±1 11±0.5 14±2 13, 11 24 
desmosterol 60±3 55±2 85±2 67±7 87, 81 97 
lathosterol 102±7 108±6 73±4 66±7 110, 120 125 
campesterol 393±36 358±19 451±29 508±50 250, 287 1491 
sitosterol 176±14 177±11 198±11 265±29 106, 113 1016 
avenasterol 51±3c 60±4 c  51±2 60±6 29, 37 146 
cholestanol 157±5 151±5 186±6 195±33 136, 144 318 
campestanol n.a. n.a. 2±0.3 7±1 1, 0 5 
sitostanol n.a. n.a. 2±1 9±1 4, 1 10 
Mean± SEM, except in Study IV; FH, familial hypercholesterolemia; HeZ, heterozygous FH; 
HoZ, homozygous FH; Hyperchol., hypercholesterolemic; n.a., not available; a subjects from 
study V included, b mean of two measurements, c including also sitostanol, * p<0.05 vs. non-
FH children 
To conclude, serum concentrations of non-cholesterol sterols were higher in FH 
children than in their normolipidemic controls, but when related to cholesterol, there 
was no difference between the FH and control children. The serum plant sterol and 
cholestanol levels were higher in subjects on statin treatment. The serum plant sterol 
levels were up to six times higher in the homozygous FH subject than in statin-treated 
heterozygous FH subjects. The positive correlations within cholesterol precursor 
sterols as well as absorption marker sterols suggest that these markers serve as 
indicators of cholesterol synthesis and absorption respectively also in this study 
population. 
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5.2.3. Lipoprotein non-cholesterol sterols 
In absolute concentrations, LDL and HDL transported most of squalene and non-
cholesterol sterols both in children and adults with FH and in healthy children (Table 
3, in Study I). In the heterozygous FH children, ~75% of the non-cholesterol sterols 
were carried by LDL, ~20% by HDL, and <10% by VLDL and IDL. In non-FH 
children, the respective proportions were ~55%, 35-40%, and <10% (Figure 4). In 
statin-treated FH subjects, 62-75% of the non-cholesterol sterols were carried by 
LDL, whereas in the homozygous subject, up to 92% of non-cholesterol sterols were 
transported by the extensively large LDL. 49%, 41%, 45%, and 70% of squalene 
were transported by LDL in FH children, in non-affected children, in statin-treated 
FH adults, and in homozygous FH subject, respectively, whereas up to 27% of 
squalene was transported by TRL. 
As ratios to cholesterol, the highest values of squalene and lathosterol, were obtained 
in VLDL and IDL in FH and non-FH children (Table 4, in Study I) and in VLDL and 
CM in adults with FH (Table 4, in Study III and Figure 3, in Study IV) and in the 
homozygous FH subject (Table 2 and Figure 3, in Study IV). The values of the 
precursor sterols in VLDL were mostly higher than the respective values in serum. 
The absorption marker sterols, sitosterol and cholestanol, less so campesterol, were 
most abundant in HDL and significantly higher than the respective ratios in serum 
(Table 4, in Study I; Table 4, in Study III; Table 2 and Figure 2, in Study IV). The 
lowest levels of absorption marker sterols were obtained in VLDL, IDL, and CM, and 
the values were significantly lower than the respective ratios in serum. 
Thus, the concentrations of most of the non-cholesterol sterols were higher in FH, and 
LDL transported the highest proportion of non-cholesterol sterols. This suggests that 
LDL predicts, in addition to cholesterol, also the serum concentrations of non-
cholesterol sterols. As with the ratios to cholesterol, the non-cholesterol sterol values 
were similar in FH and non-FH children. Cholesterol precursors were highest in 
VLDL, whereas cholesterol absorption marker sterols were most abundant in HDL. 
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Figure 4. Percentage distribution of absolute amounts of squalene and non-cholesterol sterols in 
lipoproteins of FH (n=18) and non-FH (n=29) children (Study I).  
For squalene, n=14 and n=24, respectively. Note that ordinate scale is changed at 90.          
* p<0.05 FH vs. non-FH. 
5.2.4. Red cell sterols 
Baseline ratios of squalene and non-cholesterol sterols to cholesterol in red cells of 
the hypercholesterolemic children (Study II) and statin-treated FH (Study III) are 
shown in Table 6.  
In general, the baseline values of all non-cholesterol sterols in red cells, but not that 
of cholesterol, were correlated with the respective values in plasma or serum (Table 
6). 
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Table 6. Baseline cholesterol (mg/dl), squalene, and non-cholesterol sterol ratios to cholesterol in 
red cells (102 x mmol/mol of cholesterol) and their correlation coefficients (r) to respective values 
in plasma (Study II) or in serum (Study III). 
Variable  Study II  r Study IIIa r 
                                    Hyperchol.                         FH + statin 
  Children                                               Adults 
  n=23   n=18  
cholesterol  114±2 -0.212  108±2 0.241 
squalene  34±6 0.131  41±4 -0.198  
∆8-cholestenol  9±1 -0.492*  4±2 0.480* 
desmosterol  59±2 0.497*  63±10 0.740* 
lathosterol  199±10 0.767*  132±17 0.961* 
campesterol  526±30 0.896*  580±58 0.995* 
sitosterol  231±63 0.923*  304±33 0.995* 
avenasterol  62±3 0.455*  74±6 0.969* 
cholestanol  237±12 0.508*  190±14 0.890* 
campestanol  0.4±0.2 -0.195  4±1 0.428 
sitostanol  8±2 -0.332  9±1 0.090 
Mean±SEM; FH, familial hypercholesterolemia; Hyperchol., hypercholesterolemic; asubjects 
from study V are included, * p<0.05 
5.3. Effects of phytosterols 
Dietary phytosterols lower serum cholesterol, and affect the serum non-cholesterol 
sterol values. However, the effects of especially plant sterol esters on serum non-
cholesterol sterols in hypercholesterolemic children, homozygous FH, and statin-
treated FH subjects have not been evaluated in detail. In addition, the data on the 
effects of phytosterol esters on red cell and lipoprotein non-cholesterol sterols are 
limited. Therefore, we measured serum, lipoprotein, and red cell non-cholesterol 
sterols during consumption of phytosterol esters in the present study populations. We 
were especially interested in changes occurring in plant sterol levels. 
5.3.1. Serum and lipoprotein lipids 
The effects of plant stanol and sterol ester spreads on serum, LDL, and HDL 
cholesterol and serum TG levels in hypercholesterolemic children (Study II) and in 
statin-treated FH (Study III) are shown in Figure 5. Both spreads lowered total and 
LDL cholesterol by 6-15%, but only the plant sterol ester spread significantly 
increased HDL cholesterol and decreased TG in statin-treated FH subjects in the 
present study.  
In children, the ingested amounts of plant stanol and sterol ester spreads correlated 
positively (r = 0.448 and r = 0.428, respectively, p<0.05 for both) with the decrease in 
LDL cholesterol. In statin-treated FH, the baseline LDL cholesterol was negatively 
correlated with its respective change i.e., the higher the baseline LDL cholesterol 
levels, the larger its reduction evoked by both spreads (Figure 6). Only in children, 
did the baseline campesterol ratio in plasma predict the subsequent decrease in the 
concentrations of total and LDL cholesterol during consumption of the plant sterol 
ester spread (r = 0.421 and r = 0.452, respectively, p<0.05 for both). 
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Figure 5. Percentual changes of serum lipids in hypercholesterolemic children (Study II, n=23) 
and in statin-treated FH subjects (Study III, n=18) during consumption of plant stanol (STA) 
and sterol (STE) ester spreads. 
* p<0.05 vs. baseline. Chol, cholesterol. 
In the homozygous FH subject (Study IV), the longer the interval between apheresis, 
the greater the pre-apheresis concentrations of serum total and LDL cholesterol (r = 
0.885 and 0.913, respectively, p<0.001). Comparison of the lipid values at similar 
apheresis intervals revealed ca. 8% and 9% reduction in total and LDL cholesterol, 
respectively by both spreads (Table 1, in Study IV). In the heterozygous parents, both 
spreads decreased on average 14% and 17% of the total and LDL cholesterol (Table 
1, in Study IV). 
These results suggest that plant stanol and sterol ester spreads are equally effective in 
lowering LDL cholesterol in hypercholesterolemic children and in statin-treated FH 
subjects in short-term studies. Further, the results indicate that in the statin-treated FH 
subjects the greatest decrease in LDL cholesterol was obtained in those subjects with 
the highest baseline levels of LDL cholesterol, whereas in hypercholesterolemic 
children the baseline plasma campesterol ratio predicted the best response to plant 
sterol ester spread. 
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Figure 6. Correlation between baseline LDL cholesterol to respective change in LDL cholesterol 
during consumption of plant stanol (STA) and sterol (STE) ester spreads in statin-treated FH 
subjects (Study III, n=18). 
The gray-colored symbols depict subjects having also bile acid sequestrants.  
5.3.2. Serum and lipoprotein non-cholesterol sterols 
Cholesterol precursors 
Consumption of both spreads increased serum ratios of cholesterol precursor sterols, 
significantly so for desmosterol and lathosterol, in hypercholesterolemic children 
(Study II), in statin-treated FH subjects (Study III) (Figure 7), as well as in two FH 
subjects without statin treatment (Figure 3, in Study IV). The lower the baseline ratios 
of the precursors of cholesterol, the higher were their increments with both spreads in 
hypercholesterolemic children (r ranged from –0.229 to -0.617) and statin-treated FH 
subjects (r ranged from –0.457 to –0.820, except lathosterol). In the homozygous 
subject, the precursor sterol ratios appeared to be decreased by the sterol ester spread 
but increased in VLDL by the stanol ester spread (Figure 3, in Study IV). 
No changes occurred in cholesterol precursor concentrations or ratios to cholesterol in 
different lipoproteins during the interventions in statin-treated FH subjects (Table 4, 
in Study III).  
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Figure 7. Percentual changes of squalene and cholesterol precursor sterols in 
hypercholesterolemic children (Study II, n=23) and in statin-treated FH subjects (Study III, 
n=18) during consumption of plant stanol (STA) and sterol (STE) ester spreads. 
* p<0.05 vs. baseline. 
Phytosterols and cholestanol 
Consumption of the plant sterol ester spread increased serum campesterol and 
sitosterol ratios in hypercholesterolemic children and in statin-treated FH subjects, 
whereas the respective values were decreased by the plant stanol ester spread (Figure 
8). Serum avenasterol levels were decreased in children by both spreads, but only by 
plant stanol ester spread in FH adults. In absolute concentrations, plant sterol ester 
spread increased the total amount of plant sterols from 1.5 mg/dl up to 2.3 mg/dl in 
children (Study II) and from 1.5 mg/dl to 2.4 mg/dl in statin-treated FH subjects. The 
plant stanol ester spread increased serum plant stanol concentrations several times, 
but the values remained small (e.g., campestanol 19±2 µg/dl in children and 35±3 
µg/dl in statin-treated FH). Both spreads decreased serum cholestanol levels, but this 
was significant only for the plant sterol ester spread. 
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Figure 8. Percentual changes of plant sterols and cholestanol in hypercholesterolemic children 
(Study II, n=23) and in statin-treated FH subjects (Study III, n=18) during consumption of plant 
stanol (STA) and sterol (STE) ester spreads. 
*p<0.05 vs. baseline, # p<0.001 STE vs. STA 
The baseline ratios of plasma campesterol and sitosterol predicted their respective 
changes during consumption of the spreads, such that the plant sterol ratios decreased 
most in subjects with the highest respective baseline levels during plant stanol ester 
spread in children (Study II) (e.g., r = -0.625 for campesterol, p<0.05) and in statin-
treated FH subjects (Study III) (Figure 9 for sitosterol). In statin-treated FH subjects, 
during consumption of the sterol ester spread, the increase of sitosterol (Figure 9) and 
campesterol was greatest in subjects with the highest baseline levels. In addition, a 
similar association was observed in the children of Study II (e.g., r = 0.489 for 
sitosterol, p<0.05). A more detailed analysis revealed that the increase of serum plant 
sterols was greatest in adult FH subjects with the highest statin doses. The change of 
serum cholestanol was negatively correlated with its baseline levels with both spreads 
in both study groups (r ranged from –0.361 to –0.632) (Figure 1, in Study III). 
In statin-treated FH subjects, the concentrations of campesterol and sitosterol were 
increased in CM, LDL, and HDL during consumption of plant sterol ester spread 
(Table 4, in Study III). However, the percentual proportion of campesterol and 
sitosterol was decreased in LDL and increased in HDL by both spreads (Figure 10a 
for campesterol). When the results were calculated as ratios to cholesterol, the 
percentual increments of plant sterols by plant sterol ester consumption, and the 
respective decrements by plant stanol consumption were similar in all lipoproteins 
(Figure 10b; Table 4, in Study III). 
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Figure 9. Correlations between baseline serum sitosterol to cholesterol ratio and change in serum 
sitosterol ratio to cholesterol during consumption of plant stanol (STA) and sterol (STE) ester 
spreads in statin-treated FH subjects (Study III). The gray-colored marks depict subjects 
having also bile acid sequestrants. 
 
 
Figure 10. Campesterol in different lipoproteins. 
a) The percentage distribution of absolute amounts of campesterol in different lipoproteins of 
statin-treated FH subjects at baseline (BL) and during consumption of plant stanol (STA) and 
sterol (STE) ester spreads. * p<0.05 vs. baseline.  
b) The percentual changes of campesterol ratios to cholesterol in serum and different 
lipoproteins during consumption of plant stanol (STA) and sterol (STE) ester spreads.* p<0.05 
vs. baseline. 
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In the homozygous FH subject, plant sterol ester spread increased the serum ratios of 
plant sterols by ~30%, and the changes were similar in all lipoproteins (Figure 11 for 
sitosterol). The concentration of serum total plant sterols was increased up to 14 
mg/dl, and the increase occurred mainly in LDL (Figure 11 for campesterol). During 
consumption of plant stanol ester spread, the levels of plant sterols were decreased 
even below the values obtained during consumption of the home diet. The 
concentration of cholestanol and its ratio to cholesterol were reduced by both spreads 
by ~15%. Plant stanol concentrations were increased up to 0.3 mg/dl in serum by 
plant stanol ester spread. 
 
 
Figure 11. Concentration of campesterol and ratio of sitosterol to cholesterol in serum and 
different lipoproteins of the homozygous FH subject on home diet and during consumption of 
plant sterol (STE) and stanol (STA) ester spreads (Study IV). 
 
To conclude, dietary plant sterol ester spread increased the serum and lipoprotein 
plant sterol levels in all study populations, whereas the dietary plant stanol ester 
spread decreased the respective values. The changes occurred similarly in all 
lipoproteins. The baseline serum levels of plant sterols predicted the respective 
change during consumption of phytosterol esters, such that the serum plant sterol 
levels were increased most in those subjects with the highest serum baseline plant 
sterol levels, whereas consumption of plant stanol ester spread resulted in the greatest 
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decrease of serum plant sterols in the same subjects. The changes in serum plant 
sterols did not correlate with the changes in LDL cholesterol. 
5.3.3. Red cell sterols 
The red cell cholesterol concentrations remained constant during the intervention 
periods both in hypercholesterolemic children and in statin-treated FH subjects. 
Neither the total nor the free serum cholesterol could be correlated with the red cell 
cholesterol. The changes in the ratios of cholesterol precursor sterols to cholesterol in 
red cells were inconsistent in the two study populations; the ratio of lathosterol to 
cholesterol was increased by ~20% in both studies, whereas the desmosterol ratio was 
increased by ~15% only in Study II. Negative correlations were obtained between 
most baseline cholesterol precursors and their respective change with both spreads in 
both study populations (e.g., r ranged from –0.747 to –0.813 for red cell ∆8-
cholestenol). The changes of cholesterol precursors in red cells were mostly 
correlated with the changes in serum (Table V, in Study II; Figure 12b for lathosterol 
of the combined study population). 
 
 
Figure 12. Correlations between changes of serum and red cell campesterol (a) and lathosterol 
(b) to cholesterol ratios (102 mmol/mol of cholesterol) during consumption of plant stanol (STA) 
and sterol (STE) ester spreads of combined study population (hypercholesterolemic children, 
Study II, n=23 and statin-treated FH, Study III, n=18). For sitosterol, y=0.9x+8.7 (STE), y=1.2x-1 
(STA), and for lathosterol, y=3.1x-15 (STE), y=2.3x-14 (STA). 
 
The ratios of campesterol and sitosterol to cholesterol were decreased in red cells by 
~20-35% during consumption of plant stanol esters, and increased by ~40-75% 
during consumption of plant sterol esters (Table 4, in Study II and Table 3, in Study 
III). The changes of the campesterol and sitosterol ratios to cholesterol in red cells 
correlated with the respective changes in plasma or serum (Figure 12a for sitosterol in 
the combined study population). The baseline plant sterol levels in red cells were 
negatively correlated with the change of plant sterols in red cells in both study 
populations during consumption of the stanol ester spread (e.g., r ranged from –0.652 
to –0.691 for campesterol; Table 3, in Study II). Only insignificant positive 
correlations between baseline red cell plant sterol levels and the dietary plant sterol 
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ester-induced increase were observed in both study populations (e.g., r ranged from 
0.360 to 0.371 for sitosterol). Red cell content of plant stanols was increased by the 
stanol ester spread, but the actual amounts remained small (e.g., 25 µg/dl and 41 
µg/dl for sitostanol in hypercholesterolemic children and statin-treated FH subjects, 
respectively). 
Thus, the changes of plant sterols in red cells correlated highly with the respective 
change in serum or in plasma occurring during phytosterol ester treatment in both 
study populations.  
5.3.4. Removal of intravenous Intralipid 
In FH, the clearance of postprandial lipoproteins may be impaired in general, but it is 
improved by statin therapy. In order to determine, whether inhibition of cholesterol 
absorption by dietary phytosterols further could alter the clearance of postprandial 
lipoproteins, we studied the removal of intravenous Intralipid+squalene emulsion 
during consumption of dietary phytosterol esters.  
Serum total and LDL cholesterol concentrations were significantly decreased 
(p<0.05-0.01) by both phytosterol-enriched spreads in the five subjects of this 
substudy, whereas HDL cholesterol and TG remained stable (Table 1, in Study V). 
CM and VLDL cholesterol remained unchanged between the periods, while CM TG 
was increased by both spreads. The sterol ester spread increased and the stanol ester 
spread decreased the concentrations of plant sterols in serum and CM. No significant 
changes were seen in serum, CM, and VLDL squalene levels between the dietary 
intervention periods (Table 2, in Study V).  
The Intralipid-squalene fat load test was performed at baseline during statin therapy 
and during consumption of plant stanol and sterol ester spreads. The incremental 
concentrations of cholesterol, TG, squalene, and sitosterol were subtracted from the 
baseline levels. These incremental curves are shown in Figure 13.  
At baseline and during the intervention periods, the peak concentrations of 
cholesterol, TG, squalene, and plant sterols in CM were reached at 10 min. In VLDL, 
the peak level of sitosterol and squalene was reached at 10 to 20 min, and of TG at 60 
min, while no significant increments of cholesterol and campesterol occurred in 
VLDL. The incremental curves for CM and VLDL cholesterol and TG were rather 
similar during consumption of the stanol and sterol ester spreads than at baseline 
(Figure 13). The peak concentration of sitosterol at 10 min was higher during 
consumption of the spreads than at baseline, and the increments of both campesterol 
and sitosterol at 120 min were higher during the stanol ester spread than at baseline. 
The AUICs of cholesterol, TG, and plant sterols in CM and VLDL were similar at 
baseline and during the intervention periods. 
The incremental concentrations of CM squalene were higher up to 120-180 min 
during the two spread periods vs. baseline, and at 180 min the incremental 
concentrations still exceeded the starting values (Figure 13). The AUICs of CM 
squalene were similarly higher with both spreads than at baseline (4252±917 at 
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baseline, 7424±818 by stanol esters, and 7810±688 by sterol esters, p<0.05 by 
ANOVA). The higher the incremental squalene concentration at 10 min, the higher 
the AUIC of the combined (baseline+stanol+sterol) values (r=0.836, p<0.05). The 
incremental concentrations of VLDL squalene were higher in some measurement 
points only for the stanol ester spread vs. baseline (Figure 13). The AUICs of VLDL 
squalene were only insignificantly higher with both spreads compared with baseline. 
Clearance of CM squalene and campesterol was slower than that of sitosterol and TG 
during all periods (Figure 6, in Study V). The clearance curves of squalene, plant 
sterols, and TG were similar between the periods, and the half-lives of different 
compounds did not differ between the periods. The baseline sitosterol (0.748, p<0.01) 
was positively correlated with the respective half-lives. 
Thus, removal of squalene and less so plant sterols was unexpectedly impaired during 
consumption of phytosterol esters in statin-treated FH subjects. However, the 
clearance curves and half-lives of the different compounds did not differ between the 
three periods. The altered plant sterol concentrations in serum by the spreads did not 
affect the removal of plant sterols from CM or VLDL. 
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Figure 13. The differences between incremental concentrations during consumption of plant 
stanol (closed triangle) and sterol (open circle) ester spreads vs. baseline (level 0) for chylomicron 
and VLDL cholesterol, triglycerides, squalene, and sitosterol in statin-treated FH subjects. 
Results represent means±SEM. Incremental concentration different from baseline, $ p<0.05 
by stanol esters, # p<0.05 by sterol esters, and ¤ p<0.05 from sterol esters by stanol esters. 
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6. DISCUSSION 
6.1. Study population and design 
Altogether 88 subjects, including 39 males and 49 females with an age-range of 1 to 
62 years, were recruited into the present study. Fifty-one of the subjects had DNA 
diagnosed FH, and the clinical picture and family history of a further two subjects 
(one child and one adult) were appropriate to FH, and thus they were included in the 
FH group. Six children without FH in Study II were hypercholesterolemic with 
similar serum cholesterol levels as the FH children, and were thus included in the 
intervention study. Three children from Study I participated also in Study II, and five 
adult subjects of Study V also took part of Study III. Only prepubertic children were 
included in Study II, since during pubertal development, some changes in serum 
lipids may occur (Porkka et al. 1994). The negative DNA diagnosis of the 29 
normolipidemic subjects in Study I suggested that they were non-affected members of 
FH families. However, the present normolipidemic subjects cannot be considered as a 
normal control population, since dietary recommendations given for all the FH 
families could have affected the dietary intake of fat and cholesterol and subsequently 
lowered the serum lipid levels of non-affected children as well. 
Study III consisted of FH subjects on statin therapy. For ethical reasons we decided 
not to study adults with FH without statin treatment. The two subjects in Study IV 
had refused to start statin therapy but were amenable to dietary treatment. In Study 
III, the prior statin treatment was kept unchanged. All subjects had used their statin 
treatment for many years, such that the steady state of cholesterol metabolism had 
been reached. Since the subjects were their own controls, the possible effects of 
confounding factors, e.g., different statin preparations and doses and possible 
additional treatment, such as bile acid sequestrants or hormone replacement therapy 
were thus kept to a minimum. Study IV was a family study including only three 
subjects. Due to the low prevalence of homozygous FH, a study with a larger number 
of homozygous FH adults is impossible to do in Finland. Accordingly, no statistical 
calculations could be performed.  
In Study I, the subjects visited the Outpatient Clinic once and only one blood sample 
was obtained. Due to the young age of some study subjects, the numbers of visits and 
blood samples were kept to a minimum. Studies II-V had a cross over design. Study 
II had a wash-out period, but Studies III-V were conducted without any wash-out 
period. The lack of wash-out period in Studies III-V was taken into account in the 
statistical calculations by evaluating the effect of treatment period and sequence of 
treatment.  
In the homozygous FH subject, LDL apheresis was scheduled to occur at fortnightly 
intervals, but for the patient-related reasons, the periods were sometimes prolonged. 
Since apheresis is followed by increased levels of serum sterols, including plant 
sterols, the prolonged intervals inevitably affected the results. However, we analyzed 
the data also by adjusting serum non-cholesterol sterols to the respective cholesterol 
levels. Since we could not make any statistical calculations between the homo- and 
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heterozygotes, this study gives only a profile of one homozygous subject compared 
with the heterozygous parents. 
The compliance in the intervention studies was good. In addition, increased serum 
plant stanol and sterol levels during the interventions, as well as increased serum 
cholesterol precursor sterols served as markers for good compliance. 
6.2. Serum and lipoprotein lipids 
6.2.1. Baseline 
The impaired LDL apoB receptor in FH is accompanied with high serum total and 
LDL cholesterol levels (Goldstein et al. 2001), also in children (Kwiterovich 1989). 
Thus, as expected, serum total and LDL cholesterol levels were higher in the FH than 
in the non-FH children (Study I). The serum lipid values of the two groups were 
definitely different, since there was no overlapping in the lipid values; the lowest 
LDL cholesterol value in FH was 3.89 mmol/l, whereas the highest LDL cholesterol 
value in non-affected children of same age was 2.92 mmol/l.  
ApoE phenotype affects the serum total and LDL cholesterol levels in non-FH adults 
(Davignon et al. 1988) and in normocholesterolemic children (Kallio et al. 1997). 
However, no association between serum total and LDL cholesterol and apoE 
phenotype has been obtained in adults (Gylling et al. 1989a) or children (Wiegman et 
al. 2003) with FH. We obtained similar findings in the present study. In the children 
without FH, the highest serum total and LDL cholesterol values were obtained in the 
children with apoE-4 phenotype, whereas no association between serum total and 
LDL cholesterol and apoE phenotype was present in children with FH. The authors 
from a previous study have speculated that the presence of the mutation in LDL apoB 
receptor gene could overrule other factors, including apoE phenotype (Wiegman et al. 
2003).  
The majority of the patients on statin therapy do not achieve the recommended LDL 
cholesterol levels (Andrews et al. 2001). Thus, it was not surprising that despite 
ongoing statin therapy in Study III, the serum total and LDL cholesterol values were 
above the recommended levels (5.0 mmol/l and 3.0 mmol/l, respectively) according 
to European guidelines (De Backer et al. 2003). Taking into account the fact that all 
the subjects had FH, the statin doses used by the present study subjects were 
surprisingly low. Accordingly, especially in FH, higher statin doses should be used to 
achieve the recommended serum lipid values. In fact, when the present statin-treated 
FH subjects were divided into high- and low-statin groups, LDL cholesterol levels 
were as much as 1 mmol/l lower in the high-statin group compared with subjects with 
lower statin dose. The difficulties to achieve tolerable LDL cholesterol values in 
homozygous FH subjects could also be seen in the present study. Thus, despite 
aggressive lipid-lowering therapy given to the present homozygous FH subject, the 
total and LDL cholesterol levels were at the same level as in the heterozygous parents 
who were not taking any hypolipidemic medication (Study IV). 
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6.2.2. Effects of phytosterols 
The cholesterol lowering effect of dietary phytosterols on serum lipid levels has been 
demonstrated in several earlier studies reviewed recently by Katan et al. (2003). 
These effects have mostly been studied by short-term interventions, as also in the 
present study. However, only two long-term studies, one with plant stanol esters 
(Miettinen et al. 1995) and the other one with plant sterol esters (Hendriks et al. 2003) 
have been conducted. The consumption of plant stanol esters for one year in 
hypercholesterolemic subjects led to ~9% and ~13% reduction in LDL cholesterol 
with doses of 1.8 g/day and 2.6 g/day of plant stanols (Miettinen et al. 1995), whereas 
consumption of lower dose of plant sterol esters (1.6 g/day of plant sterols) reduced 
LDL cholesterol by ~6% (Hendriks et al. 2003) when compared with placebo group. 
Closer inspection of the results showed that the LDL cholesterol reduction did not 
persist in the long-term use, and accordingly the mean LDL cholesterol value after 
one year’s consumption of plant sterols was reduced (5%) from the baseline value 
only in men (Brink and Hendricks 2000). Accordingly, the short-term studies, 
including the present intervention study, demonstrate only the cholesterol lowering 
effect of phytosterol esters over short-term use. Thus, one cannot draw any 
conclusions on the long-term benefit of dietary phytosterol esters from short-term 
studies. 
In children, dietary phytosterols offer a well-tolerated means to lower effectively 
serum total and LDL cholesterol. In particular, the treatment of children with FH 
should be started as early as possible, and dietary phytosterol esters are suitable and 
effective prior to statin therapy. The present 12% and 9% reductions obtained in LDL 
cholesterol by plant stanol and sterol esters were of the same magnitude as those 
obtained from previous studies in FH children (Gylling et al. 1995, Vuorio et al. 
2000, Amundsen et al. 2002, de Jongh et al. 2003). Accordingly, it may be concluded 
from the present and earlier studies that plant stanol and sterol ester spreads are 
equally effective in hypercholesterolemic children in short-term studies, but their 
long-term efficacy has not been evaluated. In fact, in addition to long-term efficacy of 
phytosterol esters, the long-term effects of the possible reduction in the levels of fat 
soluble vitamins and especially antioxidants (Vuorio et al. 2000, Tammi et al. 2000) 
on growth of the children will need to be assessed.  
Plant stanol esters have been shown to be most efficient in adult subjects with high 
baseline absorption of cholesterol (i.e., high baseline serum cholestanol ratio) 
(Gylling et al. 1997, Gylling and Miettinen 2002a). In the present study in children 
(Study II), high baseline cholesterol absorption predicted also efficient reduction of 
plasma total and LDL cholesterol, but this correlation was, however, seen only for the 
sterol ester spread. There were no correlations between cholesterol synthesis markers 
and reduction in plasma total or LDL cholesterol obtained by either spreads. This is in 
contrast with an earlier study with FH children consuming stanol esters (Gylling et al. 
1995). In that study, the most efficient reduction of LDL cholesterol was 
demonstrated in those subjects with the highest baseline cholesterol synthesis. This 
discrepancy in results remains unclear, but may be related to the small number of 
study subjects. The study by Gylling et al. (1995) consisted of only subjects with FH, 
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whereas the present study group included also hypercholesterolemic children without 
FH. Thus, the effects of heterogeneous study population on the present results cannot 
be ruled out. 
Adding dietary phytosterol esters to statin therapy offers an opportunity to affect both 
the synthesis of cholesterol and the intestinal absorption of dietary and biliary 
cholesterol. The additional reduction of 9-10% and 14-15% of serum total and LDL 
cholesterol with phytosterol esters in statin-treated FH subjects (Study III) is in 
accordance with previous short-term studies conducted with subjects on concomitant 
statin treatment (Table 1). Even though only one subject achieved the goal of LDL 
cholesterol <3.0 mmol/l, 2/3 of the subjects, instead of 1/3 prior to the dietary 
intervention, achieved LDL cholesterol level below 4.0 mmol/l. The present reduction 
in LDL cholesterol achieved by phytosterol esters was almost similar to the 
reductions obtained by ezetimibe (from 14% to 25%) when this drug has been added 
to ongoing statin therapy in mildly hypercholesterolemic subjects (Davidson et al. 
2002, Gagné et al. 2002a). Ezetimibe also improved HDL cholesterol and TG values 
in statin-treated subjects. Even though some improvement in HDL cholesterol and 
TG concentrations has been obtained during consumption of phytosterol esters (Katan 
et al. 2003) as found also in the present study, phytosterols in general do not affect 
either HDL cholesterol or TG levels. 
The negative correlation of baseline LDL cholesterol level with its respective change 
(Figure 6) suggests that the efficiency of phytosterol esters to lower LDL cholesterol 
is better in those subjects with higher baseline LDL cholesterol values. This would 
further suggest that subjects treated with a low dose of statin or those responding 
insufficiently to statin treatment e.g., due to high baseline cholesterol absorption 
efficiency (Miettinen et al. 2000a), may achieve optimal benefit from the cholesterol 
absorption inhibitor combined with statin. 
The hypocholesterolemic effect of phytosterol esters was difficult to evaluate in the 
homozygous FH subject because of the varying LDL apheresis intervals. However, 
some reduction in LDL cholesterol (~9%) was detectable at the comparable two-week 
post-apheresis periods during stanol and sterol ester periods. Ezetimibe combined 
with statin decreased LDL cholesterol by about 20% in 33 homozygous FH patients, 
of whom some were on LDL apheresis treatment (Gagné et al. 2002b). These results 
suggest that an additional benefit can be obtained from the inhibition of cholesterol 
absorption even in individuals with homozygous FH. 
6.3. Serum non-cholesterol sterols  
We measured serum non-cholesterol sterols in FH and normocholesterolemic children 
in Study I, and compared the serum values with those in different lipoproteins. In 
addition, since earlier studies have demonstrated that dietary plant sterols in their free 
form can increase the serum plant sterols levels markedly especially in children 
(Mellies et al. 1976a), we evaluated the effects of dietary plant sterol esters on serum 
plant sterol levels in hypercholesterolemic children. In addition, the association of 
high serum plant sterol levels and CHD (Glueck et al. 1991, Sudhop et al. 2002a, 
Assmann et al. 2003) has raised the question of how high the serum plant sterol levels 
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may be increased at baseline and during consumption of phytosterol esters in special 
study populations, such as in homozygous FH and in heterozygous FH with statin 
treatment.  
6.3.1. Baseline 
The data from Study I showed that serum non-cholesterol sterol concentrations were 
markedly higher in FH than in normolipidemic children, similarly to the situation in 
FH adults (Gylling and Miettinen 1988). In addition, the highest concentrations of all 
non-cholesterol sterols were seen in the homozygous FH subject (Study IV). Thus, it 
seems that serum non-cholesterol sterol levels follow the respective cholesterol 
levels, and in addition to serum cholesterol levels, the grossly increased LDL fraction 
also determines the concentrations of non-cholesterol sterols. 
Serum cholesterol precursors 
Despite differences in concentrations of cholesterol precursor sterols, children with 
and without FH had similar serum ratios of cholesterol precursor sterols (Study I). 
Since serum levels of cholesterol precursor sterols correlate positively with 
cholesterol synthesis (Kempen et al. 1988, Miettinen et al. 1990b), the similar ratios 
of these precursor sterols in serum in FH and non-FH children suggest that 
cholesterol synthesis was similar in the two groups of children. In fact, similar 
findings have been obtained in an earlier study in children, in whom the cholesterol 
synthesis was evaluated by the sterol balance technique (Martin and Nestel 1979).  
Surgical procedures performed in the homozygous FH subject (the portacaval shunt 
and ileal bypass operation) have apparently altered cholesterol synthesis (Miettinen 
1979), but the effects of these procedures have possibly been modified by long-term 
statin and apheresis treatments, even though only slight and inconsistent changes in 
cholesterol synthesis have been reported during long-term apheresis treatment (Pfohl 
et al. 1994, Gylling et al. 1998). However, cholesterol precursor sterol ratios were 
similar in the homozygous offspring at baseline on current treatment and in the 
heterozygous parents without statin therapy. This would suggest that cholesterol 
synthesis was similar in the members of this FH family. Since statin treatment 
inhibits cholesterol synthesis and subsequently lowers cholesterol precursor sterol 
ratios in serum (Kempen et al. 1988, Uusitupa et al. 1992, Vanhanen and Miettinen 
1992a, Vanhanen et al. 1992, Pfohl et al. 1998), the serum ratios of desmosterol and 
lathosterol were lower in statin-treated FH subjects than in the two FH subjects 
without statin treatment, and thus also lower than in the homozygous FH subject. 
Accordingly, it seems that despite high-dose statin treatment, cholesterol synthesis 
was upregulated in the homozygous subject, due to altered metabolic state caused by 
LDL apheresis treatment and surgical procedures etc. 
Serum phytosterols and cholestanol 
In healthy subjects, the total plasma plant sterols range from 0.3 to 1.0 mg/dl 
(Björkhem et al. 2001). Accordingly, the serum total plant sterol concentration of 
~0.9 mg/dl of the non-FH children was within the normal limits. However, even at 
 
73 
baseline, the mean total serum plant sterol concentration up to ~1.5 mg/dl in all FH 
subjects was doubled compared with non-affected children, and in the homozygous 
subject the total serum plant sterol concentration (~9 mg/dl) was up to ten times 
higher than in normolipidemic children. Accordingly, FH children without any 
medication as well as FH adults with statin therapy and homozygous FH subject of 
the present study all had increased serum plant sterol levels at baseline. Whether this 
increased serum plant sterol level increases the risk for CHD in these subjects, is 
unknown. 
In adults with FH, the serum plant sterol and cholestanol ratios to cholesterol have 
been shown to be higher than in a randomly selected Finnish male population 
(Gylling and Miettinen 1988). In contrast, Vuorio et al. (2002) demonstrated that at 
the age of one year, all the serum non-cholesterol sterols were similar in FH and non-
FH-children. Similarly, the present study showed that ratios of serum plant sterols 
and cholestanol to cholesterol were similar in children with FH compared to their 
non-affected controls. Cholesterol absorption efficiency has earlier been studied for 
ethical reasons only in adult subjects with FH. These studies have demonstrated that 
the absorption of cholesterol was similar in subjects with FH and their controls 
(Connor and Lin 1974, Gylling and Miettinen 1989). Accordingly, similar to the 
situation in adults with FH, the present data suggest that there is no difference in the 
cholesterol absorption efficiency between the children with FH and their 
normolipidemic controls. 
ApoE phenotype has been postulated to control cholesterol absorption efficiency in 
Finnish modestly hypercholesterolemic adults (Kesäniemi et al. 1987), as well as in 
adults with FH (Gylling et al. 1989a). In addition, serum plant sterol levels were 
higher in healthy children with apoE-4 phenotype compared with the children with 
apoE-3 phenotype (Tammi et al. 2001), hinting at more efficient cholesterol 
absorption in the children with apoE-4 phenotype. In contrast to these earlier studies, 
the sitosterol ratio to cholesterol was lowest in the non-FH children as well as in the 
combined group of FH and non-FH children with the apoE-4 phenotype (Study I). All 
the families in the present study had received dietary advice to control the children’s 
dietary intake of saturated fat and cholesterol, whereas adult subjects from an earlier 
study were studied on their regular home diet (Kesäniemi et al. 1987). Thus, the 
discrepancy of the present results and results from adults could be explained by low 
intake of dietary cholesterol by the children of the present study, since there was no 
association between different apoE phenotypes and cholesterol absorption in study 
populations consuming a low cholesterol diet (Miettinen et al. 1992a, Bosner et al. 
1999). However, the healthy 13-month old children from the study by Tammi et al. 
(2001) had received dietary recommendations, and their dietary intake of cholesterol 
was low. Thus, the discrepancy of the results from the children of the present and an 
earlier study (Tammi et al. 2001) remains a mystery.  
Statin treatment has increased the serum plant sterol levels in short- (Uusitupa et al. 
1992, Vanhanen et al. 1992, Vanhanen and Miettinen 1992a) and long-term 
(Miettinen et al. 2000a, Miettinen and Gylling 2003, Miettinen et al. 2003) studies. 
Thus, the statin-treated FH subjects in Study III in the beginning of the study had 
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higher plant sterol levels than the FH subjects of a similar age without lipid-lowering 
medication (e.g., campesterol 508±50 102 x mmol/mol of cholesterol vs. 187±20 102 
x mmol/mol of cholesterol) (Gylling and Miettinen 1988). This increase of serum 
plant sterols has been assumed to be caused by decreased biliary excretion of plant 
sterols during statin treatment (Miettinen 1991). However, recently it was also found 
out that treatment with a high dose of atorvastatin in subjects with low baseline 
cholesterol absorption led to increased cholesterol absorption efficiency accompanied 
by increased ratios of plant sterols and cholestanol (Miettinen and Gylling 2003). The 
present study also showed that those subjects being given the higher dose of statin 
had higher baseline ratios of cholestanol to cholesterol, suggesting that their 
cholesterol absorption efficiency was higher. However, no direct conclusion from 
statin-induced increase in cholesterol absorption could be made, since the true 
baseline data prior the statin treatment were not obtained. 
In the homozygous FH subject, the serum plant sterol and cholestanol ratios were 
four to nine times higher than in the heterozygous FH parents (Study IV). The 
surgical procedures as well as long-term statin and LDL apheresis treatments have 
apparently altered the sterol metabolism in the homozygous FH subject. However, 
some data exist from our homozygous FH subject gathered over the past few years. 
After the surgical procedures, but before the statin therapy was started, the levels of 
serum plant sterols were already high, and became further increased immediately 
after the start of statin treatment (Miettinen 1990). Thus, statin therapy apparently 
affects the serum plant sterol levels also in the homozygous FH subject, but the 
reason for the remarkably high serum plant sterol levels is possibly a sum of several 
factors. Due to the complicated cholesterol metabolism in the homozygous subject, 
no conclusions on cholesterol absorption efficiency compared with heterozygous 
parents can be made. 
6.3.2. Effects of phytosterols 
Serum cholesterol precursors 
Based on cholesterol homeostasis, the inhibition of cholesterol absorption by dietary 
phytosterols leads to loss of sterols in feces, and this is followed by a compensatory 
increase in cholesterol synthesis (Gylling and Miettinen 1994b, Gylling and Miettinen 
1996, Gylling et al. 1997, Jones et al. 2000). Since they are a marker of increased 
cholesterol synthesis, serum levels of cholesterol precursor sterols are increased by 
consumption of dietary phytosterols in adults (Hallikainen et al. 2000). In children 
with FH, the serum cholesterol precursor sterols have been evaluated only during 
consumption of plant stanol esters (Gylling et al. 1995, Vuorio et al. 2000). In 
accordance with these earlier studies, the ratios of cholesterol synthesis markers 
(mostly desmosterol and lathosterol) increased by as much as 36% with both spreads 
in hypercholesterolemic children (Study II). Thus, inhibited cholesterol absorption 
was partly compensated by increased cholesterol synthesis. 
Despite the simultaneous inhibition of cholesterol synthesis by statins, serum 
cholesterol precursors were increased in adult FH subjects by both phytosterol esters 
(Study III). In particular, the ratio of lathosterol to cholesterol was increased by 15% 
 
75 
by both spreads. Previous studies conducted in statin-treated subjects did not show 
any significant increments in the serum lathosterol level during consumption of plant 
sterol ester spread (Neil et al. 2001, O'Neill 2003). However, studies in statin-treated 
subjects consuming plant stanol ester spread have reported conflicting results. Two 
studies showed 16-19% increments of serum lathosterol (Vuorio et al. 2000, Gylling 
and Miettinen 2002c), whereas no significant increments were seen in other studies 
(Vanhanen 1994, Gylling and Miettinen 1996, O'Neill 2003). The negative 
correlation between baseline levels and respective changes of most cholesterol 
synthesis precursors in the statin-treated FH adults (Study III) suggests that 
cholesterol synthesis is increased to the greatest extent in those subjects with the 
lowest baseline values. Statin treatment decreases the serum ratios of cholesterol 
precursors (Kempen et al. 1988, Uusitupa et al. 1992, Vanhanen et al. 1992, 
Vanhanen and Miettinen 1992a, Pfohl et al. 1998) and the decrease was greater with 
the more potent statin, atorvastatin, than with simvastatin (Miettinen et al. 2003). In 
some earlier studies conducted with a combination of statins and phytosterols 
(Vanhanen 1994, Gylling and Miettinen 1996, Vuorio et al. 2000, Gylling and 
Miettinen 2002c) lower doses of statins were used compared with the present study. 
In addition, in the study by O´Neill (2003), the baseline levels of lathosterol were 
three times higher than in the present study, but there is no data of which statins were 
used or at which doses. However, neither the present nor the earlier studies were 
designed to evaluate the effects of different statin doses during consumption of 
phytosterol esters. However, indirect conclusions from earlier studies with the data 
from the present study can be drawn that potency and dosage of statins affect first the 
baseline values of serum precursor sterols and subsequently the response of serum 
precursor sterols to phytosterol treatment.  
Serum phytosterols and cholestanol 
Serum cholestanol is a surrogate marker of cholesterol absorption efficiency 
(Miettinen et al. 1989), and serves as the only reliable marker of cholesterol 
absorption during consumption of the phytosterol ester products. Thus, serum ratios 
of cholestanol were decreased by both spreads in hypercholesterolemic children and 
in statin-treated FH subjects suggesting that cholesterol absorption had been inhibited 
by the phytosterol ester products. However, significant reductions were obtained only 
with the sterol ester spread. In fact, similar results were obtained also earlier in a 
comparison study with plant stanol and sterol ester spreads (Hallikainen et al. 2000). 
The fact that plant stanol esters resulted in similar serum total and LDL cholesterol 
reduction as the plant sterol ester spread, does not support the idea that cholesterol 
absorption would have been inhibited more by the sterol ester spread. Additionally, 
recent studies have reported similar, ~30%, reduction in cholesterol absorption by 
plant stanol and sterol esters (Jones et al. 2000, Normén et al. 2000). Thus, the reason 
for different response of serum cholestanol levels by the two phytosterol ester 
products remains unknown, but could be related to quantitatively small changes in 
serum cholestanol levels. 
Plant sterol ester spread increased the serum campesterol and sitosterol levels in 
hypercholesterolemic children by 43-52% (Study II). The positive correlation 
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between the baseline sitosterol ratios with the respective changes suggests that in 
subjects with the highest sterol absorption, one observes the highest increase of serum 
sitosterol by dietary plant sterols. After consumption of 1.7 g of plant sterols for 5 
weeks by the children in the present study, the highest concentration of plasma 
phytosterol, calculated as the sum of sitosterol and campesterol, was 3.5 mg/dl. This 
is far from the total plant sterol values of up to >25 mg/dl (mean 9 mg/dl) reported by 
Mellies and co-workers (1976a) in infants with even smaller doses of dietary plant 
sterols (300-400 mg/day). The reason for those remarkable elevations remains 
unknown. The increments of serum plant sterols observed in the current study did not 
differ from those reported in adults (Weststrate and Meijer 1998, Hallikainen et al. 
2000). Accordingly, these results do not support the idea suggested by Mellies et al. 
(1976a) that the absorption of additional dietary plant sterols would be enhanced in 
children.  
Since statin therapy increases the serum plant sterol levels, the baseline statin 
treatment may affect the changes of serum plant sterols during phytosterol ester 
consumption. However, only two studies have reported how the combination therapy 
with statins and plant sterol esters can affect the serum levels of plant sterols (Neil et 
al. 2001, O'Neill 2003). In the present study, serum campesterol and sitosterol ratios 
were increased by 74% and 48%, respectively by plant sterol esters in statin-treated 
FH subjects. These percentual increments are almost twice as high as have been 
reported in earlier studies (Neil et al. 2001, O'Neill 2003). The increase of serum 
plant sterols was highest in subjects with the highest respective baseline levels (Study 
III). However, in the study of O’Neill (2003), the baseline values of serum plant 
sterols were similar or even higher than in the present study, suggesting that the 
different baseline serum levels of plant sterols could not account for the greater 
increase of serum plant sterols caused by the sterol ester spread in the present study. 
One reason for the discrepancy in increments of serum plant sterols could be the 
different doses of dietary plant sterols consumed (1.4 g in the study by O´Neill vs. 2.0 
g in the present study). In addition, the type of statin used and its dose, not mentioned 
in earlier studies (Neil et al. 2001, O'Neill 2003), affects the serum plant sterol levels. 
Accordingly, a more potent statin leads to a greater increase in serum plant sterol 
levels (Miettinen et al. 2003). Similar results were obtained also in the present study, 
since serum plant sterol ratios were increased most in those subjects receiving high-
dose statin. Thus, the serum plant sterol levels in statin-treated subjects are increased 
by the sterol ester spread most in subjects with the highest serum baseline plant sterol 
values, this being partly attributable to the use of a more potent and higher dose of 
statin. 
The mean concentration of total serum plant sterols in the heterozygous statin-treated 
FH subjects was ~2.5 mg/dl during consumption of the plant sterol ester spread, while 
in the two FH subjects without statin treatment, the total serum plant sterols 
amounted to ~1.6 mg/dl. Only two adult subjects without statin treatment could be 
studied, but this difference between the study groups gives some idea of the effect of 
statin treatment on serum plant sterol levels. Thus, prior statin therapy leads to even 
higher increments of serum plant sterols during consumption of plant sterol esters. 
Whether the increase of serum plant sterols of this magnitude is related to an 
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increased risk for CHD, is still unclear. However, in the homozygous subject, a major 
increase of serum concentrations of total plant sterols, up to 14 mg/dl, was obtained 
during consumption of plant sterol ester spread. This value approached the lower 
range of the serum plant sterols found in phytosterolemia (Björkhem et al. 2001), and 
thus could be considered as an additional risk factor for CHD.  
Dietary plant stanol esters have reduced serum plant sterol levels in many earlier 
studies in adults (Vanhanen et al. 1993, Vanhanen et al. 1994, Gylling et al. 1999, 
Hallikainen et al. 2000) and children (Gylling et al. 1995, Tammi et al. 2000, Vuorio 
et al. 2000), as well as in combination with statins (Vanhanen 1994, Gylling and 
Miettinen 1996, Vuorio et al. 2000, Gylling and Miettinen 2002a, O'Neill 2003). In 
the present study, the plant stanol ester spread decreased the levels of serum plant 
sterols by 20-40% in all study groups. A negative correlation between the baseline 
absorption markers and their respective change in children suggests that the decrease 
of serum plant sterol values was highest in those subjects with the highest respective 
baseline values. However, this negative correlation suggests also that the reduction in 
serum plant sterols may remain undetectable in subjects with low baseline values. 
Since serum plant sterol and cholestanol values are positively related to the 
cholesterol absorption efficiency under steady state (Tilvis and Miettinen 1986, 
Miettinen et al. 1989, Miettinen et al. 1990b), the baseline serum plant sterol and 
cholestanol values apparently predict the baseline cholesterol absorption efficiency 
also in the present study. Thus, children with the highest baseline serum cholestanol 
and plant sterol levels have the highest baseline sterol absorption efficiency, and plant 
stanol esters inhibit the sterol absorption to the greatest extent in these subjects. The 
similar correlation shown in statin-treated FH subjects (Figure 9) suggests that plant 
stanol esters could eradicate the statin-induced increase of serum plant sterols from 
the highest but not from the lowest values of serum plant sterols. Thus, by combining 
plant stanols to statin therapy in FH, serum plant sterol levels approached the levels 
found in the normal population without statin treatment. In addition, in the 
homozygous subject, the serum plant sterol levels were decreased to even lower 
levels than obtained for several years previously without any statin treatment 
(Miettinen 1990). Even though animal studies have shown regression of 
atherosclerotic changes by feeding plant sterols (Ikeda et al. 1981, Moghadasian et al. 
1997, Moghadasian et al. 1999a, Ntanios et al. 2003), recent indirect evidence 
suggests that increased serum plant sterol levels may be associated with CHD in 
humans (Glueck et al. 1991, Sutherland et al. 1998, Rajaratnam et al. 2000, Sudhop et 
al. 2002a, Assmann et al. 2003). Further data are needed to confirm the effects of 
serum plant sterol on development of atherosclerosis in non-phytosterolemic subjects. 
However, considering the possible role of high serum plant sterols as a risk factor for 
CHD, agents such as plant stanols, which reduce both LDL cholesterol and plant 
sterols in serum, could be recommended to be used alone or in combination with 
statins, especially for atherosclerosis-prone individuals, such as subjects with FH. 
What is the role of increased serum plant stanols? Since plant stanols are absorbed in 
low but detectable amounts, serum plant stanol levels are increased by consumption 
of plant stanols (Gylling et al. 1999, Hallikainen et al. 2000), but interestingly, 
however, they were elevated also by consumption of a plant sterol ester spread in one 
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study (Neil et al. 2001). Even though the percentual increments of serum plant stanols 
are huge, the actual amounts of plant stanols remain very small, as also observed in 
the present study. In fact, the serum plant sterol levels during consumption of plant 
sterols were up to 40 times higher than the serum plant stanol levels during 
consumption of plant stanol esters. In animal studies, similar to the situation with 
plant sterols, plant stanol feeding led to a regression of atheromas (Ikeda et al. 1981, 
Ntanios et al. 1998, Volger et al. 2001). However, in stroke-prone spontaneously 
hypertensive rats, feeding a diet enriched with plant stanols lowered the survival rate 
compared with diet enriched with plant sterols (Ratnayake et al. 2003). These results 
could be related to genetic background of the study animals. In humans, no 
association between serum plant stanols and CHD has been found.  
6.4. Distribution of non-cholesterol sterols in lipoproteins 
The non-cholesterol sterol levels are normally measured from serum. Only a few 
studies have evaluated the non-cholesterol sterols in different lipoproteins. Therefore, 
we measured the non-cholesterol sterols from different lipoproteins in children with 
and without FH, as well as in the FH adults.  
6.4.1. Baseline 
In terms of total concentrations, LDL transported the major proportion of not only 
cholesterol but also of all the non-cholesterol sterols in the present study population 
(Studies I, III, and IV). In the homozygous FH subject with the highest serum 
cholesterol levels, LDL transported the highest percentage, ~90%, of non-cholesterol 
sterols (Study IV). This suggests that lipoproteins transport the non-cholesterol 
sterols in conjunction with cholesterol. The increased percentual proportions of all 
sterols in LDL in FH suggests that LDL is rich in all sterols to be carried to 
extrahepatic tissues. On the other hand, the decreased proportions of all the sterols in 
HDL in FH suggests that the reverse transport of sterols may be reduced when 
compared with normolipidemic subjects. Another explanation could be increased 
CETP activity in FH (Inazu et al. 1992), which would be accompanied by decreased 
sterol levels in HDL in the FH group. This increased CETP activity could increase the 
non-cholesterol sterol contents in VLDL and IDL. In fact, the concentrations of some 
non-cholesterol sterols were higher in VLDL and IDL of FH children compared with 
non-affected controls (Table 3, in Study I), even though the proportions of non-
cholesterol sterols in TRL were lower in FH than in non-FH children (Figure 4). 
A few earlier studies have reported high plant sterol ratios in HDL and high 
cholesterol precursor ratios in VLDL in different study populations (Tilvis and 
Miettinen 1986, Koivisto and Miettinen 1988a, Gylling and Miettinen 1994a, 
Miettinen and Gylling 2003). In the present study, the non-cholesterol sterol values in 
serum and different lipoproteins were further compared especially in Study I, when 
the medication as a confounding factor was avoided. This comparison was made in 
order to find out, whether any advantages in evaluating the cholesterol metabolism 
could be obtained by analyzing the non-cholesterol sterols in different lipoproteins. In 
fact, it was determined that the serum ratios of cholesterol precursors underestimate 
the respective levels in VLDL and overestimate those in HDL (except squalene). On 
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the other hand, serum ratios of the absorption marker sterols underestimate the 
respective levels in HDL, and overestimate those in VLDL. A similar distribution 
was obtained in the other study populations (Studies III and IV). Thus, neither statin 
nor apheresis treatments affect the distribution of non-cholesterol sterols in different 
lipoproteins. Accordingly, though it does involve time-consuming ultracentrifugation 
and additional GLC-runs, cholesterol synthesis or absorption or their changes can be 
detected better by measurement of non-cholesterol sterols in different lipoprotein 
fractions than in serum. 
The present study confirmed that in terms of ratios to cholesterol, all the absorption 
markers are most abundant in HDL and less abundantly present in VLDL, whereas 
the ratios of cholesterol precursors are most abundant in VLDL. HDL is known to 
transport plant sterols from the tissues to bile, at least in phytosterolemia (Robins and 
Fasulo 1997), and LCAT, the enzyme partly responsible for the reverse cholesterol 
transport, is capable of esterifying also plant sterols (Nordby and Norum 1975). Thus, 
the high ratios of the plant sterols in HDL may reflect their reverse transport. The low 
levels of these sterols in VLDL could be attributable to the fact that plant sterols are 
not synthesized by the liver. It may also be speculated that dietary plant sterols and 
cholestanol are incorporated directly from CM to lipoproteins with higher density, 
such as LDL and HDL.  
Endogenous hepatic cholesterol synthesis increases the hepatic amounts of synthesis 
markers, some of which are released in the blood circulation in VLDL. After 
lipolysis, VLDL is converted into IDL. This could be the explanation for the large 
amount of precursors, and especially squalene and lathosterol in VLDL and IDL 
(Study I). In addition to VLDL, CM was also abundant with cholesterol precursors 
for unknown reasons in all adult FH subjects. However, even though IDL is 
converted to LDL, the ratios of squalene and and lathosterol were low in LDL. The 
lower levels of cholesterol precursors in LDL could possibly be due to their rapid 
turnover rate, i.e., their half-lives have been shown to be only a few minutes 
(Miettinen 1970). 
6.4.2. Effects of phytosterols 
The concentrations of plant sterols were increased in all lipoproteins by the sterol 
ester spread. However, the percentual proportion of plant sterols carried by HDL was 
increased and that transported by LDL was decreased by both spreads in statin-treated 
FH subjects (Figure 10a). Similarly, the percentual proportion of plant sterols was 
decreased in LDL and increased in HDL by statin treatment (Miettinen and Gylling 
2003). Thus, even though different changes occur in lipoprotein plant sterol 
concentrations during different treatment regimens, such as plant stanols, plant 
sterols, and statin therapy, their percentual proportion is decreased in LDL and 
increased in HDL, owing to the decrease occurring in LDL cholesterol levels. When 
adjusted to cholesterol, the plant sterol levels were increased similarly in all 
lipoproteins by the sterol ester spread, whereas the decrease of plant sterols was 
similar in all lipoproteins by the stanol ester spreads in FH subjects with and without 
statin treatment and in the homozygous FH subject. Accordingly, during consumption 
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of both spreads, all the absorption marker ratios were most abundant in HDL, with 
the lowest levels being seen in VLDL.  
Cholesterol precursor sterols were increased only insignificantly in different 
lipoproteins in statin-treated FH subjects during consumption of dietary phytosterols. 
This could be related to the small sample size (n=6) studied and to the simultaneous 
statin therapy, which inhibits the possible increase in cholesterol synthesis. However, 
the homozygous FH subject behaved differently from the heterozygotes. Even though 
no changes occurred in serum cholesterol precursor sterols, the lathosterol ratio to 
cholesterol was increased significantly in VLDL by the stanol ester spread. 
Surprisingly, the lathosterol ratio was even decreased by the sterol ester spread. This 
decrease in lathosterol ratios could be accompanied by decreased bile acid synthesis,  
as reported earlier for the sterol ester spread (Weststrate et al. 1999, O'Neill et al. 
2002), or the enhanced conversion of lathosterol to cholesterol for unknown reasons. 
Reduced cholesterol synthesis is not likely to have occurred, since cholesterol 
absorption was apparently still effectively inhibited.  
6.5. Red cell sterols 
Since increased sterol levels in red cells may cause episodes of hemolysis, we 
measured cholesterol and non-cholesterol sterols in red cells in hypercholesterolemic 
children and statin-treated FH adults at baseline and during consumption of 
phytosterol esters. The red cell offered also a model of a tissue cell in order to study 
simply the accumulation of different sterols in cells at baseline and during 
consumption of dietary phytosterol esters. 
6.5.1. Baseline 
The red cell membranes contain only free sterols, and only free sterols from serum 
are incorporated into the red cell membrane (Shohet 1972). In plasma, ~70% of 
cholesterol, desmosterol, and plant sterols and ~50% of lathosterol are in an esterified 
form (Salen et al. 1970, Gylling et al. 1993). Since LCAT is capable of esterifying 
also other sterols in serum (Nordby and Norum 1975), the activity of this enzyme 
regulates the levels of free sterols in serum, and indirectly influences also the levels 
of sterols in red cells. Thus, in spite of the fact that only ~30-50% of the sterols in 
serum are incorporated into the red cell membranes, the baseline data showed that the 
plant sterol, cholestanol, desmosterol, and lathosterol levels in red cells correlated 
positively with the respective values in serum (Studies II and III). This suggests that 
free non-cholesterol sterols from serum are incorporated freely into the red cell 
membranes, as shown also earlier for plant sterols (Ashworth and Green 1964, Salen 
et al. 1970).  
6.5.2. Effects of phytosterols 
Diet enriched with free sitosterol increased the plant sterol levels up to three times in 
red cells similarly as in plasma in one adult patient (Salen et al. 1970). In addition, the 
recent study by Hendriks et al. (2003) demonstrated that consumption of plant sterol 
esters for one year increased the plant sterol levels in red cells by ~80%. Thus, in 
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accordance with those earlier studies, the red cell plant sterols were increased by 40-
75% during plant sterol ester consumption in the present study (Studies II and III). 
However, the total plant sterol values in red cells (~1.5 mg/dl) remained far from the 
values obtained in two phytosterolemic patients (12-13 mg/dl) (Bhattacharyya and 
Connor 1974). On the contrary, consumption of plant stanol esters decreased the 
contents of plant sterols in red cells, with the reduction being highest in those subjects 
with the highest baseline values. The respective increase and decrease of plant sterols 
in serum during consumption of plant sterol and stanol esters correlated with the 
similar changes in red cells (e.g., Figure 12a). Thus, when the serum levels of plant 
sterols are either increased or decreased, similar changes occurred also in red cells. 
This further suggests that plant sterols exchange freely between the lipoproteins and 
red cells. Similarly, cholesterol precursor sterol ratios were increased in red cells in a 
similar manner to the changes occurring in serum. However, the proportional changes 
of lathosterol ratio were not similar in serum and in red cells, as shown in Figure 12b. 
Accordingly, the increase of lathosterol was higher in red cells than the respective 
increase seen in serum. Similarly, it was earlier demonstrated that lathosterol was 
efficiently taken up by skin fibroblasts e.g., when compared with cholesterol 
(Leppimäki et al. 2000). This could be related to the lower esterification percentage 
of serum lathosterol compared with cholesterol and plant sterols. Thus, even as much 
as 50% of lathosterol, released by the liver as a consequence of increased cholesterol 
synthesis, remains in a free form and is available to be taken up by the red cells.  
In contrast to the non-cholesterol sterols, the cholesterol concentrations in the red 
cells remained unchanged during both interventions (Studies II and III). As stated 
above, only free cholesterol is incorporated into red cell membranes. Thus, the reason 
for unchanged cholesterol levels in the red cells could be related to the fact that even 
though serum total cholesterol was decreased, the serum levels of free cholesterol 
remained unchanged during both interventions. Surprisingly, in contrast to the high 
respective correlations of plant sterols, the red cell and serum free cholesterol values 
were, however, not related to each other neither at baseline nor during consumption 
of the phytosterol esters. Accordingly, the exchange of plant sterols between serum 
and the red cells seemed to be more efficient than that of cholesterol. However, in 
vitro compared with plant sterols, plasma cholesterol exhibited the highest exchange 
with red cell cholesterol (Edwards and Green 1972, Child and Kuksis 1982, Child and 
Kuksis 1983). However, some non-cholesterol sterols appeared to replace cholesterol 
in the red cells (Bruckdorfer et al. 1969, Child and Kuksis 1982). Thus, large amounts 
of dietary plant sterols could probably replace cholesterol in red cells. This would 
apparently lead to higher ratios of plant sterols to cholesterol, and to less extensive 
elevations in cholesterol precursor sterols to cholesterol in red cells as shown in the 
present study. To conclude, during consumption of plant sterol ester spread, the total 
amount of sterols, other than cholesterol, is increased markedly in red cells. On the 
other hand, during consumption of the plant stanol ester spread, despite there being 
some increase of cholesterol precursor sterols and plant stanols, the total sterol levels 
in red cells are decreased. 
There have been no systematic studies on the effects of large amounts of dietary plant 
sterols on human red cells. High contents of plant sterols in red cells result in 
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hemolysis, in at least phytosterolemic patients (Björkhem et al. 2001), and may lead 
to increased osmotic fragility (Bruckdorfer et al. 1969). Even though contradictory 
results from animal studies during phytosterol-enriched diet do exist (Moghadasian et 
al. 1999b, Ratnayake et al. 2000, Ratnayake et al. 2003), a recent study in humans 
showed that increased plant sterol levels in red cell membranes did not contribute to 
any changes in membrane rigidity (Hendriks et al. 2003). However, according to 
another recent study, free cholesterol transported by the red cells may destabilize the 
atheromatotic plaque and make it more vulnerable to rupture (Kolodgie et al. 2003). It 
is not known whether increased levels of plant sterols or other non-cholesterol sterols 
in red cell membranes may also have a harmful effect on plaque stability. 
6.6. Removal of intravenous Intralipid 
We studied the removal of intravenous Intralipid-squalene mixture, containing in 
addition to squalene as a marker of postprandial lipoproteins also cholesterol, plant 
sterols, and TG, during consumption of phytosterol ester spreads in order to evaluate 
whether cholesterol absorption inhibition could alter the removal of an intravenously 
given CM-like emulsion.  
6.6.1. Baseline 
It should be born in mind that at baseline the removal of Intralipid-squalene mixture 
was studied in subjects with FH treated for several years with statins. Accordingly, 
although the function of their LDL apoB receptors was impaired, it could have been 
improved by the long-term statin treatment (Brown and Goldstein 1986), as also 
shown in FH (Twickler et al. 2000). LDL apoB receptor takes up postprandial 
lipoproteins, but its role in the clearance of postprandial lipoproteins in FH is not 
totally understood, since controversial results exist from studies conducted in subjects 
with FH (Weintraub et al. 1987, Rubinsztein et al. 1990, Eriksson et al. 1991, 
Cabezas et al. 1998, Mamo et al. 1998, Twickler et al. 2000, Watts et al. 2001). Thus, 
at baseline the removal of postprandial lipoproteins could have been within the 
normal limits, since even normal clearance of postprandial lipoproteins has been 
reported in FH (Weintraub et al. 1987, Eriksson et al. 1991, Watts et al. 2001). The 
clearance of Intralipid-squalene mixture has been studied before in normolipidemic 
subjects (Relas et al. 2001b), and some comparison between those earlier results with 
the present results could be made. The clearance curves of squalene and plant sterols 
were mostly similar in the present study compared with the earlier study, but longer 
half-lives for CM squalene and especially for CM campesterol, measured from the 
absolute concentrations, were observed in the present study (93±12 and 170±37 
minutes for squalene and campesterol, respectively) compared with previous data 
(74±8 and 37±5 minutes for squalene and campesterol, respectively) (Relas et al. 
2001b). This difference could be due to different study populations, or could be 
related to different time points for the first measurements (10 minutes vs. 2.5 
minutes), because the clearance of campesterol is fastest during the first ten minutes 
(Relas et al. 2001b). 
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6.6.2. Effects of phytosterols 
Since plant stanols upregulate the expression of LDL apoB receptors (Plat and 
Mensink 2002b), and plant stanols improved the clearance of postprandial lipids in 
normolipidemic subjects (Relas et al. 2000), we expected that consumption of 
phytosterol esters would improve the clearance of TRL also in the present study. 
However, in this study, there was no improvement in the clearance of postprandial 
lipoproteins. Accordingly, TG removal from CM and VLDL was not affected during 
consumption of the dietary phytosterols, but CM squalene concentrations and the 
respective AUICs were unexpectedly even higher during consumption of the two 
spreads vs. baseline. In addition, the peak concentration of sitosterol was also higher 
during consumption of phytosterol esters vs. baseline. This indicates that the 
inhibition of cholesterol absorption and subsequent changes in cholesterol 
metabolism by phytosterols had no effect on TG removal from injected CM-like 
particles, but impaired especially the removal of CM squalene. 
What is the reason for accumulation of squalene, but not TG, in CM-like particles 
after injection of intravenous Intralipid-squalene mixture? Statin treatment leads to a 
lack of liver cholesterol, and probably subsequently reduced VLDL synthesis 
(Thompson et al. 1996). Dietary phytosterols inhibit the intestinal absorption of 
cholesterol and thus prevent further entry of cholesterol into the liver. In fact, VLDL 
production was decreased in non-FH subjects during combination treatment with 
statins and plant stanols (Gylling and Miettinen 1996). Since CM and VLDL particles 
are taken up by the same hepatic receptors, the reduced release of VLDL could be 
associated with a rapid removal of injected TG during the first ten minutes when 
removal of squalene was less rapid. According to this theory, the removal of CM TG 
should have been improved during consumption of phytosterol esters. In fact, the 
peak concentrations of CM TG were lower during phytosterol ester spreads vs. 
baseline. However, the effect of cholesterol absorption inhibition by phytosterol 
esters was not sufficient enough to cause a significant difference in this small study 
population. 
Thus, what could be the reason for the increased concentrations of TRL squalene 
during consumption of phytosterol esters vs. baseline? Sitosterol was found in 
addition to TRL, also in HDL and LDL particles after the intravenous injection (Relas 
et al. 2001b). Thus, sitosterol may be transferred rapidly to more dense particles, 
probably by lipid transfer proteins. However, since squalene was not present in LDL 
and HDL particles (Relas et al. 2001b), it must be assumed that squalene, as a 
nonpolar hydrocarbon, is not transferred between the lipoproteins. This suggests that 
dietary or intravenously given squalene is carried only by d<1.006 g/ml particles and 
taken up by the liver. This suggests that the impairment in removal of TRL squalene 
would be due to decreased uptake of TRL by the liver. The reason for this impaired 
removal during phytosterol ester consumption remains unknown, but could be related 
to this special study population. Thus, this suggests that in the present statin-treated 
FH subjects, dietary phytosterols did not upregulate the LDL apoB receptors, as seen 
earlier with plant stanol esters (Plat and Mensink 2002a). Accordingly, it seems that 
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the statin-treated FH subjects have only a limited capacity to upregulate their LDL 
apoB receptor activity during consumption of dietary phytosterols. 
Consumption of plant stanol ester spread decreased the plant sterol concentrations in 
serum, CM, and VLDL, whereas plant sterol esters increased those levels. However, 
these changes did not affect the removal of postprandial plant sterols, since rather 
similar postprandial curves of plant sterols were obtained during consumption of both 
spreads. In a previous study, the immediate post-injection concentrations of plant 
sterols in CM were higher (Relas et al. 2001b) than the values obtained in the present 
study at 10 min (e.g., campesterol ~40 µg/dl vs. ~20 µg/dl). Accordingly, we 
speculate that immediate post-injection contents of CM plant sterols must have been 
higher in the present study during consumption of the sterol ester spread than with the 
stanol ester spread because of the higher pre-injection values. This indicates that the 
initial removal of plant sterols is rapid despite higher plant sterols concentrations if 
they are to reach similar incremental concentrations at 10 min and later. In fact, in the 
last measurements, the increments of plant sterols in VLDL were even lower during 
the plant sterol ester consumption compared with the respective increments during 
plant stanol ester consumption. 
To conclude, consumption of dietary phytosterols impaired the removal of 
postprandial lipids in statin-treated FH subjects, when measured with CM squalene. 
The altered plant sterol concentrations of serum, CM, and VLDL did not affect the 
removal of plant sterols. The reasons for the results are not known, but could be 
associated with impaired removal of the lipids by the abnormal LDL apoB receptors 
present in FH subjects. 
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7. SUMMARY AND CONCLUSIONS 
The results of the present thesis can be summarized as follows. 
1. The concentrations of non-cholesterol sterols in serum and most lipoproteins were 
higher in FH than in non-FH children, whereas the serum and lipoprotein ratios of 
non-cholesterol sterols to cholesterol were similar in the two groups. 
2. In all study populations, the ratios of cholesterol precursor sterols were higher in 
VLDL and those of absorption marker sterols were higher in HDL, when 
compared with the serum values. Even though analysis of non-cholesterol sterol 
ratios in serum provides a picture of cholesterol metabolism in general, the 
respective ratios in different lipoproteins may predict more exactly cholesterol 
metabolism and its changes.  
3. Dietary plant sterols increased the serum, lipoprotein, and red cell plant sterol 
levels, whereas dietary plant stanol esters resulted in a decrease in these 
respective values. The highest increase of serum plant sterols was obtained in 
those subjects with the highest baseline levels of serum plant sterols. The changes 
of plant sterols and lathosterol in red cells correlated with the changes in serum. 
The plant sterol levels became changed similarly in all lipoproteins by the 
phytosterol ester spreads. Since recent evidence has suggested that high serum 
plant sterol levels may be associated with increased risk for CHD, the evidently 
increased serum plant sterol concentrations and ratios to cholesterol by 
consumption of plant sterol esters in hypercholesterolemic children and in statin-
treated FH subjects, as well as in the homozygous FH subject may be considered 
as a possible additional risk for CHD. Based on the data from the literature, 
agents that lower both LDL cholesterol and serum plant sterols would be 
recommendable, especially in subjects with FH. 
4. Dietary plant stanol and sterol esters were equally effective at decreasing LDL 
cholesterol in hypercholesterolemic children. In addition, dietary plant stanol and 
sterol esters reduced LDL cholesterol in statin-treated FH subjects. However, the 
results from this short-term study cannot predict the long-term benefit of dietary 
phytosterol esters. 
5. Dietary phytosterols did not improve the clearance of postprandial lipoproteins in 
statin-treated FH subjects. In fact, the clearance of CM squalene, an indicator of 
postprandial lipoproteins, was even impaired during consumption of phytosterol 
ester spreads. The reason for impaired clearance of TRL remains unknown, but 
may be associated with altered sterol metabolism due to abnormal LDL apoB 
receptor function and the combination of statin and phytosterol ester treatment. 
Thus, since dietary plant stanols have improved the clearance of postprandial 
lipids in normolipidemic subjects in an earlier study, the present results could be 
attributable to this specific study population. 
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This thesis has increased our knowledge of the regulation of non-cholesterol sterols in 
serum, lipoproteins, and red cells in FH at baseline and during consumption of 
phytosterol esters. Special emphasis was paid to the levels of plant sterols in this 
study population, since awareness of the role of serum plant sterol levels as an 
additional risk factor for CHD has increased in recent years. However, the possible 
role of plant sterols in the development of atherosclerosis remains still open, and 
needs to be clarified in the future. In addition, the effects of plant stanol and sterol 
ester products as monotherapy or in combination with statins on development of 
atherosclerosis and incidence of CHD is still unknown and could be evaluated e.g., by 
measuring the intima-media thickness of the carotid artery or documenting the hard 
end points during long-term treatment. 
 
87 
8. ACKNOWLEDGEMENTS 
This study was carried out in the laboratory of Professors Tatu A. Miettinen and 
Helena Gylling in the Department of Medicine, Division of Internal Medicine and in 
Hospital for Children and Adolescents, at the University of Helsinki during the years 
1998 to 2004. I wish to thank Professors Pertti Pentikäinen and Reijo Tilvis, the 
former and present heads of the Department of Medicine and Jaakko Perheentupa and 
Veli Ylitalo, the former and present heads of the Hospital for Children and 
Adolescents, for providing me with the excellent research facilities. 
I want to express my sincere gratitude to my supervisors, Professors Tatu A. 
Miettinen and Helena Gylling, for introducing me to the world of science and lipids. 
Their excellent knowledge on cholesterol metabolism and especially Tatu’s endless 
flow of new ideas has been crucial to this thesis. I am deeply grateful that both my 
supervisors have had time for my more or less difficult problems. I especially thank 
Helena for being so encouraging during these years. There was a time when I really 
needed her optimism. 
Professor Olli Simell and Docent Timo Strandberg are acknowledged for reviewing 
carefully the manuscript and for their valuable comments and criticism. I also want to 
thank them for positive attitude towards my study. 
I express my sincere thanks for Professor Martti Siimes for collaboration. I really 
appreciate his advice on pediatric problems. I also want to thank Doctor Marjatta 
Antikainen for fruitful collaboration and helpful advice during these years. The 
nurses who helped with managing the stream of patients in Hospital for Children and 
Adolescents are also acknowledged. 
I am thankful to Alpo Vuorio for his help and for guiding me in my explorations in 
the world of familial hypercholesterolemia. I also want to thank Professor Kimmo 
Kontula for collaboration with the DNA samples. 
I want to thank Ewen McDonald for excellent editing of the language of this thesis as 
well as one original paper. Jean Margaret Perttunen is also acknowledged for editing 
the language of two original papers. 
I want to thank all the members of the “Cardiovascular risk factors”–study groups at 
Biomedicum, Helsinki for creating a warm and pleasant working athmosphere. I am 
especially thankful to all the ladies in our lab for being my workmates and sharing 
every day matters during these years. I want to acknowledge Leena Kaipiainen, for 
teaching me laboratory techniques and helping in any practical problems as well as 
serving as a study nurse, Pia Hoffström for being my personal help in computer 
matters and just being my roommate for three years, Anne Honkonen for helping in 
managing the stream of study patients and helping with laboratory analyses and Ritva 
Nissilä and Orvokki Ahlroos for helping skillfully with the laboratory analyses. Lea 
Enjala, Leena Lajunen, Raija Selivuo, and Kaiju Sysikumpu are acknowledged for 
their secretarial help. 
 
88 
I have had the opportunity to work with Doctors Nina Lindbohm, Tatu E. Miettinen, 
Markku Nissinen, Radhakrishnan Rajaratnam, Heikki Relas, and Piia Simonen. They 
are all appreciated for their company and helpful advice. I also thank Veera Vihma 
for the convivial companionship and for helping me with some practical problems 
with this thesis.  
I owe my sincere thanks to all my friends. I am especially grateful to Elina for 
listening to my problems and supporting me whenever I needed. I also want to thank 
the two Paulas (Mili and Peitsi), Heidi, and Hanna for being my friends and sharing 
some special moments outside the research world. 
I want to express my deepest thank to my mother Liisa Nyman for being the best 
mom in the world and for giving her love and support throughout my life. I also want 
to thank my dear brother Sami Ketomäki for being besides my brother also my friend. 
I am also thankful to my parents-in-law Anneli and Antero Valpas and the whole 
“Valpas” family for loving support and for bringing a second family into my life. I 
extend my thanks to my late grandparents for their love. I know that they would have 
been proud of me. 
Finally, I want to send my sincere thanks to my dear husband Rami for all the love he 
has given me and for standing by me throughout the ups and downs of this work. I 
also want to thank Rami for being my personal “backup” in any problem concerning 
computers. 
This work was financially supported by the Finnish Heart Research Foundation, the 
Finnish Medical Society Duodecim, the Research Foundation of Orion Corporation, 
the Biomedicum Foundation, the Finnish Cultural Foundation, the Ida Montin 
Foundation, and Raisio Benecol, Raisio, Finland. Finally, I warmly thank all the 
subjects who volunteered to take part in my studies. 
 
Helsinki, October 2004 
 
 
Anna Ketomäki 
 
89 
9. REFERENCES 
Aalto-Setälä K, Helve E, Kovanen PT, Kontula K. Finnish type of low density lipoprotein receptor gene 
mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an 
internalization-defective phenotype. J Clin Invest 1989; 84: 499-505. 
Akihisa T, Kokke W, Tamura T. Naturally occurring sterols and related compounds from plants. In: Physiology 
and Biochemistry of Sterols. Patterson G, Nes W, eds. Champaign, IL, American Oil's Chemists' 
Society 1991; 172-228. 
Altmann SW, Davis HR, Jr., Yao X, Laverty M, Compton DS, Zhu LJ, Crona JH, Caplen MA, Hoos LM, 
Tetzloff G, Priestley T, Burnett DA, Strader CD, Graziano MP. The identification of intestinal 
scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. 
Biochim Biophys Acta 2002; 1580: 77-93. 
Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng 
M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal 
cholesterol absorption. Science 2004; 303: 1201-1204. 
Amundsen AL, Ose L, Nenseter MS, Ntanios FY. Plant sterol ester-enriched spread lowers plasma total and 
LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 2002; 76: 338-344. 
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol 
Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 
185-191. 
Armstrong MJ and Carey MC. Thermodynamic and molecular determinants of sterol solubilities in bile salt 
micelles. J Lipid Res 1987; 28: 1144-1155. 
Ashworth LA and Green C. The transfer of lipids between human alpha-lipoprotein and erythrocytes. Biochim 
Biophys Acta 1964; 84: 182-187. 
Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Elevation in plasma sitosterol 
concentration is associated with an increased risk for coronary events in the PROCAM study. 
Circulation 2003; 108: 3300. 
Becker M, Staab D, von Bergmann K. Long-term treatment of severe familial hypercholesterolemia in children: 
effect of sitosterol and bezafibrate. Pediatrics 1992; 89: 138-142. 
Becker M, Staab D, von Bergmann K. Treatment of severe familial hypercholesterolemia in childhood with 
sitosterol and sitostanol. J Pediatr 1993; 122: 292-296. 
Berge KE. Sitosterolemia: a gateway to new knowledge about cholesterol metabolism. Ann Med 2003; 35: 502-
511. 
Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. 
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. 
Science 2000; 290: 1771-1775. 
Berge KE, von Bergmann K, Lütjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC. Heritability of 
plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and 
ABCG8. J Lipid Res 2002; 43: 486-494. 
Bergström JD, Bostedor RG, Rew DJ, Geissler WM, Wright SD, Chao YS. Hepatic responses to inhibition of 
3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim 
Biophys Acta 1998; 1389: 213-221. 
Bhattacharyya AK. Uptake and esterification of plant sterols by rat small intestine. Am J Physiol 1981; 240: 
G50-55. 
Bhattacharyya AK and Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage 
disease in two sisters. J Clin Invest 1974; 53: 1033-1043. 
Bhattacharyya AK, Connor WE, Lin DS. The origin of plant sterols in the skin surface lipids in humans: from 
diet to plasma to skin. J Invest Dermatol 1983; 80: 294-296. 
Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. 
Arteriosclerosis 1989; 9: I158-163. 
Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein 
synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J 
Clin Invest 1975; 56: 1420-1430. 
 
90 
Bilheimer DW, Stone NJ, Grundy SM. Metabolic studies in familial hypercholesterolemia: evidence for a gene 
dosage effect in vivo. J Clin Invest 1979; 64: 524-533. 
Björkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, Karpe F. 
Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a 
chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid 
Res 1996; 37: 76-86. 
Björkhem I. Mechanism of degradation of the steroid side chain in the formation of bile acids. J Lipid Res 1992; 
33: 455-471. 
Björkhem I, Boberg KM, Leitersdorf E. Inborn errors in bile acid biosynthesis and storage of sterols other than 
cholesterol. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CS, Beaudet AL, Sly 
WS, Valle D, eds. New York, McGraw-Hill 2001; 2961-2988. 
Björkhem I, Miettinen T, Reihnér E, Ewerth S, Angelin B, Einarsson K. Correlation between serum levels of 
some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 1987; 28: 
1137-1143. 
Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total 
cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing 
spread to statin therapy. Am J Cardiol 2000; 86: 46-52. 
Blomstrand R and Gürtler J. Separation and identification of some neutral steroids in human lymph 
chylomicrons by gas-liquid chromatography and mass spectrometry. Arkiv Kemi 1968; 30: 233-245. 
Boberg KM, Einarsson K, Björkhem I. Apparent lack of conversion of sitosterol into C24-bile acids in humans. 
J Lipid Res 1990; 31: 1083-1088. 
Borgström B. Quantification of cholesterol absorption in man by fecal analysis after the feeding of a single 
isotope-labeled meal. J Lipid Res 1969; 10: 331-337. 
Borgström B. On the interactions between pancreatic lipase and colipase and the substrate, and the importance of 
bile salts. J Lipid Res 1975; 16: 411-417. 
Bosner MS, Lange LG, Stenson WF, Ostlund RE, Jr. Percent cholesterol absorption in normal women and men 
quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999; 40: 
302-308. 
Bosner MS, Ostlund RE, Jr., Osofisan O, Grosklos J, Fritschle C, Lange LG. Assessment of percent 
cholesterol absorption in humans with stable isotopes. J Lipid Res 1993; 34: 1047-1053. 
Brink EJ and Hendricks HFJ. Long-term follow-up study on the use of a spread enriched with plant sterols. 
TNO report V99.869 TNO Nutrition and food research institute. 2000. 
Brown MS and Goldstein JL. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J 
Clin Invest 1983; 72: 743-747. 
Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-
47. 
Bruce C, Chouinard RA, Jr., Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse 
cholesterol transport. Annu Rev Nutr 1998; 18: 297-330. 
Bruckdorfer KR, Demel RA, De Gier J, van Deenen LL. The effect of partial replacements of membrane 
cholesterol by other steroids on the osmotic fragility and glycerol permeability of erythrocytes. Biochim 
Biophys Acta 1969; 183: 334-345. 
Cabezas MC, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW. Delayed chylomicron remnant clearance 
in subjects with heterozygous familial hypercholesterolaemia. J Intern Med 1998; 244: 299-307. 
Carlson LA. Studies on the fat emulsion Intralipid. I. Association of serum proteins to Intralipid triglyceride 
particles (ITP). Scand J Clin Lab Invest 1980; 40: 139-144. 
Carlson LA and Rössner S. A methodological study of an intravenous fat tolerance test with Intralipid R 
emulsion. Scand J Clin Lab Invest 1972; 29: 271-280. 
Carter GA, Connor WE, Bhattacharyya AK, Lin DS. The cholesterol turnover, synthesis, and absorption in 
two sisters with familial hypercholesterolemia (type IIa). J Lipid Res 1979; 20: 66-77. 
Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 
443-463. 
Child P and Kuksis A. Differential uptake of cholesterol and plant sterols by rat erythrocytes in vitro. Lipids 
1982; 17: 748-754. 
Child P and Kuksis A. Uptake of 7-dehydro derivatives of cholesterol, campesterol, and beta-sitosterol by rat 
erythrocytes, jejunal villus cells, and brush border membranes. J Lipid Res 1983; 24: 552-565. 
 
91 
Clifton PM, Noakes M, Sullivan D, Erichsen N, Ross D, Annison G, Fassoulakis A, Cehun M, Nestel P. 
Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J Clin 
Nutr 2004; 58: 503-509. 
Clouse SD. Plant development: A role for sterols in embryogenesis. Curr Biol 2000; 10: R601-604. 
Cobb MM, Salen G, Tint GS. Comparative effect of dietary sitosterol on plasma sterols and cholesterol and bile 
acid synthesis in a sitosterolemic homozygote and heterozygote subject. J Am Coll Nutr 1997; 16: 605-
613. 
Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the 
triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988; 29: 925-
936. 
Compassi S, Werder M, Boffelli D, Weber FE, Hauser H, Schulthess G. Cholesteryl ester absorption by small 
intestinal brush border membrane is protein-mediated. Biochemistry 1995; 34: 16473-16482. 
Connor WE and Lin DS. The intestinal absorption of dietary cholesterol by hypercholesterolemic (type II) and 
normocholesterolemic humans. J Clin Invest 1974; 53: 1062-1070. 
Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38: 2173-2192. 
Crouse JR and Grundy SM. Evaluation of a continuous isotope feeding method for measurement of cholesterol 
absorption in man. J Lipid Res 1978; 19: 967-971. 
Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH. Increased hepatic secretion 
of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a 
stable isotope study. Atherosclerosis 1995; 113: 79-89. 
Cuthbert JA, East CA, Bilheimer DW, Lipsky PE. Detection of familial hypercholesterolemia by assaying 
functional low-density-lipoprotein receptors on lymphocytes. N Engl J Med 1986; 314: 879-883. 
Czubayko F, Beumers B, Lammsfuss S, Lütjohann D, von Bergmann K. A simplified micro-method for 
quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid 
Res 1991; 32: 1861-1867. 
Dane-Stewart CA, Watts GF, Mamo JC, Barrett PH, Martins IJ, Dimmitt SB, Redgrave TG. Effect of 
Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia. Eur J Clin 
Invest 2002; 32: 493-499. 
Dane-Stewart CA, Watts GF, Mamo JC, Dimmitt SB, Barrett PH, Redgrave TG. Elevated apolipoprotein B-
48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur J Clin 
Invest 2001; 31: 113-117. 
Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. 
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll 
Cardiol 2002; 40: 2125-2134. 
Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 
1-21. 
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, 
Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyorälä K, Rodicio 
JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on 
cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610. 
de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores 
endothelial function in children with familial hypercholesterolemia [comment]. J Am Coll Cardiol 
2002a; 40: 2117-2121. 
de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy 
MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, 
Kastelein JJ, Simvastatin in Children Study G. Efficacy and safety of statin therapy in children with 
familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. 
Circulation 2002b; 106: 2231-2237. 
de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES. Plant sterols lower LDL cholesterol 
without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J 
Inherit Metab Dis 2003; 26: 343-351. 
de Sauvage Nolting PR, Twickler MB, Dallinga-Thie GM, Buirma RJ, Hutten BA, Kastelein JJ, 
Examination of P, Relatives in Statin Studies with Familial Hypercholesterolemia Study G. 
 
92 
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin 
therapy. Circulation 2002; 106: 788-792. 
de Vries JHM, Jansen A, Kromhout D, van de Bovenkamp P, van Staveren WA, Mensink RP, Katan MB. 
The fatty acid and sterol content of food composites of middle-aged men in seven countries. J Food 
Comp Anal 1997; 19: 115-141. 
Denke MA. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men 
with moderate hypercholesterolemia. Am J Clin Nutr 1995; 61: 392-396. 
Detmers PA, Patel S, Hernandez M, Montenegro J, Lisnock JM, Pikounis B, Steiner M, Kim D, Sparrow C, 
Chao YS, Wright SD. A target for cholesterol absorption inhibitors in the enterocyte brush border 
membrane. Biochim Biophys Acta 2000; 1486: 243-252. 
Devaraj S, Jialal I, Vega-Lopez S. Plant sterol-fortified orange juice effectively lowers cholesterol levels in 
mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24: e25-28. 
Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein 
homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-1659. 
Edwards PA and Green C. Incorporation of plant sterols into membranes and its relation to sterol absorption. 
FEBS Lett 1972; 20: 97-99. 
Eriksson M, Angelin B, Henriksson P, Ericsson S, Vitols S, Berglund L. Metabolism of lipoprotein remnants 
in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression 
of the low density lipoprotein receptor. Arterioscler Thromb 1991; 11: 827-837. 
Field FJ, Born E, Mathur SN. Effect of micellar beta-sitosterol on cholesterol metabolism in CaCo-2 cells. J 
Lipid Res 1997; 38: 348-360. 
Field FJ and Mathur SN. beta-sitosterol: esterification by intestinal acylcoenzyme A: cholesterol acyltransferase 
(ACAT) and its effect on cholesterol esterification. J Lipid Res 1983; 24: 409-417. 
Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to 
chromosome 19: synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci U S A 1984; 
81: 2826-2830. 
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein 
cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502. 
Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. Efficacy 
and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary 
hypercholesterolemia. Am J Cardiol 2002a; 90: 1084-1091. 
Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or 
simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002b; 105: 2469-
2475. 
Geelen A, Zock PL, de Vries JH, Katan MB. Apolipoprotein E polymorphism and serum lipid response to plant 
sterols in humans. Eur J Clin Invest 2002; 32: 738-742. 
Glueck CJ, Speirs J, Tracy T, Streicher P, Illig E, Vandegrift J. Relationships of serum plant sterols 
(phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of 
phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and 
their first-degree relatives. Metabolism 1991; 40: 842-848. 
Goldammer A, Wiltschnig S, Heinz G, Jansen M, Stulnig T, Horl WH, Derfler K. Atorvastatin in low-density 
lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. 
Metabolism 2002; 51: 976-980. 
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic Bases of Inherited 
Disease. Scriver CS, Beaudet AL, Sly WS, Valle D, eds. New York, McGraw-Hill 2001; 2863-2913. 
Goodman DS. Squalene in human and rat blood plasma. J Clin Invest 1964; 43: 1480-1485. 
Gordon DA and Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in 
apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 2000; 1486: 72-83. 
Gotto AM, Jr., Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol 1986; 128: 3-
41. 
Gould RG, Jones RJ, LeRoy GV, Wissler RW, Taylor CB. Absorbability of beta-sitosterol in humans. 
Metabolism 1969; 18: 652-662. 
Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJr, Stein EA, Lupien PJ, Brewer 
HB, Jr., Raper SE, Wilson JM. A pilot study of ex vivo gene therapy for homozygous familial 
hypercholesterolaemia. Nat Med 1995; 1: 1148-1154. 
 
93 
Grundy SM. Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 1983; 3: 71-96. 
Grundy SM, Ahrens EH, Jr., Davignon J. The interaction of cholesterol absorption and cholesterol synthesis in 
man. J Lipid Res 1969; 10: 304-315. 
Grundy SM, Ahrens EH, Jr., Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of 
total fecal bile acids. J Lipid Res 1965; 63: 397-410. 
Gylling H, Kuusi T, Vanhanen H, Miettinen TA. Apolipoprotein E phenotype and cholesterol metabolism in 
familial hypercholesterolemia. Atherosclerosis 1989a; 80: 27-32. 
Gylling H and Miettinen TA. Serum noncholesterol sterols related to cholesterol metabolism in familial 
hypercholesterolemia. Clin Chim Acta 1988; 178: 41-49. 
Gylling H and Miettinen TA. Absorption and metabolism of cholesterol in familial hypercholesterolaemia. Clin 
Sci 1989; 76: 297-301. 
Gylling H and Miettinen TA. Postabsorptive metabolism of dietary squalene. Atherosclerosis 1994a; 106: 169-
178. 
Gylling H and Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in 
hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. 
Diabetologia 1994b; 37: 773-780. 
Gylling H and Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and 
lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 
37: 1776-1785. 
Gylling H and Miettinen TA. Baseline intestinal absorption and synthesis of cholesterol regulate its response to 
hypolipidaemic treatments in coronary patients. Atherosclerosis 2002a; 160: 477-481. 
Gylling H and Miettinen TA. Inheritance of cholesterol metabolism of probands with high or low cholesterol 
absorption. J Lipid Res 2002b; 43: 1472-1476. 
Gylling H and Miettinen TA. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis 
and absorption of cholesterol in hypercholesterolemic coronary subjects. Nutr Metab Cardiovasc Dis 
2002c; 12: 19-23. 
Gylling H, Puska P, Vartiainen E, Miettinen TA. Serum sterols during stanol ester feeding in a mildly 
hypercholesterolemic population. J Lipid Res 1999; 40: 593-600. 
Gylling H, Rajaratnam RA, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with 
previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester 
margarine: women and dietary sitostanol. Circulation 1997; 96: 4226-4231. 
Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial 
hypercholesterolemia. J Lipid Res 1995; 36: 1807-1812. 
Gylling H, Strandberg T, Tilvis R, Miettinen TA. Regulation of serum cholesterol level in middle-aged and 
elderly men. Relation of cholesterol absorption and synthesis to lipoprotein metabolism. Arterioscler 
Thromb 1994; 14: 694-700. 
Gylling H, Vanhanen H, Miettinen TA. Effects of acipimox and cholestyramine on serum lipoproteins, non-
cholesterol sterols and cholesterol absorption and elimination. Eur J Clin Pharmacol 1989b; 37: 111-
115. 
Gylling H, Vanhanen H, Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density 
lipoprotein kinetics in hypercholesterolemia. J Lipid Res 1993; 34: 59-67. 
Gylling H, Virtanen KS, Syvänne M, Miettinen TA. Two years of low density lipoprotein apheresis in familial 
hypercholesterolemia: effects on cholesterols metabolism and coronary artery disease. Nutr Metab 
Cardiovasc Dis 1998; 8: 164-171. 
Hallberg D. Studies on the elimination of exogenous lipids from the blood stream. The kinetics of the elimination 
of a fat emulsion studied by single injection technique in man. Acta Physiol Scand 1965; 64: 306-313. 
Hallikainen MA, Sarkkinen ES, Gylling H, Erkkilä AT, Uusitupa MI. Comparison of the effects of plant 
sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in 
hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr 2000; 54: 715-725. 
Hartmann M-A. Plant sterols and the membrane environment. Trends Plant Sci 1998; 3: 170-175. 
Hauser H, Dyer JH, Nandy A, Vega MA, Werder M, Bieliauskaite E, Weber FE, Compassi S, Gemperli A, 
Boffelli D, Wehrli E, Schulthess G, Phillips MC. Identification of a receptor mediating absorption of 
dietary cholesterol in the intestine. Biochemistry 1998; 37: 17843-17850. 
Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein 
E phenotyping directly in serum. J Lipid Res 1987; 28: 455-463. 
 
94 
Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5: 102-109. 
Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated 
lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353. 
Havel RJ and Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: The Metabolic Bases 
of Inherited Diseases. Scriver CS, Beaudet, A L, Sly, W S, Valle, D, ed. New York, McGraw-Hill 2001; 
2705-2716. 
Hazzard WR and Bierman EL. Delayed clearance of chylomicron remnants following vitamin-A-containing 
oral fat loads in broad-beta disease (type III hyperlipoproteinemia). Metabolism 1976; 25: 777-801. 
Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different 
plant sterols in man. Eur J Clin Invest 1993; 23: 827-831. 
Heinemann T, Kullak-Ublick GA, Pietruck B, von Bergmann K. Mechanisms of action of plant sterols on 
inhibition of cholesterol absorption. Comparison of sitosterol and sitostanol. Eur J Clin Pharmacol 1991; 
40 Suppl 1: S59-63. 
Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant 
sterol esters-enriched spread. Eur J Clin Nutr 2003; 57: 681-692. 
Hendriks HF, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of 
vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly 
hypercholesterolaemic subjects. Eur J Clin Nutr 1999; 53: 319-327. 
Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of 
coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 
290-297. 
Hopkins PN. Familial hypercholesterolemia--improving treatment and meeting guidelines. Int J Cardiol 2003; 89: 
13-23. 
Howles PN, Carter CP, Hui DY. Dietary free and esterified cholesterol absorption in cholesterol esterase (bile 
salt-stimulated lipase) gene-targeted mice. J Biol Chem 1996; 271: 7196-7202. 
Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. Intravenous lipid emulsions: removal mechanisms as 
compared to chylomicrons. J Lipid Res 1995; 36: 2174-2184. 
Igel M, Giesa U, Lütjohann D, von Bergmann K. Comparison of the intestinal uptake of cholesterol, plant 
sterols, and stanols in mice. J Lipid Res 2003; 44: 533-538. 
Ikeda I, Kawasaki A, Samezima K, Sugano M. Antihypercholesterolemic activity of beta-sitostanol in rabbits. J 
Nutr Sci Vitaminol 1981; 27: 243-251. 
Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Discrimination between cholesterol and sitosterol for 
absorption in rats. J Lipid Res 1988a; 29: 1583-1591. 
Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Inhibition of cholesterol absorption in rats by plant 
sterols. J Lipid Res 1988b; 29: 1573-1582. 
Illingworth DR. How effective is drug therapy in heterozygous familial hypercholesterolemia? Am J Cardiol 
1993; 72: 54D-58D. 
Inazu A, Koizumi J, Mabuchi H, Kajinami K, Takeda R. Enhanced cholesteryl ester transfer protein activities 
and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res 1992; 
24: 284-288. 
Ishida F, Sato A, Iizuka Y, Kitani K, Sawasaki Y, Kamei T. Effects of MK-733 (simvastatin), an inhibitor of 3-
hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol 
acyltransferase activity in rabbits. Biochim Biophys Acta 1989; 1004: 117-123. 
Isusi E, Aspichueta P, Liza M, Hernández ML, Díaz C, Hernández G, Martínez MJ, Ochoa B. Short- and 
long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl 
esters and VLDL secretion in rat hepatocytes. Atherosclerosis 2000; 153: 283-294. 
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus 
simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES 
study). Am J Cardiol 1998; 81: 582-587. 
Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid 
levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res 2000; 41: 697-705. 
Jones PJ, Vanstone CA, Raeini-Sarjaz M, St-Onge MP. Phytosterols in low- and nonfat beverages as part of a 
controlled diet fail to lower plasma lipid levels. J Lipid Res 2003; 44: 1713-1719. 
 
95 
Jones PJH and Kubow S. Lipids, sterols, and their metabolites. In: Modern Nutrition in Health and Disease. 
Shils ME, Olson JA, Shike M, Ros AC, eds. Baltimore, Maryland, Lippincott, Williams & Wilkins 
1999; e-book. 
Kallio MJ, Salmenperä L, Siimes MA, Perheentupa J, Gylling H, Miettinen TA. Apoprotein E phenotype 
determines serum cholesterol in infants during both high-cholesterol breast feeding and low-cholesterol 
formula feeding. J Lipid Res 1997; 38: 759-764. 
Kanakaraj P and Singh M. Influence of hypercholesterolemia on morphological and rheological characteristics 
of erythrocytes. Atherosclerosis 1989; 76: 209-218. 
Karjalainen A, Heikkinen J, Savolainen MJ, Bäckström AC, Kesäniemi YA. Regulation of plasma low 
density lipoprotein levels in postmenopausal women. Atherosclerosis 2000; 151: 559-566. 
Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999; 246: 341-355. 
Karpe F. Postprandial lipemia--effect of lipid-lowering drugs. Atheroscler Suppl 2002; 3: 41-46. 
Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins 
during alimentary lipemia. J Clin Invest 1993; 91: 748-758. 
Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and 
sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78: 965-978. 
Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is 
an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149-1155. 
Kesäniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to 
apoprotein E phenotype. J Clin Invest 1987; 80: 578-581. 
Kesäniemi YA and Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the 
Finnish population. Eur J Clin Invest 1987; 17: 391-395. 
Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, Buller HR, 
Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial 
hypercholesterolemia. Pediatr Res 1996; 39: 867-871. 
Kohno M, Murakawa K, Yasunari K, Yokokawa K, Horio T, Kano H, Minami M, Yoshikawa J. 
Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in 
hypercholesterolemic patients. Metabolism 1997; 46: 287-291. 
Koivisto PV and Miettinen TA. Effect of ileal exclusion on lipoprotein sitosterol in familial 
hypercholesterolaemia. Scand J Clin Lab Invest 1988a; 48: 193-198. 
Koivisto PV and Miettinen TA. Increased amounts of cholesterol precursors in lipoproteins after ileal exclusion. 
Lipids 1988b; 23: 993-996. 
Koivisto UM, Hämäläinen L, Taskinen MR, Kettunen K, Kontula K. Prevalence of familial 
hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based 
on diagnosis by polymerase chain reaction. J Lipid Res 1993; 34: 269-277. 
Koivisto UM, Turtola H, Aalto-Setälä K, Top B, Frants RR, Kovanen PT, Syvänen AC, Kontula K. The 
familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene 
deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest 1992; 90: 
219-228. 
Koivisto UM, Viikari JS, Kontula K. Molecular characterization of minor gene rearrangements in Finnish 
patients with heterozygous familial hypercholesterolemia: identification of two common missense 
mutations (Gly823-->Asp and Leu380-->His) and eight rare mutations of the LDL receptor gene. Am J 
Hum Genet 1995; 57: 789-797. 
Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, 
Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary 
atheroma. N Engl J Med 2003; 349: 2316-2325. 
Konlande JE and Fisher H. Evidence for a nonabsorptive antihypercholesterolemic action of phytosterols in the 
chicken. J Nutr 1969; 98: 435-442. 
Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on 
erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin 
Pharmacol 2002; 58: 501-506. 
Kramer W, Girbig F, Corsiero D, Burger K, Fahrenholz F, Jung C, Muller G. Intestinal cholesterol 
absorption: identification of different binding proteins for cholesterol and cholesterol absorption 
inhibitors in the enterocyte brush border membrane. Biochim Biophys Acta 2003; 1633: 13-26. 
 
96 
Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans: a 
reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and 
their remnants. Metabolism 1990; 39: 357-365. 
Kritchevsky D, Tepper SA, Czarnecki SK, Wolfe B, Setchell KD. Serum and aortic levels of phytosterols in 
rabbits fed sitosterol or sitostanol ester preparations. Lipids 2003; 38: 1115-1118. 
Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF. LDL-
Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid 
lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-1835. 
Kudchodkar BJ, Horlick L, Sodhi HS. Effects of plant sterols on cholesterol metabolism in man. 
Atherosclerosis 1976; 23: 239-248. 
Kuksis A, Marai L, Myher JJ, Geher K. Identification of plant sterols in plasma and red blood cells of man and 
experimental animals. Lipids 1976; 11: 581-586. 
Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ, Breg WR, Jones HW, Jr., Rary 
JM. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl 
Acad Sci U S A 1977; 74: 1245-1249. 
Kwiterovich PO, Jr. Pediatric implications of heterozygous familial hypercholesterolemia. Screening and dietary 
treatment. Arteriosclerosis 1989; 9: I111-120. 
Kwiterovich PO, Jr., Chen SC, Virgil DG, Schweitzer A, Arnold DR, Kratz LE. Response of obligate 
heterozygotes for phytosterolemia to a low-fat diet and to a plant sterol ester dietary challenge. J Lipid 
Res 2003; 44: 1143-1155. 
Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe 
BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J. Treatment of familial 
hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children 
Study Group. Pediatrics 1996; 97: 619-628. 
Laraki L, Pelletier X, Mourot J, Debry G. Effects of dietary phytosterols on liver lipids and lipid metabolism 
enzymes. Ann Nutr Metab 1993; 37: 129-133. 
Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, 
Srivastava AK, Salen G, Dean M, Patel SB. Identification of a gene, ABCG5, important in the 
regulation of dietary cholesterol absorption. Nat Genet 2001; 27: 79-83. 
Lee YM, Haastert B, Scherbaum W, Hauner H. A phytosterol-enriched spread improves the lipid profile of 
subjects with type 2 diabetes mellitus--a randomized controlled trial under free-living conditions. Eur J 
Nutr 2003; 42: 111-117. 
Lees AM, Mok HY, Lees RS, McCluskey MA, Grundy SM. Plant sterols as cholesterol-lowering agents: 
clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis 1977; 
28: 325-338. 
Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, 
Meiner V, Wurm M, Bard J-M, Fruchart JC, Stein Y. Genetic determinants of responsiveness to the 
HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial 
hypercholesterolemia. Circulation 1993; 87: III35-44. 
Leppimäki P, Mattinen J, Slotte JP. Sterol-induced upregulation of phosphatidylcholine synthesis in cultured 
fibroblasts is affected by the double-bond position in the sterol tetracyclic ring structure. Eur J Biochem 
2000; 267: 6385-6394. 
Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols 
and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J Lipid Res 2002; 43: 
1072-1077. 
Liu GC, Ahrens EH, Jr., Schreibman PH, Crouse JR. Measurement of squalene in human tissues and plasma: 
validation and application. J Lipid Res 1976; 17: 38-45. 
Lopez-Candales A, Bosner MS, Spilburg CA, Lange LG. Cholesterol transport function of pancreatic 
cholesterol esterase: directed sterol uptake and esterification in enterocytes. Biochemistry 1993; 32: 
12085-12089. 
Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Miettinen T, 
Björkhem I, Bruckert E, Pandya A, Brewer HB, Jr., Salen G, Dean M, Srivastava A, Patel SB. 
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of 
mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum 
Genet 2001; 69: 278-290. 
 
97 
Lütjohann D, Björkhem I, Beil UF, von Bergmann K. Sterol absorption and sterol balance in phytosterolemia 
evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 1995; 36: 1763-1773. 
Lütjohann D, Meese CO, Crouse JRr, von Bergmann K. Evaluation of deuterated cholesterol and deuterated 
sitostanol for measurement of cholesterol absorption in humans. J Lipid Res 1993; 34: 1039-1046. 
Mahley RW and Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate 
proteoglycans and apolipoprotein E. J Lipid Res 1999; 40: 1-16. 
Mamo JC, Smith D, Yu KC, Kawaguchi A, Harada-Shiba M, Yamamura T, Yamamoto A. Accumulation of 
chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur J Clin Invest 
1998; 28: 379-384. 
Maranhão RC, Feres MC, Martins MT, Mesquita CH, Toffoletto O, Vinagre CG, Gianinni SD, Pileggi F. 
Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 
1996; 126: 15-25. 
Mardones P, Quiñones V, Amigo L, Moreno M, Miquel JF, Schwarz M, Miettinen HE, Trigatti B, Krieger 
M, VanPatten S, Cohen DE, Rigotti A. Hepatic cholesterol and bile acid metabolism and intestinal 
cholesterol absorption in scavenger receptor class B type I-deficient mice. J Lipid Res 2001; 42: 170-
180. 
Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of 
familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14. 
Martin GM and Nestel P. Changes in cholesterol metabolism with dietary cholesterol in children with familial 
hypercholesterolaemia. Clin Sci 1979; 56: 377-380. 
Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J. Erythrocyte membrane 
cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia 
treated with lovastatin. Thromb Res 1996; 83: 375-388. 
Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol absorption in man. 
Am J Clin Nutr 1982; 35: 697-700. 
Mattson FH, Volpenhein RA, Erickson BA. Effect of plant sterol esters on the absorption of dietary cholesterol. 
J Nutr 1977; 107: 1139-1146. 
McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial 
hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J 
Pediatr 2003; 143: 74-80. 
McNamara DJ, Davidson NO, Samuel P, Ahrens EH, Jr. Cholesterol absorption in man: effect of 
administration of clofibrate and/or cholestyramine. J Lipid Res 1980; 21: 1058-1064. 
McNamara DJ, Kolb R, Parker TS, Batwin H, Samuel P, Brown CD, Ahrens EH, Jr. Heterogeneity of 
cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J 
Clin Invest 1987; 79: 1729-1739. 
McNamara DJ, Proia A, Miettinen TA. Thin-layer and gas--liquid chromatographic identification of neutral 
steroids in human and rat feces. J Lipid Res 1981; 22: 474-484. 
McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, 
Broccardo C, Chimini G, Francone OL. High density lipoprotein deficiency and foam cell 
accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad 
Sci U S A 2000; 97: 4245-4250. 
Mellies M, Glueck CJ, Sweeney C, Fallat RW, Tsang RC, Ishikawa TT. Plasma and dietary phytosterols in 
children. Pediatrics 1976a; 57: 60-67. 
Mellies MJ, Ishikawa TT, Glueck CJ, Bove K, Morrison J. Phytosterols in aortic tissue in adults and infants. J 
Lab Clin Med 1976b; 88: 914-921. 
Miettinen TA. Detection of changes in human cholesterol metabolism. Ann Clin Res 1970; 2: 300-320. 
Miettinen TA. Cholesterol production in obesity. Circulation 1971; 44: 842-850. 
Miettinen TA. New insights into cholesterol dynamics. Arch Surg 1978; 113: 45-49. 
Miettinen TA. Comparison of cholestyramine, ileal by-pass and portacaval shunt in the treatment of familial 
hypercholesterolemia. In: Atherosclerosis V, Proceedings of the fifth international symposium. Gotto 
AMJ, Smith LC, Allen B, eds. New York, Heidelberg, Berlin, Springer-Verlag 1979; 470-473. 
Miettinen TA. Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high 
plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest 
1980; 10: 27-35. 
 
98 
Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma 
lipoproteins. J Lipid Res 1982; 23: 466-473. 
Miettinen TA. Cholesterol and bile acid synthesis in two families with homozygous and heterozygous 
hypercholesterolemia. Arteriosclerosis 1984; 4: 383-388. 
Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 1988; 29: 43-51. 
Miettinen TA. Cholesterol metabolism during hypolipidemic treatment with inhibitors of cholesterol synthesis. 
In: Diabetes, Obesity, and Hyperlipidemias-IV. Crepaldi G, Tiengo A, Enzi G, eds. Amsterdam, New 
York, Oxford, Excerpta Medica 1990; 139-144. 
Miettinen TA. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor. Eur J Clin Pharmacol 1991; 
40 Suppl 1: S19-21. 
Miettinen TA, Ahrens EH, Jr., Grundy SM. Quantitative isolation and gas-liquid chromatographic analysis of 
total dietary and fecal neutral steroids. J Lipid Res 1965; 79: 411-424. 
Miettinen TA and Gylling H. Cholesterol absorption efficiency and sterol metabolism in obesity. Atherosclerosis 
2000; 153: 241-248. 
Miettinen TA and Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a 
large dose of statin treatment. Eur J Clin Invest 2003; 33: 976-982. 
Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Serum noncholesterol 
sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003; 141: 131-137. 
Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary 
events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998; 
316: 1127-1130. 
Miettinen TA, Gylling H, Vanhanen H, Ollus A. Cholesterol absorption, elimination, and synthesis related to 
LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler 
Thromb 1992a; 12: 1044-1052. 
Miettinen TA and Kesäniemi YA. Cholesterol absorption regulates cholesterol metabolism and within-
population variation of serum cholesterol. In: Hyperlipidaemia and Atherosclerosis. Suckling KE, Groot 
PHE, eds. London, Academic Press 1988; 73-82. 
Miettinen TA and Kesäniemi YA. Cholesterol absorption: regulation of cholesterol synthesis and elimination 
and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989; 49: 629-635. 
Miettinen TA and Koivisto P. Non-cholesterol sterols and bile acid production in hypercholesterolaemic patients 
with ileal bypass. In: Bile Acids and Cholesterol in Health Disease. Paumgartner G, Stiehl A, Gerok W, 
eds. Lancaster, MTP Press Limited 1983; 183-187. 
Miettinen TA and Lempinen M. Cholestyramine and ileal by-pass in the treatment of familial 
hypercholesterolaemia. Eur J Clin Invest 1977; 7: 509-514. 
Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-
ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308-1312. 
Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term 
simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb 
Vasc Biol 2000a; 20: 1340-1346. 
Miettinen TA, Tikkanen MJ, Helve E, Ojala JP. Inhibition of dietary cholesterol absorption during lovastatin 
(mevinolin) treatment. Drug Investig 1990a; 2 (Suppl. 2): 29-35. 
Miettinen TA, Tilvis RS, Kesäniemi YA. Serum cholestanol and plant sterol levels in relation to cholesterol 
metabolism in middle-aged men. Metabolism 1989; 38: 136-140. 
Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol 
absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990b; 
131: 20-31. 
Miettinen TA and Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol 
in different apolipoprotein E phenotypes. Atherosclerosis 1994a; 105: 217-226. 
Miettinen TA and Vanhanen H. Serum concentration and metabolism of cholesterol during rapeseed oil and 
squalene feeding. Am J Clin Nutr 1994b; 59: 356-363. 
Miettinen TA, Vanhanen H, Ojala JP, Tikkanen MJ. Non-cholesterol sterols and faecal elimination of 
cholesterol during statin and fibrate treatment. Atheroscler Suppl 1992b; 97: S73-S80. 
Miettinen TA, Vuoristo M, Gylling H. Plant sterols regulate absorption and serum levels of different sterols. In: 
Fat Digestion and Absorption. Christophe AB, de Vriese S, eds. Champaign, IL, AOCS Press 2000b; 
276-286. 
 
99 
Miettinen TA, Vuoristo M, Nissinen M, Järvinen HJ, Gylling H. Serum, biliary, and fecal cholesterol and 
plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J 
Clin Nutr 2000c; 71: 1095-1102. 
Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic 
effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. 
Circulation 1999a; 99: 1733-1739. 
Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ. "Tall oil"-derived phytosterols reduce 
atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 119-126. 
Moghadasian MH, Nguyen LB, Shefer S, McManus BM, Frohlich JJ. Histologic, hematologic, and 
biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols. Lab 
Invest 1999b; 79: 355-364. 
Mohandas N and Morrow JS. Plasma membrane dynamics and organization. In: Hematology: Basic Principles 
and Practice. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen JH, Silberstein LE, McGlave P, eds. 
Philadelphia, Churchill Livingstone 2000; 40-48. 
Moutafis CD, Simons LA, Myant NB, Adams PW, Wynn V. The effect of cholestyramine on the faecal 
excretion of bile acids and neutral steroids in familial hypercholesterolaemia. Atherosclerosis 1977; 26: 
329-334. 
Muratti EN, Peters TK, Leitersdorf E. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the 
response to combination treatment. Am J Cardiol 1994; 73: 30D-38D. 
Mussner MJ, Parhofer KG, von Bergmann K, Schwandt P, Broedl U, Otto C. Effects of phytosterol ester-
enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal 
cholesterol and fat intake. Metabolism 2002; 51: 189-194. 
Naito Y, Nagata T, Takano Y, Nagatsu T, Ohara N. Rapeseed oil ingestion and exacerbation of hypertension-
related conditions in stroke prone spontaneously hypertensive rats. Toxicology 2003; 187: 205-216. 
Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, 
Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti 
apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71. 
Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a 
vegetable oil sterol-enriched fat spread. Atherosclerosis 2001; 156: 329-337. 
Nestel P, Cehun M, Pomeroy S, Abbey M, Weldon G. Cholesterol-lowering effects of plant sterol esters and 
non-esterified stanols in margarine, butter and low-fat foods. Eur J Clin Nutr 2001; 55: 1084-1090. 
Nguyen LB, Cobb M, Shefer S, Salen G, Ness GC, Tint GS. Regulation of cholesterol biosynthesis in 
sitosterolemia: effects of lovastatin, cholestyramine, and dietary sterol restriction. J Lipid Res 1991; 32: 
1941-1948. 
Nissinen M, Gylling H, Vuoristo M, Miettinen TA. Micellar distribution of cholesterol and phytosterols after 
duodenal plant stanol ester infusion. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1009-1015. 
Nissinen MJ, Gylling H, Kaski M, Tammisto P, Mieskonen S, Ignatius J, Miettinen TA. Smith-Lemli-Opitz 
syndrome and other sterol disorders among Finns with developmental disabilities. J Lab Clin Med 2000; 
136: 457-467. 
Noakes M, Clifton P, Ntanios F, Shrapnel W, Record I, McInerney J. An increase in dietary carotenoids when 
consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J 
Clin Nutr 2002; 75: 79-86. 
Nordby G and Norum KR. Substrate specificity of lecithin:cholesterol acyltransferase. Esterification of 
desmosterol, b-sitosterol, and cholecalciferol in human plasma. Scand J Clin Lab Invest 1975; 35: 677-
682. 
Normén L, Dutta P, Lia Å, Andersson H. Soy sterol esters and beta-sitostanol ester as inhibitors of cholesterol 
absorption in human small bowel. Am J Clin Nutr 2000; 71: 908-913. 
Norum KR, Lilljeqvist AC, Helgerud P, Normann ER, Mo A, Selbekk B. Esterification of cholesterol in 
human small intestine: the importance of acyl-CoA:cholesterol acyltransferase. Eur J Clin Invest 1979; 
9: 55-62. 
Ntanios FY, Jones PJ, Frohlich JJ. Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl 
transferase activity in rabbits. Atherosclerosis 1998; 138: 101-110. 
Ntanios FY, van de Kooij AJ, de Deckere EA, Duchateau GS, Trautwein EA. Effects of various amounts of 
dietary plant sterol esters on plasma and hepatic sterol concentration and aortic foam cell formation of 
cholesterol-fed hamsters. Atherosclerosis 2003; 169: 41-50. 
 
100 
O'Neill FH. Effects of dietary plant sterols and stanols on cholesterol metabolism in humans. Thesis. Academic 
Institution. University of London, London, 2003.  
O'Neill FH, Brynes AE, Mandeno R, Seed M, Thompson GR. Head to head comparison of the cholesterol-
lowering efficacy of plant sterol and plant stanol esters. Circulation suppl 2002; 106: 676 (abstr). 
Ostlund RE, Jr., Bosner MS, Stenson WF. Cholesterol absorption efficiency declines at moderate dietary doses 
in normal human subjects. J Lipid Res 1999; 40: 1453-1458. 
Ostlund RE, Jr., McGill JB, Zeng CM, Covey DF, Stearns J, Stenson WF, Spilburg CA. Gastrointestinal 
absorption and plasma kinetics of soy ∆5-phytosterols and phytostanols in humans. Am J Physiol 
Endocrinol Metab 2002; 282: E911-916. 
Parker TS, McNamara DJ, Brown C, Garrigan O, Kolb R, Batwin H, Ahrens EH, Jr. Mevalonic acid in 
human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. 
Proc Natl Acad Sci U S A 1982; 79: 3037-3041. 
Patel SB, Salen G, Hidaka H, Kwiterovich PO, Stalenhoef AF, Miettinen TA, Grundy SM, Lee MH, 
Rubenstein JS, Polymeropoulos MH, Brownstein MJ. Mapping a gene involved in regulating dietary 
cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998; 102: 
1041-1044. 
Pfohl M, Naoumova RP, Kim KD, Thompson GR. Use of cholesterol precursors to assess changes in 
cholesterol synthesis under non-steady-state conditions. Eur J Clin Invest 1998; 28: 491-496. 
Pfohl M, Naoumova RP, Klass C, Knisel W, Jakober B, Risler T, Thompson GR. Acute and chronic effects 
on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase 
inhibitor therapy. J Lipid Res 1994; 35: 1946-1955. 
Phillips KM, T T-TM, Stewart KK. Phytosterol content of experimental diets differing in fatty acid 
composition. Food Chem 1999; 64: 415-422. 
Piironen V, Lindsay DG, Miettinen TA, Toivo J, Lampi A-M. Plant sterols: biosynthesis, biological function 
and their importance to human nutrition. J Sci Food Agric 2000a; 80: 939-966. 
Piironen V, Toivo J, Lampi A-M. Natural sources of dietary plant sterols. J Food Comp Anal 2000b; 13: 619-
624. 
Plat J and Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and 
hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000; 148: 101-112. 
Plat J and Mensink RP. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor 
and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. 
FASEB Journal 2002a; 16: 258-260. 
Plat J and Mensink RP. Increased intestinal ABCA1 expression contributes to the decrease in cholesterol 
absorption after plant stanol consumption. FASEB Journal 2002b; 16: 1248-1253. 
Plat J, van Onselen EN, van Heugten MM, Mensink RP. Effects on serum lipids, lipoproteins and fat soluble 
antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant 
stanol esters. Eur J Clin Nutr 2000; 54: 671-677. 
Pollak OJ. Reduction of blood cholesterol in man. Circulation 1953; 7: 702-706. 
Pollak OJ. Effect of plant sterols on serum lipids and atherosclerosis. Pharmacol Ther 1985; 31: 177-208. 
Pollak OJ and Kritchevsky D. Sitosterol. In: Monographs on Aherosclerosis. Clarkson TB, Kritchevsky D, 
Pollak OJ, eds. New York, Basel, Karger 1981; 1-219. 
Porkka KV, Viikari JS, Rönnemaa T, Marniemi J, Åkerblom HK. Age and gender specific serum lipid and 
apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns 
Study. Acta Paediatr 1994; 83: 838-848. 
Quintão E, Grundy SM, Ahrens EH, Jr. Effects of dietary cholesterol on the regulation of total body cholesterol 
in man. J Lipid Res 1971a; 12: 233-247. 
Quintão E, Grundy SM, Ahrens EH, Jr. An evaluation of four methods for measuring cholesterol absorption by 
the intestine in man. J Lipid Res 1971b; 12: 221-232. 
Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black 
DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. 
Atherosclerosis 2000; 150: 421-428. 
Rajaratnam RA, Gylling H, Miettinen TA. Impaired postprandial clearance of squalene and apolipoprotein B-
48 in post-menopausal women with coronary artery disease. Clin Sci 1999; 97: 183-192. 
Rajaratnam RA, Gylling H, Miettinen TA. Independent association of serum squalene and noncholesterol 
sterols with coronary artery disease in postmenopausal women. J Am Coll Cardiol 2000; 35: 1185-1191. 
 
101 
Ratnayake WM, L'Abbe MR, Mueller R, Hayward S, Plouffe L, Hollywood R, Trick K. Vegetable oils high 
in phytosterols make erythrocytes less deformable and shorten the life span of stroke-prone 
spontaneously hypertensive rats. J Nutr 2000; 130: 1166-1178. 
Ratnayake WM, Plouffe L, L'Abbe MR, Trick K, Mueller R, Hayward S. Comparative health effects of 
margarines fortified with plant sterols and stanols on a rat model for hemorrhagic stroke. Lipids 2003; 
38: 1237-1247. 
Redgrave TG, Vassiliou GG, Callow MJ. Cholesterol is necessary for triacylglycerol-phospholipid emulsions to 
mimic the metabolism of lipoproteins. Biochim Biophys Acta 1987; 154-157. 
Redgrave TG, Watts GF, Martins IJ, Barrett PH, Mamo JC, Dimmitt SB, Marais AD. Chylomicron remnant 
metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. J Lipid Res 
2001; 42: 710-715. 
Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B. Influence 
of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N 
Engl J Med 1990; 323: 224-228. 
Relas H, Gylling H, Miettinen TA. Effect of stanol ester on postabsorptive squalene and retinyl palmitate. 
Metabolism 2000; 49: 473-478. 
Relas H, Gylling H, Miettinen TA. Acute effect of dietary stanyl ester dose on post-absorptive alpha-tocopherol, 
beta-carotene, retinol and retinyl palmitate concentrations. Br J Nutr 2001a; 85: 141-147. 
Relas H, Gylling H, Miettinen TA. Fate of intravenously administered squalene and plant sterols in human 
subjects. J Lipid Res 2001b; 42: 988-994. 
Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding 
cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 
2002; 277: 18793-18800. 
Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, 
Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR 
heterodimers. Science 2000; 289: 1524-1529. 
Robins SJ and Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol 
transport to bile. J Clin Invest 1997; 99: 380-384. 
Rubinsztein DC, Cohen JC, Berger GM, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron 
remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with 
defined receptor defects. J Clin Invest 1990; 86: 1306-1312. 
Salen G, Ahrens EH, Jr., Grundy SM. Metabolism of beta-sitosterol in man. J Clin Invest 1970; 49: 952-967. 
Salen G and Grundy SM. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous 
xanthomatosis. J Clin Invest 1973; 52: 2822-2835. 
Salen G, Kwiterovich PO, Jr., Shefer S, Tint GS, Horak I, Shore V, Dayal B, Horak E. Increased plasma 
cholestanol and 5 alpha-saturated plant sterol derivatives in subjects with sitosterolemia and 
xanthomatosis. J Lipid Res 1985; 26: 203-209. 
Salen G, Tint GS, Shefer S, Shore V, Nguyen L. Increased sitosterol absorption is offset by rapid elimination to 
prevent accumulation in heterozygotes with sitosterolemia. Arterioscler Thromb 1992; 12: 563-568. 
Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B. 
Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004. 
Samuel P, Crouse JR, Ahrens EH, Jr. Evaluation of an isotope ratio method for measurement of cholesterol 
absorption in man. J Lipid Res 1978; 19: 82-93. 
Santos RD, Spósito AC, Ventura LI, Cesar LA, Ramires JA, Maranhão RC. Effect of pravastatin on plasma 
removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol 2000; 85: 
1163-1166. 
Schaefer EJ, Brousseau ME, Diffenderfer MR, Cohn JS, Welty FK, O'Connor J, Jr., Dolnikowski GG, 
Wang J, Hegele RA, Jones PJ. Cholesterol and apolipoprotein B metabolism in Tangier disease. 
Atherosclerosis 2001; 159: 231-236. 
Schlierf G, Oster P, Heuck CC, Raetzer H, Schellenberg B. Sitosterol in juvenile type II hyperlipoproteinemia. 
Atherosclerosis 1978; 30: 245-248. 
Schwarz KB, Witztum J, Schonfeld G, Grundy SM, Connor WE. Elevated cholesterol and bile acid synthesis 
in a young patient with homozygous familial hypercholesterolemia. J Clin Invest 1979; 64: 756-760. 
Sehayek E, Nath C, Heinemann T, McGee M, Seidman CE, Samuel P, Breslow JL. U-shape relationship 
between change in dietary cholesterol absorption and plasma lipoprotein responsiveness and evidence 
 
102 
for extreme interindividual variation in dietary cholesterol absorption in humans. J Lipid Res 1998; 39: 
2415-2422. 
Shefer S, Hauser S, Bekersky I, Mosbach EH. Biochemical site of regulation of bile acid biosynthesis in the rat. 
J Lipid Res 1970; 11: 404-411. 
Shefer S, Salen G, Bullock J, Nguyen LB, Ness GC, Vhao Z, Belamarich PF, Chowdhary I, Lerner S, Batta 
AK, Tint GS. The effect of increased hepatic sitosterol on the regulation of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase and cholesterol 7 alpha-hydroxylase in the rat and sitosterolemic 
homozygotes. Hepatology 1994; 20: 213-219. 
Shohet SB. Hemolysis and changes in erythrocyte membrane lipids 1. N Engl J Med 1972; 286: 577-583. 
Simonen H and Miettinen TA. Coronary artery disease and bile acid synthesis in familial hypercholesterolemia. 
Atherosclerosis 1987; 63: 159-166. 
Simonen PP, Gylling HK, Miettinen TA. Diabetes contributes to cholesterol metabolism regardless of obesity. 
Diabetes Care 2002; 25: 1511-1515. 
Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein 
cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90: 737-740. 
Siperstein MD, Chaikoff IL, Reinhardt WO. C14-Cholesterol. V. Obligatory function of bile in intestinal 
absorption of cholesterol. J Biol Chem 1952; 198: 111-114. 
Slota T, Kozlov NA, Ammon HV. Comparison of cholesterol and beta-sitosterol: effects on jejunal fluid 
secretion induced by oleate, and absorption from mixed micellar solutions. Gut 1983; 24: 653-658. 
Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates 
intestinal cholesterol transport. Proc Natl Acad Sci U S A 2004; 101: 3450-3455. 
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus 
conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a 
prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581. 
Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial chylomicron response may be predicted by a 
single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 1999; 29: 204-
209. 
Sodhi HD, Kudchodkar BJ, Mason DT. Cholesterol metabolism in clinical hyperlipidemias. In: Advances in 
Lipid Research. Paoletti R, Kritchesky D, eds. New York, Academic Press 1980; 107-153. 
Sodhi HS, Kudchodkar BJ, Varughese P, Duncan D. Validation of the ratio method for calculating absorption 
of dietary cholesterol in man. Proc Soc Exp Biol Med 1974; 145: 107-111. 
Stalenhoef AF, Hectors M, Demacker PN. Effect of plant sterol-enriched margarine on plasma lipids and sterols 
in subjects heterozygous for phytosterolaemia. J Intern Med 2001; 249: 163-166. 
Starzl TE, Putnam CW, Chase HP, Porter KA. Portacaval shunt in hyperlipoproteinaemia. Lancet 1973; 2: 
940-944. 
Stein EA, Illingworth DR, Kwiterovich PO, Jr., Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, 
Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, 
Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of 
lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized 
controlled trial. Jama 1999; 281: 137-144. 
Strandberg TE, Salomaa V, Vanhanen H, Miettinen TA. Associations of fasting blood glucose with 
cholesterol absorption and synthesis in nondiabetic middle-aged men. Diabetes 1996; 45: 755-761. 
Strandberg TE, Tilvis RS, Miettinen TA. Metabolic variables of cholesterol during squalene feeding in humans: 
comparison with cholestyramine treatment. J Lipid Res 1990; 31: 1637-1643. 
Sudhop T, Gottwald BM, von Bergmann K. Serum plant sterols as a potential risk factor for coronary heart 
disease. Metabolism 2002a; 51: 1519-1521. 
Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition 
of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002b; 106: 1943-1948. 
Sudhop T, Sahin Y, Lindenthal B, Hahn C, Lüers C, Berthold HK, von Bergmann K. Comparison of the 
hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux 
transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut 2002c; 51: 860-
863. 
Sudhop T and von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. 
Drugs 2002; 62: 2333-2347. 
 
103 
Sugano M, Morioka H, Ikeda I. A comparison of hypocholesterolemic activity of beta-sitosterol and beta-
sitostanol in rats. J Nutr 1977; 107: 2011-2019. 
Sutherland WHF, Williams MJA, Hye ER, Restieaux NJ, de Jong SA, Walker HL. Association of plasma 
noncholesterol sterol levels with severity of coronary artery disease. Nutr Metab Cardiovasc Dis 1998; 
8: 386-391. 
Swell L, Trout EC, Jr., Hopper JR, Field H, Jr., Treadwell CR. Specific function of bile salts in cholesterol 
absorption. Proc Soc Exp Biol Med 1958; 98: 174-176. 
Tammi A, Rönnemaa T, Gylling H, Rask-Nissilä L, Viikari J, Tuominen J, Pulkki K, Simell O. Plant stanol 
ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy 
children: the STRIP project. Special Turku Coronary Risk Factors Intervention Project. J Pediatr 2000; 
136: 503-510. 
Tammi A, Rönnemaa T, Miettinen TA, Gylling H, Rask-Nissilä L, Viikari J, Tuominen J, Marniemi J, 
Simell O. Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters 
in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project. Acta Paediatr 
2002; 91: 1155-1162. 
Tammi A, Rönnemaa T, Rask-Nissilä L, Miettinen TA, Gylling H, Valsta L, Viikari J, Välimäki I, Simell O. 
Apolipoprotein E phenotype regulates cholesterol absorption in healthy 13-month-old children--The 
STRIP Study. Pediatr Res 2001; 50: 688-691. 
Tanner JM. Growth and endocrinology of the adolescent. In: Endocrine and Genetic Disease of Childhood. 
Gardner L, ed. Philadelphia, Saunders 1969; 19-60. 
Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the 
liver. J Lipid Res 1996; 37: 439-447. 
Thurnhofer H and Hauser H. Uptake of cholesterol by small intestinal brush border membrane is protein-
mediated. Biochemistry 1990; 29: 2142-2148. 
Thurnhofer H, Schnabel J, Betz M, Lipka G, Pidgeon C, Hauser H. Cholesterol-transfer protein located in the 
intestinal brush-border membrane. Partial purification and characterization. Biochim Biophys Acta 
1991; 1064: 275-286. 
Tilvis RS and Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 
1986; 43: 92-97. 
Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bonaa KH. Risk factors related to 
carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control 
subjects. Arterioscler Thromb Vasc Biol 1996; 16: 984-991. 
Twickler TB, Dallinga-Thie GM, de Valk HW, Schreuder PC, Jansen H, Cabezas MC, Erkelens DW. High 
dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous 
familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2422-2427. 
Uusitupa MI, Miettinen TA, Happonen P, Ebeling T, Turtola H, Voutilainen E, Pyorälä K. Lathosterol and 
other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with 
cholestyramine or guar gum. Arterioscler Thromb 1992; 12: 807-813. 
Vahouny GV, Borja CR, Treadwell CR. Absorption and esterification of micellar free and esterified 
cholesterol-4-C14 Arch Biochem Biophys 1964; 106: 440-446. 
van Deenen L, de Haas G, Heemskerk CH. Hydrolysis of synthetic mixed-acid phosphatides by phospholipase 
A from human pancreas. Biochim Biophys Acta 1963; 67: 295-304. 
Vanhanen H. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated 
hypercholesterolaemic patients. Eur J Clin Pharmacol 1994; 47: 169-176. 
Vanhanen H, Kesäniemi YA, Miettinen TA. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, 
fecal steroids, and cholesterol absorption in man. Metabolism 1992; 41: 588-595. 
Vanhanen H and Miettinen TA. Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor 
levels in familial hypercholesterolaemia. Eur J Clin Pharmacol 1992a; 42: 127-130. 
Vanhanen HT, Blomqvist S, Ehnholm C, Hyvönen M, Jauhiainen M, Torstila I, Miettinen TA. Serum 
cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different 
apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res 1993; 34: 1535-1544. 
Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficiency, faecal 
elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in 
hypercholesterolaemic subjects. Clin Sci 1994; 87: 61-67. 
 
104 
Vanhanen HT and Miettinen TA. Effects of unsaturated and saturated dietary plant sterols on their serum 
contents. Clin Chim Acta 1992b; 205: 97-107. 
Vanhanen HT and Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their 
combination. Atherosclerosis 1995; 115: 135-146. 
Vanstone CA and Jones PJ. Limitations of plasma plant sterols as indicators of cholesterol absorption. Am J 
Clin Nutr 2004; 79: 340-341. 
Vanstone CA, Raeini-Sarjaz M, Jones PJ. Injected phytosterols/stanols suppress plasma cholesterol levels in 
hamsters. J Nutr Biochem 2001; 12: 565-574. 
Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-
cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr 2002; 76: 
1272-1278. 
Warnick GR and Alberts JJ. Quantitation of the lipoproteins. In: Manual of Laboratory Operations, Lipid 
Research Clinics Program, Lipid and Lipoprotein Analysis. Hainline A, Karon J, Lippel K, eds. 
Bethesda, Maryland, 1982; 63-77. 
Watts GF, Barrett PH, Marais AD, Dane-Stewart CA, Martins IJ, Dimmitt SB, Redgrave TG. Chylomicron 
remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. 
Atherosclerosis 2001; 157: 519-523. 
Weihrauch JL and Gardner JM. Sterol content of foods of plant origin. J Am Diet Assoc 1978; 73: 39-47. 
Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, 
type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with 
cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-1119. 
Westergaard H and Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and 
cholesterol uptake into the intestinal mucosal cell. J Clin Invest 1976; 58: 97-108. 
Weststrate JA, Ayesh R, Bauer-Plank C, Drewitt PN. Safety evaluation of phytosterol esters. Part 4. Faecal 
concentrations of bile acids and neutral sterols in healthy normolipidaemic volunteers consuming a 
controlled diet either with or without a phytosterol ester-enriched margarine. Food Chem Toxicol 1999; 
37: 1063-1071. 
Weststrate JA and Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-
cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J 
Clin Nutr 1998; 52: 334-343. 
Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997; 1345: 
136-150. 
Wiegman A, Sijbrands EJ, Rodenburg J, Defesche JC, de Jongh S, Bakker HD, Kastelein JJ. The 
apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia. 
Pediatr Res 2003; 53: 1008-1012. 
Williams CL, Bollella MC, Strobino BA, Boccia L, Campanaro L. Plant stanol ester and bran fiber in 
childhood: effects on lipids, stool weight and stool frequency in preschool children. J Am Coll Nutr 
1999; 18: 572-581. 
Wilson MD and Rudel LL. Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J 
Lipid Res 1994; 35: 943-955. 
Virkola K, Pesonen E, Åkerblom HK, Siimes MA. Cholesterol and carotid artery wall in children and 
adolescents with familial hypercholesterolaemia: a controlled study by ultrasound. Acta Paediatr 1997; 
86: 1203-1207. 
Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, Princen HM. Dietary vegetable oil and wood 
derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic 
mice. Atherosclerosis 2001; 157: 375-381. 
von Bergmann K, Lütjohann D, Lindenthal B, Steinmetz A. Efficiency of intestinal cholesterol absorption in 
humans is not related to apoE phenotype. J Lipid Res 2003; 44: 193-197. 
Vuorio AF, Aalto-Setälä K, Koivisto UM, Turtola H, Nissen H, Kovanen PT, Miettinen TA, Gylling H, 
Oksanen H, Kontula K. Familial hypercholesterolaemia in Finland: common, rare and mild mutations 
of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med 2001; 33: 410-421. 
Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol ester margarine alone and 
with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the 
FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000; 20: 500-506. 
 
105 
Vuorio AF, Miettinen TA, Turtola H, Oksanen H, Gylling H. Cholesterol metabolism in normal and 
heterozygous familial hypercholesterolemic newborns. J Lab Clin Med 2002; 140: 35-42. 
Vuoristo M and Miettinen TA. Absorption, metabolism, and serum concentrations of cholesterol in vegetarians: 
effects of cholesterol feeding. Am J Clin Nutr 1994; 59: 1325-1331. 
Vuoristo M and Miettinen TA. Absorption and malabsorption of cholesterol. In: Fat Digestion and Absorption. 
Christophe AB, de Vriese S, eds. Champaign, IL, AOCS Press 2000; 244-275. 
Yamamoto A, Harada-Shiba M, Kawaguchi A, Oi K, Kubo H, Sakai S, Mikami Y, Imai T, Ito T, Kato H, 
Endo M, Sato I, Suzuki Y, Hori H. The effect of atorvastatin on serum lipids and lipoproteins in 
patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. 
Atherosclerosis 2000; 153: 89-98. 
Yu L, Hammer RE, Li-Hawkins J, von Bergmann K, Lütjohann D, Cohen JC, Hobbs HH. Disruption of 
Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci 
U S A 2002a; 99: 16237-16242. 
Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH. Overexpression of ABCG5 
and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary 
cholesterol. J Clin Invest 2002b; 110: 671-680. 
Zavoral JH, Laine DC, Bale LK, Wellik DL, Ellefson RD, Kuba K, Krivit W, Kottke BA. Cholesterol 
excretion studies in familial hypercholesterolemic children and their normolipidemic siblings. Am J Clin 
Nutr 1982; 35: 1360-1367. 
Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-485. 
 
 
 
 
 
 
 
 
 
 
 
 
 
